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ABSTRACT
Purpose: Circadian rhythms are important in adipose physiology as adipokine plasma 
concentration, and approximately 20% of the murine adipose transcriptome, undergo diurnal 
variation. Additionally, overweight and diabetic mice exhibit suppressed amplitude clock and 
adipokine mRNA rhythms. However, the cellular basis of adipose rhythms is unclear, and 
clock gene rhythms have not been compared between lean versus overweight or diabetic 
human subjects. I tested the hypotheses that an endogenous adipocyte oscillator drives 
rhythmic synthesis and secretion of adipokines, and that rhythms of gene expression are 
suppressed in overweight or type 2 diabetic patients. Methods: Murine 3T3-L1 pre-adipocyte 
and adipocyte cultures were characterised. These cells were then ‘pulsed’ with 50% horse 
serum for 2 hours, and sampled every 4-hours over a 48-hour period. Additionally, lean, 
overweight, and type 2 diabetic subjects had 4 subcutaneous adipose biopsies taken, one every 
6 hours. mRNA expression of clock genes and other genes key to adipose physiology were 
analysed by quantitative real-time PCR. Secretion of the adipokines leptin and adiponectin 
were also measured in culture medium from 3T3-L1 adipocytes. Results: Following a serum 
pulse of characterised 3T3-L1 cultures, circadian rhythms of clock genes Perl, NR1D1 (Rev- 
erba) and Dbp, but not Perl, Cryl and Amtl {Email), were observed in both pre- and post­
differentiated adipocytes. Ppara, Ppary, and Srebfl {Srebpl) also failed to exhibit temporal 
mRNA changes. Moreover, in the absence of Lep {Leptin) or AdipoQ {Adiponectin) mRNA 
rhythms in adipocytes, leptin accumulated in the culture medium in a circadian manner. In 
human adipose samples, PERI-3, CRY2, BMAL1, REV-ERBa and DBP showed diurnal 
oscillations, but CRY1 did not. In contrast, transription factors NRIP1 {RIP140) and 
PPARGC1A {PGCla) exhibited temporal variation of expression, but this was not rhythmic 
over the timecourse. Interestingly, BMAL1 expression was lower in the overweight group, 
and PER! showed lower mRNA levels in medicated versus non-medicated type 2 diabetic 
patients. Conclusion: 3T3-L1 pre- and post differentiated adipocytes possess an endogenous 
oscillator, which may control adipocyte leptin secretion, but only drives detectable rhythms of 
some genes. Additionally, there is only minimal effect of obesity and type 2 diabetes on 
circadian rhythms in human subcutaneous adipose tissue, although drug regimens may affect 
clock gene rhythms in type 2 diabetic patients. Together, these data increase understanding of 
circadian rhythms in adipose biology, and suggest avenues for future research.
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CHAPTER 1:
Introduction
1.1 OVERVIEW
Over the last decade, obesity has become an increasingly global problem. As a result of 
lifestyle and eating habits, approximately 1 billion people are predicted to be overweight or 
obese (Yach et a l, 2006). To date, humoral agents, such as the fat tissue hormone leptin, 
have been utilised as anti-obesity drugs in individuals with diet-induced obesity, but with little 
success. Due to the associated risks of obesity in development of type 2 diabetes and the 
metabolic syndrome, it is becoming increasingly important to understand fat tissue biology at 
both the whole organism and molecular level. Recent advances in the field of chronobiology 
suggest the presence of a functional circadian clock in mammalian adipose tissue. 
Furthermore, findings that disruption of the clock, across the whole organism, can lead to 
metabolic dysfunction have opened a whole new area of research into causative aspects of the 
multi-factorial disease. This review will describe circadian clocks and adipose tissue biology, 
from fat digestion, adipocyte differentiation and fat storage, to metabolic syndrome. Finally, 
evidence will be provided for a link between obesity, metabolism and clock function.
1.2 CIRCADIAN RHYTHMS AND CLOCK GENES
Circadian rhythms are endogenously driven cyclic patterns of physiology and behaviour that 
occur approximately every 24 hours (Schibler, 2005). These rhythms are temperature 
compensated, such that a change in internal body temperature does not affect the period 
length of the oscillator (Reyes et a l, 2008), and are entrained to the external environment by 
cues termed zeitgebers (Albrecht, 2002; Kalsbeek et a l, 2006; Merrow et a l, 2005; Schibler, 
2005; Yach et a l, 2006). The most common zeitgeber across species is light, with organisms 
responding and entraining to photic cues. For example, nocturnal mice placed in a 12 hours 
light: 12 hours dark schedule show peak activity after lights out. If the photoperiod is then 
shifted by 12 hours, such that the light phase is now in the previous dark phase, the mice 
entrain to the new routine over a period of multiple days. As well as photic cues, other 
zeitgebers include food supply, temperature, and predator presence (Merrow et a l, 2005). 
Outputs of the clock are tied to specific phases of the oscillator and allow the organism to, for 
example, feed and hunt at a time when there are less predators. Thus, clocks confer a 
selective advantage on the individual in terms of life-history strategy. Linked to this, one key 
feature of the clock is that it permits temporal dissociation of metabolic processes that are not 
compatible at certain times of the day. For example, in diurnal species, expression of
enzymes that promote energy storage is more beneficial during the day following a meal than 
at night-time when circulating fuel is low.
In humans, circadian rhythmicity controls sleep/wake cycles, thus time of activity and rest, 
and also controls daily fluctuation in many hormones. For example, cortisol shows increasing 
concentrations at the start of the wake period, acting as an alerting signal to begin the day 
(Buckley and Schatzberg, 2005). Another example is insulin sensitivity, which shows marked 
reduction at night (Morgan et a l, 1998) at a time when we would normally not be feeding. 
Thus, the body is able to predict changes over the course of the day and alter its physiology 
accordingly.
Pathology also exhibits circadian rhythmicity, such as the incidence of myocardial infarction. 
There is a higher incidence of acute myocardial infarction in the morning (Maemura et al., 
2007; Muller et al., 1985), which poses an increased threat to individuals suffering from 
cardiovascular disease (CVD). This high risk is associated with increased blood pressure due 
to a circadian reduction in arterial wall dilation in the morning. Another influence is the 
simultaneous increased chance of platelet accumulation in the morning, raising the likelihood 
of thrombosis (Muller et a l, 1989). This is caused by reduced ability of tissue thrombolytic 
agents, such as tissue plasminogen activator (tPA), to break down clots and fibrin meshes. 
One key vascular endothelial circadian gene involved in raised thrombosis risk is the 
plasminogen activator inhibitor gene {Pail). Pail, an enzyme that is more abundant in the 
morning, reduces the thrombolytic activity of tPA (Angleton et a l, 1989), resulting in 
increased risk of clot formation and, as a result, myocardial infarction. Therefore, as a bi­
product of a beneficial circadian oscillator disease states also exhibit diurnal fluctuations 
(Wang et a l, 2006).
1.2.1 Mammalian rhythms
1.2.1.1 The suprachiasmatic nuclei and photic entrainment
The suprachiasmatic nuclei (SCN) are a pair of nuclei in the anterior hypothalamus that are 
located immediately above the optic chiasm and house the master pacemaker. It is comprised 
of densely packed neurons and has subdivisions, termed the ventral and dorsomedial regions. 
These can be characterised by both their neuropeptide expression and by their receipt of 
visual information. The ventral region, or core, receives direct photic input via the
retinohypothalamic tract (RHT), as well as indirect photic input from a thalamic relay
structure termed the intergeniculate leaflet (IGL). The ventral region also possesses a large
number of vasoactive intestinal polypeptide-containing (VIP) neurons and has low amplitude 
rhythms, but appears to be essential for rhythmic SCN output signals. In contrast, the 
dorsomedial area (shell) shows high amplitude circadian rhythms in gene expression, but does 
not receive significant visual input. This region is characterised by a population of 
vasopressin-containing neurons. Both the ventral and dorsomedial regions also possess y- 
aminobutyric acid (GABA)-containing neurons (Klein et a l, 1991).
There is now a plethora of evidence to show that the SCN is the central pacemaker in 
mammals. Not only do SCN lesions result in the loss of behavioural and physiological 
rhythms (Moore and Eichler, 1972; Stephan and Zucker, 1972; Van den Pol and Powley, 
1979), but cells of the SCN neurons continue to exhibit circadian patterns of electrical activity 
in vitro (Green and Gillette, 1982; Groos and Hendriks, 1982). Transplantation of embryonic 
SCN can restore rhythmicity in SCN-lesioned rodents (Lehman et a l, 1987), and small neural 
grafts from the SCN of short-period mutant Syrian hamsters can restore circadian wheel- 
running activity to arrhythmic animals whose own nucleus has been ablated. Additionally, 
reinstated rhythms always exhibit the period of the donor genotype, irrespective of the 
genotype of the host, illustrating that the basic period of the endogenous circadian rhythm is 
dictated by the SCN (Ralph et a l, 1990).
SCN entrainment to the solar day requires a functional retina, and is achieved through direct
innervation, for example glutamatergic input, via the RHT (De Haro and Panda, 2006), and 
indirectly via the IGL. Photic input is detected by opsins in rods and cones and melanopsin, 
the latter of which is a homologue of a photoreceptor found in amphibian skin (Foster et a l, 
1991; Hastings et a l, 2003), and is located in a sub-population of retinal-ganglion cells 
(RGCs) in mammals. Light depolarises the RGCs, activating the RHT (Foster and Hankins,
2007), and resulting in glutamate release from RHT nerve terminals. This subsequently 
activates SCN cells via V-methyl-D-aspartate (NMDA) receptors and increases firing rate in 
the SCN ventral neurons, such as GABA-containing neurons. These neurons also synchronise 
the signals among SCN neurons and couple the dorsomedial and ventral SCN regions 
(Hastings et a l, 2003).
The activation of SCN receptors also leads to downstream binding of promoter elements to 
core clock genes, resulting in light induced clock gene expression (Albrecht et a l, 1997). For
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example, glutamatergic signals activating the glutamate specific NMDA receptor leads to 
downstream phosphorylation of cyclic adenosine monophosphate (cAMP) response element 
binding protein (CREB) (O'Neill et a l, 2008). Binding sites (CREs) for CREB are found in 
some promoters of core clock genes (Travnickova-Bendova et a l, 2002), resulting in gene 
transcription of core clock elements, which will be described in Section 1.2.1.4 (Etchegaray et 
a l, 2003; Kuhlman and McMahon, 2006; Sehgal, 2004).
A second light-dependent pathway involves activation of protein kinase C (PKC), which is 
upregulated in response to evening light. Knock-out studies, and those using 
immunoprécipitation and Western blotting have shown that PKC binds to several clock 
proteins, causing sequestering of the proteins in the cytoplasm and phase delaying the 
circadian clock (Jakubcakova et a l, 2007; Lee et a l, 2007).
Evidence now suggests the presence of a morning and an evening oscillator in the SCN 
(Pittendrigh and Daan, 1976). Inagaki et a l (2007) showed in clock gene transgenic mice 
that, while the posterior SCN has oscillations that are phase-locked to the end of activity, the 
anterior SCN exhibits bimodality. The anterior SCN, locked to the onset of activity, 
possesses two subsets of cells of early and late phases respectively. The difference is largest 
between the two anterior peaks during long days, and becomes a single peak during normal, 
or short days (Hazlerigg et al, 2005). This phenomenon provides information to the clock 
regarding photoperiod.
As well as receiving neural and hormonal input, the SCN regulates a plethora of physiological 
parameters. Some examples of rhythmic output include core body temperature, 
sleep/wakefulness, activity, feeding/fasting, plasma glucose concentrations, water intake, and 
rhythmic hormone production (Bartness et a l, 2001; Cailotto et a l, 2005), including 
melatonin synthesis (Figure 1.1).
1.2.1.2 Melatonin
Melatonin (N-acetyl-5-methoxytryptamine) is a hormone secreted in a circadian manner by 
the pinealocytes of the pineal gland, with peak production occurring in the dark phase in both 
diurnal and nocturnal species, and a half-life in human plasma of approximately 30 minutes 
(Mallo et a l, 1990). Melatonin travels in plasma with approximately 70% reversibly bound 
to albumin (Cardinali et a l, 1972). The SCN efferent neuronal pathway connecting to the
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pineal gland comprises the hypothalamic paraventricular nucleus (PVN), intermediolateral 
cell column (IML), and superior cervical ganglion (SCG), which innervates noradrenergic 
projections to the pineal gland (Kalsbeek et ai,  1999). Noradrenergic stimulation of the 
pineal gland results in increased activity of N-acetyltransferase, a key enzyme involved in 
melatonin synthesis (Kalsbeek et ai, 2000).
63 -,
40 -
2 0 -
0
37.1 -,
36.9 -
a
E 36.7 - 2
36.5
60 -,
20 -
0 J
1 .6 -
■5
s
(e)
IfII
2 .0 - ,
1.8
1.6
1.4
1.2
1030 1400 1800 2200 0200 0600 1000 1400
Clock lime (h)
Figure 1.1: Representation of human circadian rhythms. Rhythms of plasma melatonin, core body temperature, 
alertness, task performance and plasma triglyceride concentrations in humans held in constant routine conditions 
(Skene and Arendt, 2006).
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During the day, the SCN exhibits increased spontaneous neural firing rate, inhibiting PVN 
neurons by GABA-ergic signalling (Kalsbeek et a l, 1999) and therefore preventing 
downstream noradrenergic stimulation of the pineal gland (Kalsbeek et a l, 2000). As such, 
melatonin is produced at night when SCN activity is low. Plasma melatonin acrophase in 
humans occurs between 02:00-04:00 (Morgan et a l, 1998).
Melatonin is degraded in the liver (Kopin et a l, 1961; Skene et a l, 2001). The primary 
metabolite of melatonin, 6-sulphatoxymelatonin (aMT6), which accounts for approximately 
80% of melatonin metabolites (Arendt et a l, 1985), is measured in either saliva or urine 
(Deacon and Arendt, 1994), whereas melatonin itself is measured in plasma (Kennaway et a l, 
1999). It is due to the robust rhythm of melatonin that dim light melatonin onset (DLMO) 
and peak (acrophase) are used as markers of circadian phase and integrity.
In mammals, the primary role of melatonin is believed to be the transduction of day and night 
length to the rest of the body (Arendt et a l, 1985; von Gall et a l, 2002), with other roles 
including development and hormone control, and key roles in seasonal physiology (Arendt, 
1988; Seamark et a l, 1981; Waldhauser et a l, 1984). In many species, the distribution of the 
three melatonin receptors (MTi, MT2 and MT3) is limited. However, the MT2 receptor has 
been found on human fat cells (Brydon et a l, 2001), where it is suggested that melatonin 
controls fat cell hormone expression (Alonso-Vale et a l, 2006; Alonso-Vale et a l, 2008; 
Alonso-Vale et a l, 2005), and may also aid in entraining of peripheral clocks, which will be 
discussed in the next section (von Gall et a l, 2002).
1.2.1.3 Peripheral clocks
Circadian molecular oscillators have been found in many tissue types outside of the SCN, 
including the liver, lung, kidney, fat (adipose) tissue, ovary (Ball, 2007; Sakamoto et a l, 
1998) and several brain regions (Figure 1.2) (Shearman et a l, 1997). These are collectively 
termed peripheral clocks, and are proposed to regulate localised physiological processes, such 
as metabolism, thereby enhancing the functional message of the master pacemaker in the 
SCN. For example, in the liver, enzymes involved in glucose, lipid and protein metabolism 
are governed (Hastings et a l, 2003; Kohsaka and Bass, 2007; Kudo et a l, 2007a; Kudo et a l, 
2007b). Peripheral clock genes also exhibit a range of different phases when compared to the 
SCN (Balsalobre et a l, 1998; Cailotto et a l, 2005). For example, under 12L: 12D, murine
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lung clock gene expression exhibits a 6-hour phase delay compared to the SCN (Yoo et a l ,  
2004).
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Figure 1.2: Circadian rhythms in peripheral tissues. Clock gene-driven luciferase activity showing circadian 
rhythmicity in various body regions (Hastings e ta l ,  2003).
Unlike the SCN, peripheral clocks do not possess visual input, and thus are incapable of 
entraining to external light cues via the RHT. It is believed that peripheral clocks are 
predominantly entrained by SCN-controlled release of humoral and neural factors under 
normal conditions (Balsalobre et a l ,  2000a; Balsalobre et a l ,  2000b; Buijs et a l ,  2003; 
Cailotto et a l ,  2005; Kalsbeek et a l ,  2006; Kuhlman and McMahon, 2006). The ability of 
the SCN to control timing of peripheral clocks is termed hierarchical dominance. Such 
control has been demonstrated by implanting ‘clock mutant’ mouse embryonic fibroblasts, 
which display a shortened circadian period of 20 hours, into a host animal with a functional
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SCN (Pando et a l, 2002). The fibroblasts adopted circadian characteristics of the host, 
namely an identical period length. This demonstrates that SCN hierarchical dominance can 
compensate for severe intrinsic defects in the peripheral circadian clock, and has been shown 
for peripheral oscillators both within and outside the brain. The SCN has also been shown to 
control phasing of peripheral organs as there was phase dispersion between numerous tissues 
in SCN-lesioned mice compared to control animals (Yoo et a l, 2004).
By definition, circadian clocks are capable of self-sustained rhythms in the absence of 
rhythmic input. This was demonstrated by Welsh et a l (1995) who showed that neurons from 
neonatal rat SCN exhibit rhythmic, cell autonomous firing in vitro. Peripheral tissue explants 
also retain rhythmicity in vitro. Using a clock: luciferase fusion protein or Luciferase under 
the control of a circadian gene promoter as real-time reporters of circadian dynamics in mice, 
it was shown that SCN-lesioned animals maintained in constant conditions for 3-5 weeks still 
exhibited oscillations in bioluminescence readings in explanted liver, lung, kidney and 
pituitary tissues (Yoo et a l, 2004).
It has been suggested that blood borne macronutrients that oscillate over the course of the day 
may aid in entraining the peripheral clocks. Balsalobre et al. (1998) used serum pulse 
methodology, which involved providing Rat-1 fibroblasts with a high concentration of horse 
serum for two hours followed by serum free medium, to synchronise the circadian clock. 
They showed that immortalised rat fibroblasts that have been maintained in cell culture for 
over 25 years still exhibit an accurate circadian clock.
Provision of a serum pulse synchronises previously oscillatory but de-synchronised cells 
across the culture. Nagoshi et al. (2004) used a reporter gene driven by a circadian promoter 
to show oscillations in individual unsynchronised NIH-3T3 cells displayed robust but out-of­
phase bioluminescence recordings, and provision of a serum pulse enabled synchronisation of 
intracellular rhythms across the culture, even when cells were previously 12 hours out of 
phase with the new induced timing. Similarly, Welsh et al. (2004) monitored single-cell 
circadian rhythm bioluminescence of clock gene expression in Rat-1 fibroblasts, or primary 
fibroblasts dissociated from clock gene: Luciferase knock-in mice. In both experiments, 
individual cells possessed robust and independent circadian rhythms. However, as cells 
possess different period circadian rhythms (varying from 19.1 to 30.3 hours), there is a 
gradual loss of synchrony between individual cells. Therefore, although cells in culture 
possess a self-sustained endogenous oscillator, lack of intercellular coupling in dissociated
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fibroblast cell cultures leads to loss of rhythm synchronisation at the population level (Welsh 
et a l, 2004).
Following serum pulse observations, similar pulse experiments have been conducted by 
numerous groups and using a wide variety of pharmacological stimuli, including 
dexamethasone and glucose (Balsalobre et a l, 2000a; Hirota et a l, 2002). Using Luciferase 
under the control of a circadian gene promoter in vitro revealed that a serum pulse causes 
transcription of the clock gene Period followed by cyclic mRNA expression of other core 
clock elements. These macronutrients likely activate intracellular kinases, such as mitogen- 
activated protein kinase (MAPK), protein kinase A, and protein kinase C, which subsequently 
activate the CREB sequences in the promoters of core clock genes (Hastings et a l, 2003). 
For example, in NIH-3T3 fibroblasts, the inhibition of MAPK using a specific inhibitor of an 
upstream kinase prevents induction of circadian gene expression of core clock genes in a 
serum pulsed culture (Akashi and Nishida, 2000). Following degradation of early serum- 
induced clock genes, circadian gene transcription is then capable of beginning simultaneously 
across the cell culture, resulting in entrainment.
Interestingly, some core clock genes in peripheral tissues are capable of circadian rhythmicity 
in the absence of a functional oscillator. Robust ex vivo rhythms in one core clock gene were 
observed in mice with a liver-specific clock knock-out. However, rhythms from liver 
explants cultured in vitro could only be observed when the liver clock was functional 
(Kommann et a l, 2007). This suggests that, in the liver at least, local oscillators and systemic 
signals are capable of generating rhythms in some core clock genes, supporting the notion that 
peripheral clock entrainment occurs through systemic or neuronal cues that could be 
generated by the SCN.
Importantly, as with the retina (Tosini and Menaker, 1998), explants of peripheral tissues, 
such as the lung and cornea, cultured under temperatures ranging from 31-37°C exhibit tissue 
specific period lengths across the gradient. They are temperature compensated (Reyes et a l,
2008). This is imperative in maintaining set period length under differential temperature 
conditions around the internal set mean, whereas other biological reactions outside the clock 
mechanism proceed with a Qi0 of approximately 2 so that with every 10°C temperature 
increase, the reaction rates double.
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1.2.1.4 Mammalian molecular oscillator
Whilst photic input to mammalian clock gene expression entrains the endogenous oscillator to 
external cues as described earlier, the mechanism underlying this is the molecular oscillator. 
The molecular oscillator is comprised of a series of interconnected 
transcriptional/translational feedback loops, the cycle length of which equates to 
approximately 24-hours. Interestingly, the same core mechanisms function in both the SCN 
and peripheral tissues (Yagita et a l, 2001), although there are some differences, which will be 
discussed below.
Core members of the positive limb of the loop include basic helix-loop-helix (bHLH-PAS) 
proteins encoded by circadian locomotor output cycle kaput {Clock), its homologue neuronal 
Per-Amt-Sim (PAS) protein 2 {Npasl) (King et al, 1997), and brain and muscle amt-like 
proteins 1 and 2 (Email and Email) (Gekakis et a l, 1998). bHLH-PAS proteins are 
transcription factors with a bHLH motif facilitating DNA-binding, and a PAS region for 
protein heteromeric interactions (Edery, 2000; Sehgal, 2004). Key members of the negative 
limb include proteins encoded by two cryptochrome genes (Cryl and Cryl), and three period 
genes (Perl, Perl, and Per3) which also possess PAS regions (King and Takahashi, 2000; 
Sun et a l, 1997; Tei et a l, 1997). The orphan nuclear receptors, retinoid-related orphan 
receptor (Ror) and reverse of erythroblastic leukaemia virus a (Rev-erba) form part of a 
secondary loop.
In the positive limb, CLOCK and BMAL1 heterodimerise to form a complex capable of 
binding to E-box promoter sequences, for example the CACGTG motif (Edery, 2000; 
Gekakis et a l, 1998; Ueda et a l, 2005) and stimulating transcription of target genes, such as 
Per, Cry and Rev-erba. Clock mRNA and protein is constitutively expressed throughout the 
circadian day and night, whereas Email mRNA expression peaks in the middle of the night. 
Interestingly, the circadian oscillator is capable of functioning without CLOCK. Indeed, the 
presence of NPAS2 in the SCN of Clock'A mice rescues circadian rhythmicity by substituting 
for CLOCK to heterodimerise with BMAL1 and facilitate gene transcription through E-boxes 
(DeBruyne et a l, 2006; Kennaway et a l, 2006). However, in double mutants (Clockv~ and 
NpasTA), mice become arrhythmic in all tissues (DeBruyne et a l, 2007a). Additionally, some 
tissues require Npasl, for example in the forebrain to enable Perl expression (Hastings et a l,
2003), whereas liver and lung explants from Clock'A mice are arrhythmic despite
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compensatory Npas2 expression (DeBruyne et a l,  2007b). This suggests that CLOCK is 
obligatory in some peripheral tissues to maintain rhythmicity.
The most important regulatory mechanism of the B MALI/CLOCK transcription complex is 
the result of feedback inhibition from BMALI/CLOCK regulated output (Figure 1.3). 
Following translation in the cytoplasm, PER binds with itself, other PER proteins, CRY1 or 
CRY2 (Kume et a l, 1999) and, as shown using coprecipitation studies, forms large 
multimeric complexes with other proteins, such as casein kinases (CKIe and CKIÔ) (Lee et 
a l,  2001). It is these multimeric complexes that are believed to be important in the negative 
loop of the clock mechanism.
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Figure 1.3: Mammalian circadian clock mechanism. B MALI/CLOCK facilitates transcription of Per, Cry and 
Rev-erba. REV-ERBa negatively regulates transcription of Sm all. PER and CRY heterodimerise and enter the 
nucleus where the complex inhibits transcriptional activity of BMAL1/CLOCK. Black lines denote positive, and 
red lines negative regulation.
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Perl shows a higher amplitude rhythm than Perl in pre-adipocytes in NIH3T3 cells, which is 
suggested to be due to differential promoter activity between the two genes (Akashi et a l,
2006). For example, Perl has a classical E box sequence (CTCGTG), whereas Perl has a 
different E box motif (CTCGTT), both of which facilitate BMAL1/CLOCK binding. When 
the CTCGTT E box was replaced by the classical E box in the Perl promoter, Perl showed 
lower amplitude expression comparable to Perl. Interestingly, transgenic mPerl:Luciferase 
animals failed to show rhythms in reporter gene activity in peripheral tissues (Yoo et a l,
2004). Although the method for generation of the transgenic animals could explain this 
finding, another explanation is that Perl may be more dependent on external signals, such as 
blood-boume factors, rather than be cell autonomous like Perl. This may explain why Perl 
shows acute induction within 2 hours following a pulse, but lower amplitude rhythmicity 
thereafter.
PER and CRY do not possess bHLH regions to facilitate DNA binding, and thus must 
influence BMAL1/CLOCK transcriptional activity without promoter attachment (Sehgal,
2004). Once the PER/CRY multimeric complex reaches the nucleus, CRY interacts with 
BMALI/CLOCK, possibly via the C-terminus of BMAL1 (Kiyohara et a l, 2006), inducing 
post-translational modification of BMALI/CLOCK and/or recruitment of co-repressors 
(Etchegaray et a l, 2003). This blocks BMAL1/CLOCK E-box-mediated gene transcription 
(Kiyohara et a l, 2006; Sato et a l, 2006). Indeed, histones at the promoter regions of Perl, 
Perl, and Cryl have been shown to undergo rhythmic acétylation, a post-translational 
mechanism that is required for structural changes in chromatin to facilitate gene transcription. 
It is believed that the binding of negative regulators to the CRY/BMAL1/CLOCK complex 
disrupts the transcriptional co-activator complex, which contains histone acteyltransferase, 
and therefore blocks histone acétylation and thus transcription (Etchegaray ef a l, 2003). This 
results in new repressor functionality of the BMALI/CLOCK complex, and down-regulation 
of Per, Cry, and Rev-erba transcription. It is important to note that degradation of PER/CRY 
is essential for maintenance of rhythmicity. If negative regulators were allowed to 
accumulate, clock factors would reach equilibrium in the nucleus, and rhythmicity would be 
destroyed. Post-translational modifications (described in Section 1.2.1.4.1) of PER/CRY 
target the proteins for degradation, removing feedback inhibition of their transcription and 
enabling the cycle to begin again.
The molecular oscillator also possesses a secondary loop comprising RORa and REV-ERBa, 
which belong to the family of nuclear orphan receptors that bind to retinoid-related response
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elements (ROREs). There are two RORE sites located on the promoter of Email. Whereas 
RORa is a constitutively expressed activator of Email transcription, REV-ERBa is circadian, 
driven by BMALI/CLOCK E-box mediated transcription as described above, and competes 
with RORa for the RORE elements. At peak REV-ERBa levels in mice, the protein binds to 
the RORE elements as a monomer and dimerises with a consecutively bound REV-ERBa on 
the second RORE site of the same promoter (Preitner et a l, 2002). Subsequent recruitment of 
histone deacetylase and co-repressors results in chromatin remodelling, rendering 
transcription unfavourable (Wang et a l, 2006). Thus, Email expression is inhibited until 
REV-ERBa has been degraded as described in Section 1.2.1.4.1 (Gallego and Virshup, 2007; 
Preitner et a l, 2002; Wang et a l, 2006).
1.2.1.4.1 Post-translational modifications
Post-translational modification of clock proteins is essential for normal molecular oscillator 
function, and enables the clock to oscillate over 24 hours. This is achieved by altering 
cellular localisation of core oscillator components and/or by modifying protein stability. 
Some key mechanisms will be described below.
Accumulation of BMAL1/CLOCK in the nucleus is not circadian and therefore does not 
account for rhythmic gene transcription (Ripperger and Schibler, 2006). Although the 
BMALI/CLOCK complex appears to remain permanently bound to E-boxes throughout the 
circadian cycle, BMAL1 exhibits circadian protein turnover (Lee et a l, 2001). 
Immunoprécipitation analysis has shown that BMAL1 is rhythmically SUMOylated, which 
involves covalent linking of small ubiquitin-related modifier proteins (SUMO) to BMAL1 
lysine residues between the PAS domains of the BMAL1/CLOCK complex. This results in 
reduced BMAL1 stability, and subsequent circadian degradation (Cardone et a l, 2005).
PER/CRY complexes also undergo post-translational modification. One of the key regulators 
of PER/CRY and REV-ERBa activity is casein kinase I epsilon (CKIs). CKIe is one of a few 
casein kinase molecules, including CKIS and CKIy2, that is capable of phosphorylating PER 
proteins on multiple sites (Eide et a l, 2005; Shirogane et a l, 2005). Syrian hamster tau 
mutants have a natural mutation in the CKIe, resulting in a shortened circadian period, as 
defined by wheel running behaviour (Kuhlman and McMahon, 2006).
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Lee et a l (2001) showed that post-translational modification of PER/CRY enables 
translocation of the multimeric complex to the nucleus. Phosphorylation of PER by CKI is 
associated with the nuclear localisation signal, whereas CRY is required in the complex for 
PER stability (Lee et a l, 2001). Interestingly, CRY and CKIs are always expressed at higher 
levels than PER. Thus it appears that PER transcription or translation is the rate limiting step 
in cellular localisation. In contrast, CKIs-mediated hyperphosphorylation above threshold 
targets the PER/CRY complex for degradation and reaches a zenith prior to breakdown.
Emerging evidence suggests that CKI-mediated degradation of PER and CRY attracts F box 
proteins, which bind to clock proteins and act as adaptor molecules for ubiquitin ligases, such 
as SKP1-CUL1 -F-box-protein (SCF)Fbox E3 ubiquitin ligase (Shirogane et a l, 2005). This 
ubiquitin proteasome pathway subsequently involves covalent modification of lysines on the 
targeted protein with a small peptide monomer, ubiquitin. Polyubiquitin chains facilitate the 
binding of the targeted protein to a 26S-proteasome. This macromolecule unfolds 
ubiquitinated substrates, forces the polypeptide backbone through a proteolytic core, and 
thereby degrades the protein (Sehgal, 2004).
To date, numerous F box proteins have been identified in mammals, including FBXL3, 
FBXL21 and (3-transducin repeat-containing protein ((3-TrCP). FBXL3 is involved in the 
degradation of CRY, since a mutation in (Godinho ei a l, 2007), or silencing of (Busino et a l,
2007), the Fbxl3 gene results in an extended period, and suppression of Perl and Per2 
expression. This is consistent with increased CRY half-life (Siepka et a l, 2007), and 
therefore extended suppression of BMALI/CLOCK activity on E box-mediated Per 
transcription in FbxlS mutants. In contrast, FBXL21 binds to CRY1, and impairs CRY1- 
mediated transcriptional suppression of the BMAL1/CLOCK complex (Dardente et a l,
2008).
In comparison, (3-TrCP has been shown to bind to and facilitate PERI (Shirogane et a l, 2005) 
and PER2 (Reischl et a l, 2007) degradation in a phosphorylation dependent manner. Eide et 
a l (2005) showed that a dominant-negative form of (3-TrCP inhibits proteasome-mediated 
degradation of PER2. Interestingly, although there is evidence of circadian Fbxl21 
transcription driven by members of the proline and acidic amino acid-rich basic leucine zipper 
(PAR-bZip) family in the SCN (Dardente et a l, 2008), other F box proteins show no 
circadian rhythm (Busino et a l, 2007).
21
1.2.1.4.2 Clock controlled genes
The core oscillator regulates the expression of clock-controlled genes (CCGs) which, 
although not inside the core loop, are transcribed periodically as an output of the molecular 
clock. The first evidence for a direct circadian output from the molecular transcriptional 
machinery of the core clockwork was provided by Jin et a l (1999), who showed that 
BMALI/CLOCK acted through an E-box element in the Vasopressin gene to activate 
transcription in murine SCN. Other CCGs include the secretory signalling peptides 
transforming growth factor a (TGFa), arginine vasopressin (AVP), prokineticin 2 (PK2), as 
well as transcription factors such as albumin-D-element binding protein (Dbp), which has E- 
box sequences in the promoter region (Ripperger et a l, 2000), and the bHLH proteins Decl 
and Dec2. The latter are involved in downstream cascades of circadian gene expression, 
many products of which are involved in metabolism and homeostatic control of blood 
triglyceride and glucose (Schibler, 2005; Staels, 2006; Stratmann and Schibler, 2006). There 
are also genes that cycle in phase with BMAL1. These genes are characteristically enriched 
with RORE sequences and therefore under the control of REV-ERBa.
System-level identification of evolutionarily conserved cis elements show that clock-related 
and clock-controlled genes activate or repress transcription through binding to either E boxes, 
E’ boxes, D boxes or RREs (Ueda et a l, 2005). For example, microarray analysis has shown 
that more than 100 genes fluctuating from day to night in the liver are controlled by CLOCK 
through E-box elements (Duffield, 2003; Oishi et a l, 2003). Additionally, 7% to 21% of 
active genes in murine liver and fat tissue follow daily oscillatory patterns of expression 
(Ptitsyn et a l, 2006). However, whether these genes are directly regulated by the core clock 
elements, or whether they oscillate as a result of downstream rhythmic proteins remains to be 
elucidated.
1.2.1.5 Food entrainment
In preparation for feeding, animals exhibit food anticipatory activity (FAA), which includes 
increased locomotion, corticosterone secretion, body temperature and metabolic activity 
(Martinez-Merlos et a l, 2004). The presence of FAA was originally linked to the SCN. 
Evidence suggests that there is a coupling between light-entrainable rhythms and FAA, as 
phase shifting mice under DD with a light pulse also shifts the FAA (as measured by activity 
bursts prior to feeding), which is non-photosensitive (Challet et a l, 1998). However, FAA
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still exists in SCN-ablated animals, and in the absence of food. It is believed that this free- 
running rhythm in FAA is generated by a food entrained oscillator (FEO).
As the name suggests, the FEO is capable of being entrained by food provision under 
temporally restricted feeding regimens. This causes peripheral clocks to track food cues, 
over-riding the entraining signals from the SCN, which remains synchronised by photic input. 
To date, studies using restricted feeding schedules coupled with lesioning and analysis or 
downstream gene expression have suggested numerous candidates for housing the FEO and 
generating FAA. These include wake-promoting orexinergic neurons, mesencephalonic 
orphan nuclear receptors which are involved in sleep/wake cycles, such as Ear2 (Mendoza,
2007), and the dorsomedial hypothalamus (DMH), which is a neural site responsible for 
integrating circadian and energy information, with subsequent output to behavioural and 
physiological processes (Feillet et a l, 2006; Gooley et a l, 2006; Mieda et a l, 2006). 
However, DMH ablation and restricted daytime feeding caused no change in the reduction of 
FAA (Landry and Mistlberger, 2007; Landry et a l, 2007), and therefore the location of the 
FEO remains unknown.
Despite the controversy surrounding location of the FEO and key components responsible for 
driving FAA, possession of an FEO enables an organism to adjust to food availability in the 
wild. Thus, the organism is capable of assimilating sufficient nutrients even under caloric 
restriction (Choi et a l, 1998). Such a scenario may be replicated under laboratory conditions. 
In nocturnal rodents fed ad libitum, feeding occurs predominantly during the night phase. 
However, temporally restricting feeding to the light phase causes advances of circadian gene 
expression in peripheral tissues, such as the liver (Hara et a l, 2001), but not SCN (Cailotto et 
a l, 2005; Damiola e ta l, 2000).
Interestingly, the SCN is capable of being entrained to a temporally restricted hypocaloiic 
diet. This was shown through phase advanced pineal melatonin, locomotor activity, and 
vasopressin in the SCN, and also advanced Perl and Cryl oscillations (Mendoza et a l, 2005). 
The phase-response curve to light is also altered, with mice on a restricted hypocaloiic diet 
exhibiting no ‘dead zone’ which would normally occur in mid-light phase in normal fed mice 
(Resuehr and Olcese, 2005). Mice on a hypercaloric diet also exhibit altered SCN 
entrainment to photic stimuli through reduced light-mediated induction of c-fos (Mendoza et 
a l, 2008). This suggests that feeding can influence the timing of the central clock, although 
the exact mechanism has not yet been elucidated. Additionally, results to date show that the
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FEO is capable of generating a sustained free-running rhythm in both behavioural (such as 
FAA) and peripheral clock rhythms in vivo (Mistlberger, 1994; Stephan, 2002).
There is now increasing evidence for a link between peripheral clocks and food entrainment 
(Oishi et a l, 2002) as macronutrients and numerous metabolic hormones, such as 
glucocorticoids, are capable of entraining the peripheral oscillators (Balsalobre et a l, 2000a). 
Not only is the synthetic glucocorticoid, dexamethasone, able to synchronise cells in vitro 
(Balsalobre et a l, 2000a), but the hormone also delays entrainment of peripheral clocks in the 
liver and kidney to restricted daytime feeding (Le Minh et a l, 2001). Interestingly, this did 
not occur on the reverse protocol from day-feeding to night-feeding. This was supported by 
studies in mice with glucocorticoid receptor (GR) null alleles that exhibited hepatic 
entrainment to daytime feeding in two days comparable to the entrained state observed after 
one week in wild-type mice (Le Minh et a l, 2001). The mechanism may be via Rev-erba 
suppression as, in the rat liver and isolated rat hepatocytes, Northern blot analysis has shown 
that dexamethasone decreases Rev-erba expression in a dose-dependent manner via the GR 
(Torra et a l, 2000). Whether this is a separate function from the molecular clock is unknown. 
However, while these data suggest glucocorticoids could be one potential mechanism 
whereby the peripheral clocks could be entrained, other inputs, such as the sympathetic 
nervous system, might be involved. Therefore, the factors most important for entrainment to 
restricted feeding continue to be speculated, and a combination of multiple redundant factors 
may be involved.
To date, both neuronal and humoral agents have been examined, with most evidence 
supporting a role for blood-borne factors (Stratmann and Schibler, 2006). It is possible that 
feeding itself may directly affect phase resetting of peripheral clocks via restricted 
macronutrient provision (Schibler et a l, 2003). This has been shown in vitro where 
previously oscillatory, but desynchronised, cell populations have become entrained following 
a serum pulse (Balsalobre et a l, 1998).
Restricted feeding also alters the catabolic/anabolic state of the cell. In vitro, it has been 
shown that the redox co-factors NADH and NADPH increase the affinity of BMAL1/CLOCK 
and BMAL1/NPAS2 for their target DNA (Shimba et a l, 2005). Therefore, a ‘redox’ model 
has been proposed, which will be influenced by the metabolic state of the cell and, therefore, 
feeding regimens (Nakahata et a l, 2009; Ramsey et a l, 2009; Rutter et a l, 2001).
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The presence of both hormonal, neural, and macronutrient control over phase resetting of 
peripheral clocks suggests that the FEO is not a single component, but rather food 
entrainment and FAA involves a complex mechanism controlled by many factors. The 
dissociation of peripheral oscillators from the SCN observed under restricted feeding 
regimens is caused by abrupt dissociation of behaviour from endogenous rhythms. This could 
account for many problems observed in shift workers, such as increased plasma triglyceride 
concentrations, insulin resistance, obesity, and type 2 diabetes. Shift workers exhibit altered 
feeding patterns, which could potentially result in uncoupling of peripheral oscillators from 
the master clock (Young and Bray, 2007). Indeed it is now well known that a shift in the 
external time cues, such as a phase advance, causes re-entrainment of the SCN and peripheral 
tissues at different rates. A murine study used a 6-hour phase advance in light, resulting in 
SCN, thymus and lung re-entrainment after 3 days, but up to 5 days for spleen and 
oesophagus resetting (Davidson et a l, 2008). Therefore, any shift in timing will cause 
desynchrony of clocks across the body, and altered metabolic capability as a result.
Numerous studies have analysed effects of timing of feeding, and type of food, on peripheral 
clocks, but these have predominantly focussed on the liver. Another key metabolic regulator 
is adipose tissue. The rest of this review will describe the physiology of adipose tissue and 
the link between metabolism and the circadian clock.
1.3 ADIPOSE TISSUE
There are two types of adipose tissue; brown adipose tissue (BAT) and white adipose tissue 
(WAT). BAT plays an important role in non-shivering thermogenesis, which explains the 
high metabolic activity observed in this tissue type. Thermogenesis occurs primarily through 
metabolism of fatty acids following noradrenaline stimulation through ^-receptors (Cannon 
and Nedergaard, 2004). In humans, most BAT disappears after birth and, therefore, this 
review will focus on WAT.
1.3.1 White adipose tissue
WAT is a highly vascularised, heterogeneic tissue, comprised of various cell types, including 
macrophages, fibroblasts, pre fat cells (pre-adipocytes) and mature fat cells (adipocytes) 
(Haugen and Drevon, 2007). In addition to acting as an energy storage site and providing 
protection in the form of padding and insulation, WAT has been linked to the control of
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energy homeostasis, feeding behaviour, reproductive function, and metabolic regulation 
(Grégoire et a l, 1998). These effects are mediated by production and release of cytokines, 
chemokines and adipose-derived hormones. These adipose-derived factors are collectively 
termed adipokines, which have enabled WAT to be recognised as an endocrine organ, and 
will be discussed later in Section 1.3.5. Although adipose tissue forms in many different 
sites, it is generally in areas of loose connective tissue (e.g. subcutaneous adipose tissue), and 
around body organs (visceral adipose tissue), such as the heart and kidneys, where it plays a 
protective role under normal conditions (Rosen et a l, 2000) and both provides and stores 
energy. This energy is stored in the form of triglyceride.
Triglyceride accounts for approximately 77% of total energy stored in the body (Mathews et 
a l, 2000). When energy needs of the body cannot be met by circulating fuel or stored 
carbohydrate, WAT lipolysis liberates energy, from stored triglycerides, to the circulation in 
the form of free fatty acids (FFAs) and glycerol (Feve, 2005; Schaefer et a l, 1983).
1.3.2 Adipocyte differentiation
Production of mature adipocytes can be explained by the adipocyte lifecycle hypothesis, 
which states that adipocytes ‘accumulate triacylglycerols during their life cycle, up to a 
maximum, after which proliferation is triggered’ (Smith et a l, 2006). Adipocyte proliferation 
occurs as a result of the differentiation process, during which pre-adipocytes, derived from 
mesenchymal stem cells, become mature adipocytes (Rosen and MacDougald, 2006). Two 
phases of adipocyte differentiation exist. The first is termed determination, where a 
pluripotent stem cell is committed to the adipocyte lineage. The resultant adipoblast pre­
adipocyte cell is morphologically identical to its precursor, but has lost the ability to 
differentiate into any other cell type. In the second, terminal differentiation phase, the cell 
becomes a mature adipocyte (Figure 1.4), which involves acquisition of gene expression to 
control lipogenesis and lipolysis, insulin sensitivity (Rosen, 2005), and other factors 
characteristic of a mature adipocyte (Rosen and MacDougald, 2006).
Thanks to the availability of suitable in vitro models, terminal adipocyte differentiation is now 
temporally and biochemically well characterised. To date, various immortalised cell lines, 
which recapitulate key features of differentiation in vivo, have been used to model adipocyte 
differentiation in vitro; committed murine 3T3-L1 and 3T3-F442A pre-adipocyes are 
examples.
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Figure 1.4: Phases of adipocyte differentiation. Diagram illustrating the different stages of adipocyte
differentiation and some of the factors expressed (Feve, 2005).
Adipogenesis is controlled by numerous humoral factors. Glucocorticoids form one of a 
variety of agents used to differentiate adipocytes in vitro. An example is dexamethasone, 
which is a synthetic glucocorticoid. Glucocorticoids activate expression of early 
differentiation factors, such as peroxisome proliferator activated receptor y (PPARy) and 
CCAAT/enhancer binding protein [3 (C/EBP(3) (discussed in more detail in Section 1.3.2.3), 
and also suppress transcription of Pre-adipocyte factor 1 (Pref-1), an inhibitor of 3T3-L1 
adipocyte differentiation (Feve, 2005).
Insulin is able to stimulate MAPK activation via the ERK pathway, providing a stimulant to 
drive clonal expansion and begin differentiation (Post et a l, 2005; Feve, 2005). Insulin 
signalling through insulin-like growth factor 1 (IGF-1) receptors at the start of differentiation 
also promotes CREB phosphorylation, and therefore allows gene transcription to occur via 
stimulation of CREs. Hence, insulin plays an important pro-adipogenic role in in vitro 
differentiation ‘cocktails’ (Rosen and MacDougald, 2006).
1.3.2.1 Humoral factors stimulating adipocyte differentiation
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1.3.2.2 Cellular and Phenotypic changes
Following induction of differentiation, pre-adipocytes undergo various morphological and 
phenotypic changes. In vitro adipogenesis in immortalised cell lines, such as 3T3-L1 cells, is 
characterised by cessation of growth upon reaching cell confluence (although confluence is 
not required as other agents are capable of inducing growth arrest) (Rosen et a l, 2000). There 
is a subsequent DNA amplification phase, resulting in approximately two rounds of cell 
division and, therefore, clonal expansion. In vivo, such clonal expansion does not occur, but 
humoral agents and locally produced factors account for stimulation of adipogenesis.
As can be seen in Figure 1.5, terminal adipocyte differentiation includes morphological 
changes in cell shape from stellate pre-adipocytes, to mature spherical adipocytes. This is 
accompanied by de novo lipogenesis, with accumulated intracellular lipid droplets coalescing 
to form large unilocular triglyceride globules (Azain, 2004; Rosen, 2005).
Figure 1.5: Morphological changes in adipocyte differentiation. Diagram illustrating the different phases of 
adipocyte differentiation where yellow depicts triglyceride droplets.
28
Although differentiating adipocytes accumulate triglyceride (Grégoire et a l, 1998), fat 
content is not responsible for adipocyte morphology. Rather, morphology is controlled by 
structural changes in the extra-cellular matrix (Kubo et a l, 2000). Coincident with this is the 
expression of key transcription factors regulating adipogenesis, which will be discussed in the 
following Section.
1.3.2.3 Transcriptional control of adipocyte differentiation
In both in vitro and in vivo systems, terminal adipocyte differentiation is followed by the 
appearance of early (within hours), intermediate (before 6 days) and late (after 6 days) gene 
expression (lessen and Stevens, 2002). This illustrates the change in gene expression from 
genes activated to promote early differentiation to those expressed later, which signal 
adipocyte maturity and are involved with general adipocyte function.
There are many molecules involved in the regulation of adipocyte differentiation, but only the 
main coordinators will be discussed here. Key transcriptional regulators of adipogenesis 
include members of the PPAR, C/EBP, and bHLH families, such as sterol-regulatory element 
binding proteins (SREBP) (Feve, 2005).
PPARs are early expressed, ligand activated transcription factors that form a family of nuclear 
hormone receptors. In humans, there are three main PPARs: PPARy, PPARS (also called 
PPARP) and PPARcc (Hong et a l, 2005). Although Ppara and —<5 are expressed in early 
differentiation, the most predominant form in adipogenesis is Ppary, which is also required 
for maintenance of the differentiated state (Rosen and MacDougald, 2006). PPARy ligands, 
which include natural fatty acids, enable PPARy heterodimerisation with retinoid X receptor 
gamma (RXRy) in the nucleus. The resultant heterodimer binds to the peroxisome 
proliferator response element (PPRE) in the promoter regions of target genes. Cofactors with 
histone acetylase activity are recruited, facilitating the transcription of PPARy target genes 
(Kota et a l, 2005).
In contrast, C/EBPs belong to the basic-leucine zipper class of transcription factors. In 
adipogenesis, the key isoforms are C/EBPa, -(3, and -5. They act as homo- or heterodimers, 
and are not adipocyte specific, but are also found in hepatocytes and granulocytes where they 
are involved in terminal differentiation of cells (Rosen et a l, 2000). C/Ebpfi and -JmRNA 
increases early in adipogenesis in response to adipogénie factors, causing a downstream exit
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from the cell cycle, which is required for continuance of adipogenesis (Feve, 2005). C/EBPp 
and -5 are also responsible for the expression of early adipogénie markers Ppary and, 
subsequently, C/Ebpa, which are also anti-mitotic. Support for C/EBPa in adipogenesis 
arises from over expression of the gene in 3T3-L1 cells, where it induces pre-adipocyte 
differentiation into mature adipocytes and promotes insulin sensitivity (Rosen and 
MacDougald, 2006). Antisense RNA targeted to C/Ebpa mRNA  blocks adipogenesis in vitro 
(Lin and Lane, 1992).
PPARy and C/EBPot activate expression of genes characteristic of the adipocyte phenotype, 
such as fatty acid synthase (FAS), glycerophosphate dehydrogenase, acyl CoA carboxylase, 
glucose transporter 4 (GLUT- 4), insulin receptors and adipocyte protein 2 (aP2) (Laitinen et 
a l, 2005). Lipid droplets appear during this process and form large cytoplasmic fat globules. 
Although PPARy ligands have not yet been fully characterised, it is believed that they act in a 
cAMP-dependent manner during the first two days of 3T3-L1 differentiation (Rosen and 
MacDougald, 2006).
Both PPARy and C/EBPa are required for terminal differentiation of pre-adipocytes into 
mature adipose cells. Indeed, homozygous knock-out of either Ppary or C/Ebpa genes results 
in failure of adipose tissue to develop in vivo (Wang et a l, 1995). Evidence now suggests a 
strong synergistic link between the two genes as each increases expression of the other (Feve,
2005). For instance, PPARy is required to release histone deacetylase-1 from the C/EBPa 
promotor, thus allowing transcription.
Srebplc transcription is also important for adipogenesis, particularly the lipogenic pathway. 
It is believed that the transcription factor SREBP 1c induces expression of Ppary through 
transcription of a PPARy ligand (Feve, 2005). A summary of relationships between pro- 
adipogenic factors can be seen in Figure 1.6.
1.3.3 Fatty acid uptake by adipocytes
In the post-prandial phase, mature adipocytes take up large amounts of glucose in response to 
insulin, and absorb both non-esterified fatty acids free in plasma (Pegorier et a l, 2004), and 
fatty acids liberated from circulating chylomicrons (preferentially) or low density lipoprotein 
(LDL) (Bickerton et a l, 2007).
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Release of fatty acids from chylomicrons requires lipoprotein lipase (LPL), a cell surface 
enzyme particularly prevalent in capillaries running through adipose tissue, but also expressed 
by adipocytes. LPL hydrolyses triglycerides on chylomicron surfaces, allowing adjacent cells 
to absorb and subsequently oxidise fatty acids for energy (Bickerton et a l, 2007). 
Monoglycerides and glycerol remain in the blood and are eventually metabolised by the liver, 
or used to make glucose, as in the case of glycerol (Germann and Stanfield, 2002).
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Figure 1.6: Links between transcription factors important for adipogenesis.
For utilisation of circulating LDL, specific receptors migrate to adipocyte cell surfaces where 
they cluster in clathnn-coated pits and bind to LDL apoprotein. Once bound to its receptor, 
the LDL is internalised in endocytotic vesicles, with vesicular fusion to form an endosome. 
LDL is then disassociated from the receptor by hydrogen ion pumping into the vesicle, and 
fusion with a lysosome results in cholesterol ester hydrolysis to give cholesterol, and FFA 
liberation (Mathews et a l, 2000). In adipocytes, fatty acids are recombined with glycerol 
synthesised within the cell to make triglycerides. These can then be stored within the cell in 
the form of lipid droplets.
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Although insulin acutely stimulates glucose uptake into adipocytes post-prandially, this is 
only a small amount (approximately 10-15%) compared to that taken into muscles (Kahn, 
1996). Insulin causes recruitment of the GLUT-4 from an intracellular pool to the plasma 
membrane (Host et a l, 2005). Glucose is then transported into the adipocyte where it is 
stored in the form of triglyceride (Azain, 2004; Bartness and Bamshad, 1998).
1.3.4 Control of fatty acid release from adipose depots
To date, there is evidence for both neural and humoral control of adipocyte lipolytic function.
1.3.4.1 Neural regulation: the sympathetic nervous system
Evidence for the role of sympathetic nervous system (SNS) innervation of WAT arises from 
studies showing that adipocytes express adrenoceptors, and approximately three percent of 
adipocytes possess direct neural links (Turtzo et a l, 2001). More recent studies using 
transneuronal tract tracers reveal innervation from the brain down to WAT (Kalsbeek et a l, 
2001; Song et a l, 2009). Furthermore, Bartness and Bamshad et a l (1998) report that 
denervation of adipose connections impairs lipolysis, suggesting a role for the SNS in 
lipolytic control. However, much debate has surrounded the theory, as it is possible that the 
reduced lipolytic function in denervated adipose tissue could be the result of decreased blood 
flow, and thus reduced blood-boume adrenergic agonists.
Pi-3- and 012-adrenoceptors co-exist on the same adipocytes, and share the catecholamine 
agonists noradrenaline and adrenaline. However, adrenaline possesses higher affinity for 012- 
adrenoceptors while noradrenaline preferentially activates (3-adrenoceptors (Carmen and 
Victor, 2006). When lipolysis predominates, the primary catalytic enzyme in triglyceride 
breakdown (hormone-sensitive lipase, HSL) is activated through cAMP-dependent 
phosphorylation (Brasaemle et a l, 2000), yielding di- and monoacylglycerol and ultimately 
leading to the liberation of FFAs and glycerol (Slavin et a l, 1994). However, the (3 and a 
receptors have different effects on the second messenger adenylate cyclase responsible for 
cAMP production. Whereas B-adrenoceptors stimulate adenylate cyclase, 012-adrenoceptors 
inhibit this enzyme. Therefore, the net lipolytic response to catecholamines is determined by 
the balance of (3- and a2-adrenoceptor-mediated signal transduction (Lafontan et a l, 1995). 
That is, the more (3-adrenoceptor in relation to «2 receptor activity, the greater the lipolytic 
action of HSL in the adipocyte (Lafontan, 2005).
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Although humoral catacholamines are likely the predominant mode of adipose adrenergic 
receptor stimulation, they are not at high enough concentrations in the blood to stimulate the 
Bg-adrenoceptor (Lafontan et a l, 1995). Thus, for effective stimulation of the latter receptor 
subtype, innervation would be important, further supporting a role for the SNS neuron- 
derived catecholamines in adipose tissue lipolysis.
Not only does the degree of sympathetic activity affect the activation of these receptors, but 
numerous physiological factors influence which receptor type predominates. Fasting has been 
shown to increase (3-adrenoceptor activity whilst reducing a-adrenoceptor numbers (Ostman 
et a l, 1984), while exercise acutely increases the (3-adrenoceptor-mediated lipolytic effect 
(Wahrenberg et a l, 1987). There are also regional differences in the distribution of these 
receptor subtypes between adipose sites, such as a higher o^-: (3-adrenoceptor ratio in the 
subcutaneous depot (Mauriege et a l, 1987). Other hormones have also been shown to 
regulate adrenoceptor expression, for example dexamethasone increases (3-adrenoceptor 
expression (Hadcock and Malbon, 1988), while thyroid hormones increase lipolytic activity 
(Giudicelli, 1978). It is the overall balance between these various factors that influences the 
lipolytic: antilipolytic activity in the adipocyte.
1.3.4.2 Humoral regulation
Other than adrenaline, the key humoral factors involved in controlling adipocyte lipolysis in 
humans are insulin and natriuretic peptides.
Insulin potently inhibits lipolysis by binding to, and causing tyrosine phosphorylation of, 
insulin receptors. Subsequent interactions with insulin-like receptor substrates (IRS-1 and 
IRS-2) result in phosphatidyl inositol 3-kinase activity, and phosphodiesterase-3 A activation 
through phosphorylation. Phosphodiesterase-3A is responsible for the breakdown of cAMP, 
and thus reduced activity of HSL (Amer, 2005). Hyperinsulinaemia is capable of 
antagonising the catecholamine (3-adrenoceptor pathway.
In contrast to insulin, natriuretic peptides, a family of peptides exerting potent diuretic, 
natriuretic and vasodilator effects, are lipolytic in humans. Atrial natriuretic peptide (ANP) is 
involved in exercise related lipid mobilisation from adipocyte triglyceride stores (Moro et a l, 
2004a). This is achieved by ANP binding to fat cell plasma membrane receptors (NPR-A), 
activating guanylyl cyclase with subsequent production of cyclic guanylyl monophosphate
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(cGMP). In contrast to the increase in phosphodiesterase-3A activity observed following 
insulin stimulation, the cGMP pathway results in inhibitory phosphorylation of 
phosphodiesterase-3A, resulting in increased HSL activity (Moro et a l, 2004b).
1.3.5 Adipokines
In addition to being an energy storage site, which receives input from the endocrine system, 
adipose tissue itself synthesises and secretes a number of signalling molecules, collectively 
termed adipokines. Here, key adipokines will be described.
1.3.5.1 Leptin
Leptin is a 16 kDa proteohormone product of the ob gene (Gimeno and Klaman, 2005), the 
synthesis of which is restricted to mature adipocytes. To date, various splice isoforms of the 
leptin receptor (Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd and Ob-Re) have been discovered (Meier and 
Gressner, 2004). Leptin exerts effects both centrally, in the hypothalamus, and in numerous 
peripheral tissues, including the liver, skeletal muscle, adipose tissue, and the pancreas. 
Circulating leptin levels are also positively correlated with the amount of adipocyte 
triglyceride (Langendonk et a l, 1998).
In the hypothalamus, leptin acts as a satiety hormone to suppress appetite. This is likely 
mediated through Ob-Rb, which is expressed at high levels in the feeding centres of the 
hypothalamus (Myers et a l, 2009). Leptin crosses the blood-brain barrier via leptin 
transporters Ob-Ra and Ob-Rc. Once bound to Ob-Rb at the hypothalamus, leptin activates 
the JAK-STAT3 pathway, acting as an afferent signal to inform the feeding centre of the 
hypothalamus of body fat status (Bjorbaek et a l, 1997; Ghilardi and Skoda, 1997).
The key roles of leptin in adipose tissue include glucose uptake, fat storage and metabolism 
(Meier and Gressner, 2004; Mistry et a l, 2004). Stimulators of leptin synthesis include 
overfeeding, insulin, and glucocorticoids. Increased insulin levels after feeding result in 
raised leptin production. In contrast, fasting, cAMP and Ps-adrenoceptor agonists cause 
suppression of leptin levels (Meier and Gressner, 2004).
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1.3.5.2 Adi pone clin
Adiponectin is a 30 kDa adipokine secreted specifically by mature adipocytes. Its secretion 
is stimulated by insulin and IGF-1 in WAT. Adiponectin assembles into trimers, hexamers 
and higher molecular weight structures (Chandran et a l, 2003; Gimeno and Klaman, 2005). 
To date, two receptors have been cloned: AdipoRl and AdipoR2 (Bjursell et a l, 2007; Liu et 
a l, 2007b). AdipoRl is found primarily on skeletal muscle, whereas AdipoR2 is more 
prevalent on hepatocytes.
The location of adiponectin receptors is consistent with its known roles in glucose and lipid 
homeostasis. Adiponectin increases fatty acid oxidation and metabolism in skeletal muscle, 
and reduces lipid and glucose synthesis in the liver (Yoon et a l, 2006). As a result of the 
latter, there are reductions in circulating glucose and FFA concentrations, and subsequent 
reduced triglyceride formation in adipocytes (Meier and Gressner, 2004).
Adiponectin plays a protective role against insulin resistance. This is achieved in two ways. 
Firstly, adiponectin enhances insulin actions through binding to the insulin receptor and 
increasing receptor affinity for insulin. Secondly, adiponectin increases GLUT-4 receptor 
production, and potentiates translocation to the cell surface (Fu et a l, 2005). Uptake of 
glucose by adipocytes occurs through the GLUT-4 receptor (Bost et a l, 2005), which resides 
on intracellular membranes, but is translocated to the cell surface following acute insulin 
stimulation.
1.3.5.3 Resistin
Resistin is a 12.5 kDa adipokine, which has divergent roles between mice and humans, as 
demonstrated by the incomplete homology between human and mouse resistin, and the 
absence in humans of one of the three murine resistin isoforms. The protein circulates in the 
blood as a dimeric protein linked by a disulphide bridge (Arana et a l, 2003) and is secreted 
exclusively by adipocytes in mice, but by the stromovascular fraction of adipose tissue, 
primarily macrophages, in humans (Meier and Gressner, 2004). In mice, resistin has been 
shown to increase circulating insulin and glucose concentrations, but to reduce insulin- 
mediated glucose uptake (Li et a l, 2009). This is characteristic of insulin resistance. In 
contrast, although resistin has been suggested to cause insulin resistance in humans (Luo et
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a l, 2009), it appears to be primarily involved in the recruitment of other immune cells, and 
the secretion of pro-inflammatory factors (Barnes and Miner, 2009).
1.3.5.4 Visfatin
Visfatin is a recently discovered 52 kDa adipokine of the visceral fat depot that exerts insulin 
mimetic activity by binding to and activating the insulin receptor at a site distinct from insulin 
(Ando et a l, 2005; Gimeno and Klaman, 2005; Klein et a l, 2006). Because circulating levels 
of visfatin are lower than the affinity for insulin receptors, it is believed that visfatin acts in an 
autocrine or paracrine manner.
1.3.5.5 Inflammatory mediators
Adipose tissue produces many inflammatory mediators, including tumour necrosis factor a 
(TNFa), interleukin-6 (IL-6), IL-8, IL-10, and macrophage inflammatory proteins (Lumeng et 
a l, 2007). Most are produced primarily by adipose macrophages, although adipocytes do 
secrete some (Gimeno and Klaman, 2005; Juge-Aubry et a l, 2005). To date, it has been 
shown that TNFa has paracrine effects on adipocyte metabolism and endocrine function 
(Rajala and Scherer, 2003).
TNFa has been shown to increase leptin levels, decrease adiponectin secretion, and 
antagonise PPARy, thus reducing lipogenesis (Trujillo and Scherer, 2006). It is also capable 
of upregulating HSL activity within the adipocyte through cAMP elevation and HSL 
phosphorylation. This lipolytic role is supported by a TNFa-mediated reduction in perilipin 
levels. Perilipin is an adipocyte specific protein that coats the adipose lipid droplets, 
protecting them from HSL-mediated hydrolysis. TNFa signalling pathways are capable of 
both reducing perilipin production, and phosphorylating the protein. This reduces the lipid 
droplet perilipin protection against HSL activity, and thus FFA liberation occurs (Amer,
2005).
1.4 METABOLIC SYNDROME: OBESITY. INSULIN
RESISTANCE AND TYPE 2 DIABETES MELLITUS
The term ‘metabolic syndrome’ covers such disorders as obesity, type 2 diabetes mellitus, 
atherosclerosis, and various other pathologies. Although adipose tissue regulates many of
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these diseases, for example through secretory products, here the focus will be on obesity and 
subsequent insulin resistance and type 2 diabetes (Gimeno and Klaman, 2005; Havel, 2004).
1.4.1 Obesity
Obesity is an increasing global problem, and is known to be associated with high dietary 
calorie intake, lack of physical activity, and genetic susceptibility. It is characterised by low- 
grade inflammation of adipose tissue, raised plasma FFA levels, and changes in cytokine and 
adipokine expression (Rajala and Scherer, 2003). Obesity is also linked with increased 
adipocyte triglyceride content to levels above normal (hypertrophy) and to recruitment of 
higher numbers of new adipocytes from precursor cells (hyperplasia). Thus, obesity is 
partially dependent on regulation of adipocyte differentiation (Bost et a l, 2005) and 
subsequent lipid uptake.
Inflammation during obesity results from the recruitment of macrophages from circulation 
into adipose tissue (Lumeng et a l, 2007). Both the increased presence of pro-inflammatory 
cells, such as monocytes and macrophages, and adipocyte hypertrophy, result in expression of 
cytokines that can modify whole body insulin sensitivity. Simultaneously, adipokine 
production is altered. For example, elevated leptin production and secretion, together with 
suppressed adiponectin levels, result in whole body metabolic disturbance as will be described 
in Section 1.4.3.1.
1.4.2 Insulin resistance and type 2 diabetes
Type 2 diabetes, previously known as ‘adult onset’ diabetes, is also termed non-insulin 
dependent diabetes as insulin infusion does not negate the pathology. This type of diabetes is 
often secondary to obesity. Under normal physiological conditions, post-prandial insulin 
surges lower blood glucose levels by facilitating glucose uptake into peripheral tissues, such 
as skeletal muscle and adipose tissue. Simultaneously, insulin suppresses glucose production 
by the liver, for example by inhibiting phosphoenolpyruvate carboxykinase (PEPCK), a key 
enzyme in gluconeogenesis (Schinner et a l, 2005).
However, during type 2 diabetes, normal plasma insulin and glucose concentrations are 
disturbed for two key reasons. Firstly, there is impaired responsiveness of skeletal muscle 
and adipose tissue to insulin, termed ‘insulin resistance.’ This results in increased
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compensatory insulin output from the pancreatic (3-cells and hyperinsulinaemia. 
Hypertriglyceridaemia also develops at this stage as the liver, still insulin responsive and now 
exposed to day long increases in plasma insulin and FFA, upregulates very low density 
lipoprotein (VLDL) triglyceride synthesis and secretion (Reaven et a l, 1967). Secondly, 
there is a failure of (3-cells to secrete the required levels of insulin to maintain normal fasting 
glucose levels. This results in reduced insulin-dependent clearance of plasma glucose, which 
is exacerbated as the liver, by this time insulin resistant, continues to release glucose. The 
consequence is hyperglycaemia. These changes result in type 2 diabetes (Guilherme et a l,
2008), which is characterised by insulin resistance, persistent hyperglycaemia due to reduced 
glucose uptake and use by many tissues, and relative hypoinsulinaemia as, although still 
within normal range, insulin levels are too low in relation to the hyperglycaemia (Germann 
and Stanfield, 2002).
1.4.3 Obesity as a causal factor in type 2 diabetes
Although there are genetic risk factors associated with diabetes, there is now much evidence 
to support a major role for increased adiposity and obesity in the onset and pathology of type 
2 diabetes. This occurs primarily through the secretion of inappropriate levels of adipokines, 
increased adipose FFA output and decreased adipogenesis (Dubois et a l, 2006).
1.4.3.1 Altered adipokine and cytokine secretion
1.4.3.1.1 Adiponectin and TNFa
In lean and healthy individuals, adiponectin reduces secretion of TNFa from macrophages. 
However, as a result of macrophage recruitment to adipose tissue during obesity, increased 
levels of adipocyte- and macrophage-derived TNFa inhibit adipocyte adiponectin production 
(Lacasa et a l, 2007; Wame, 2003). Thus, irregularly low levels of adiponectin detected in 
hypertrophic adipocytes remove inhibitory effects on TNFa production, thus further 
increasing TNFa concentration in adipose tissue (Meier and Gressner, 2004).
TNFa inhibits insulin signalling at the whole body level, and also adiponectin-mediated 
insulin sensitising effects in adipose tissue (Trujillo and Scherer, 2006). Thus both low 
adiponectin levels, and raised TNFa concentrations, are implicated in the pathology of type 2 
diabetes, particularly insulin resistance (Meier and Gressner, 2004). TNFa also raises plasma
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FFA levels in circulation via perilipin deactivation and HSL upregulation, thus contributing to 
the elevated FFA levels observed in type 2 diabetes (Amer, 2005).
1.4.3.1.2 IL-6
Like TNFa, the cytokine IL-6 is overexpressed in adipose tissue, predominantly the 
stromovascular fraction (including macrophages), during obesity and type 2 diabetes. IL-6 
interferes with insulin signalling, and also increases leptin secretion and lipolysis (Permana et 
a l, 2006). Thus, IL-6 promotes elevated circulating FFA levels, exacerbates problems of
insulin resistance, and contributes to endocrine changes of leptin seen with metabolic
syndrome.
1.4.3.1.3 Leptin
Leptin production is positively correlated with adipocyte triglyceride content. However, 
whilst hypertrophic adipocytes express higher levels of leptin (hyperleptinaemia), either 
saturable transport of the proteohormone across the blood-brain barrier, or anomalies in Ob-R 
activation and signal transduction, result in leptin resistance. As such, obese individuals 
become hyperphagic, exacerbating the problem of obesity by continuing to raise caloric intake 
(Meier and Gressner, 2004).
Leptin is also partially responsible for elevated plasma FFA observed in type 2 diabetes. 
Leptin stimulates lipolysis in adipocytes, and inhibits Srebpl expression in adipose tissue, 
resulting in reduced lipogenesis (Fruhbeck et a l, 1997; Yu and Ginsberg, 2005).
1.4.3.1.4 Resistin
In murine models, circulating resistin concentration has been positively correlated with type 2 
diabetes and obesity. Infiltration of macrophages and monocytes during inflammation 
associated with obesity in mice, results in elevated resistin levels, and increased insulin 
resistance. This infiltration process is likely induced by inflammatory mediators, such as 
TNFa and lipopolysaccharides (Gimeno and Klaman, 2005). However, the role of resistin in 
human type 2 diabetes is controversial as, in contrast to mice, no correlation has been found 
with obesity, diabetes, or insulin sensitivity (Meier and Gressner, 2004).
39
1.4.3.2 Elevated FFA release
As adipocyte size increases, efflux of FFA into circulation also rises (Amer, 2005). Insulin 
normally stimulates adipocyte triglyceride synthesis but when insulin resistance and relative 
hypoinsulinaemia occurs in type 2 diabetes, lipolysis predominates resulting in further efflux 
of FFA into the blood (Kahn and Flier, 2000).
Sustained elevation of FFA leads to increased pancreatic |3-cell intracellular FFA. To begin 
with, this causes increased insulin production as part of the insulin resistance syndrome (albeit 
hypoinsulinaemia relative to circulating glucose levels). However, as FFA accumulates, they 
are converted to ceramides by the (3-cell via non-oxidative metabolism. This leads to 
downstream production of nitric oxide, resulting in (3-cell apoptosis and decline in (3-cell 
function, ultimately resulting in an inability of (3-cells to maintain plasma hyperinsulinaemia. 
This augments the development of type 2 diabetes (Lee et a l, 1994; Wyne, 2003).
1.5 LINKING CIRCADIAN BIOLOGY TO OBESITY
AND TYPE 2 DIABETES
There is now a plethora of evidence linking the circadian clock to metabolism and adipose 
tissue biology. Shift work data has shown that disturbance of circadian rhythms leads to 
increased risk of metabolic syndrome, and metabolic disturbances such as elevated 
triglyceride (Morgan et a l, 1998; Ribeiro et a l, 1998). Other data include rhythmic 
expression and plasma circulation of adipokines (Kalsbeek et a l, 2001; Sinha et a l, 1996), 
and circadian rhythms in important metabolic enzymes, including adipose LPL (Benavides et 
a l, 1998). More recently, studies have begun to address possible links between adipose 
physiology and molecular components of the circadian clock. There is now evidence derived 
from studies of clock mutant animals, interactions between clock proteins and metabolic 
factors, and analysis of central and peripheral clocks in disease states, that provides 
compelling evidence for a cross-link between the molecular oscillator and metabolism.
1.5.1 Effects of sleep and shift-work on metabolic risk factors
As well as disrupting sleep patterns, it is common during shift-work for the endogenous clock 
and external environment to be dissociated from the sleep/wake cycle. Such dyssynchrony in
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the body results from the phase advances and delays that shift-workers undergo when 
changing shift patterns. These lead not only to dyssynchrony between the SCN pacemaker 
and external time cues, but also peripheral circadian clocks becoming desynchronised from 
the central pacemaker and each other. Using the Per2:Luciferase transgenic mouse or 
Perl:Luciferase rat it has been shown that it takes the SCN 1-5 days and peripheral oscillators 
up to 8 days to resynchronise to a phase advance of 6 hours in the light schedule (Davidson et 
a l, 2008; Yamazaki et a l, 2000). Such dyssynchrony between all aspects of circadian 
physiology and sleep means that shift-workers eat during biological night when there is 
relative insulin resistance, resulting in increased circulating glucose (Van Canter et a l, 1991), 
decreased LPL, increased hepatic VLDL output, and therefore increased plasma triglyceride 
(Morgan et a l, 1998; Ribeiro et a l, 1998) and risk factors for metabolic syndrome.
To date, shift-work has been associated with numerous disorders, including elevated body 
mass index (BMI), insulin resistance, type 2 diabetes, cardiovascular disease and 
gastrointestinal disorders (Knutsson, 2003). Some of these may be attributed to disturbed 
sleep, poor sleep quality, and altered feeding patterns.
Sleep possesses a homeostatic drive, which is the increasing need for sleep as a function of 
the amount of time elapsed since the previous sleep episode (Daan et a l, 1984). However, 
sleep is also under circadian control, particularly through outputs of the SCN (Borbely et a l, 
1982; Buckley and Schatzberg, 2005; Czeisler et al, 1980). The circadian system produces a 
wake-promoting signal during the daytime, which opposes the homeostatic drive and then 
decreases prior to the nadir in the circadian core body temperature rhythm (Dijk and Czeilser, 
1994; Shochat et a l, 1997). Sleep is additionally consolidated by the circadian system 
through diurnal variation in body temperature and plasma melatonin (Dijk et a l, 1997). 
Disruption of sleep and circadian biology has been linked to metabolic syndromes, such as 
obesity and diabetes, with key effects involving the disturbance of hormone rhythms and 
concentration in plasma as detailed below.
Due to our modem 24-hour lifestyle, 2005 figures showed that 40% of US adults report 
weekday sleep duration of less than 7 hours (National Sleep Foundation 2005; Sleep in 
America Poll: Summary Findings). There are now numerous studies showing that sleep 
duration of less than 7, or greater than 9 hours causes increased risk for obesity (Taheri et a l, 
2004) and type 2 diabetes (Gottlieb et a l, 2005). Indeed, selective suppression of slow wave 
sleep leads to reduced insulin sensitivity without compensatory insulin release and reduced
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glucose tolerance (Tasali et a l, 2008). Obstructive sleep apnoea and narcolepsy have also 
been associated with increased incidence of type 2 diabetes (Botros et a l, 2009; Honda et a l, 
1986).
Reduced sleep duration (Gottlieb et a l, 2005) and quality (Tasali et a l, 2008) has been shown 
not only to increase the incidence of metabolic syndrome, but also to increase consumption of 
calorie-rich foods (Stamatakis and Brownson, 2008). Sleep restriction also increases the 
circulating concentrations of pro-inflammatory cytokines, such as TNFa and IL-6, the 
presence of which has been implicated in the pathology of obesity and type 2 diabetes 
(Martins et a l, 2008; Vgontzas et a l, 2004). Sleep restriction has also been reported to
decrease the anorexigenic leptin: orexigenic ghrelin ratio (Knutson et a l, 2007; Rayner and
Trayhum, 2001), resulting in increased appetite (Spiegel et a l, 2004a; Spiegel et a l, 2004b; 
Taheri et a l, 2004) and there is now evidence from human studies that increase in body 
weight is inversely related to the nocturnal rise in serum leptin (Langendonk et a l, 1998), 
resulting in overeating over a long period of time (Matkovic et a l, 1997).
Altered adipokine production as a result of sleep loss could subsequently have a deleterious 
effect on sleep quality. Genetically obese and diabetic mice (db/db) harbour a mutation in the 
long-form of the leptin receptor that is important for transducing the leptin signal to the brain. 
Presence of the mutation renders the mouse leptin resistant, and this has been shown to 
increase sleep fragmentation, reduce diurnal rhythmicity of REM sleep, and decrease the 
compensatory response to acute (6 hour) sleep deprivation (Laposky et a l, 2008).
1.5.2 The molecular clock in WAT
Clock genes are expressed in both WAT from animals on a 12L:12D dark schedule (Zvonic et 
a l, 2006), humans (Gomez-Santos et a l, 2009), and also 3T3-L1 murine adipocytes (Aoyagi 
et a l, 2005). Zvonic et a l (2006) also showed comprehensively that adipose tissue possesses 
robust diurnal rhythms of clock gene expression, similar to that observed in the liver and other 
peripheral tissues. Email and Npas2 expression was also found to oscillate in antiphase to 
Per and Cry as described previously in the SCN (Figure 1.7) (Zvonic et a l, 2006). 
Additionally, large-scale microarray experiments revealed that the expression of at least 7% to 
21% of active genes in WAT (4398 genes in inguinal WAT), including core clock genes, 
follow a daily oscillatory pattern, with many of these linked to basic metabolism and adipose 
function, such as Lpl, C/Ebpa and C/Ebpô (Ptitsyn et a l, 2006; Zvonic et a l, 2006).
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1.5.3 Effect of obesity and diabetes on the clock
Adipokines, such as leptin and adiponectin, have been shown to exhibit diurnal rhythms in 
plasma, which are often absent in obese subjects (Yildiz et a l, 2004). Additionally, Per2 and 
Email show altered expression in livers of db/db mice (Kudo et a l, 2004), which harbour a 
mutation in the long-form of the leptin receptor that is important for transducing the leptin 
signal to the brain, rendering the animal genetically obese and diabetic (Chen et a l, 1996). 
Presence of the mutation renders the mouse leptin resistant (Kudo et a l, 2004). This 
prompted a study of clock gene expression in adipose tissue of normal (C57BL/6J), obese 
(KK) and severe obese/diabetic (KK-Ay) mice by Ando et a l (2005) (Figure 1.8).
These results clearly indicate diurnal rhythms of clock gene expression in adipose tissue. As 
expected, there is antiphase cycling of Per expression relative to Email in C57BL/6J mice. 
C57BL/6J animals also exhibited rhythmic adipokine mRNA expression following a similar 
phase to Per (Figure 1.8C). However, in KK and KK-Ay mice, the diurnal rhythm of 
adiponectin is severely blunted. Coupled with attenuated peak amplitude of clock gene 
expression, this suggests that obesity may affect not only adipokine production, but also clock 
gene expression (Figure 1.8A & B). Attenuated rhythmic expression of Dbp, as well as other 
metabolic genes, has also been replicated in KK-Ay livers, suggesting that obesity impacts 
whole body circadian biology (Ando et a l, 2006). These data are consistent with the 
hypothesis that obesity and type 2 diabetes affect the intracellular clock system in visceral 
adipose tissue.
There also appears to be depot specific effects of obesity when analysing WAT. Gomez- 
Abelian et a l (2007) compared the expression of BMAL1, PER2, and CRY1 from a single 
timepoint in adipose tissue biopsies from both visceral and subcutaneous abdominal depots of 
humans with metabolic syndrome. While BMAL1, CRY1 and PER2 were significantly and 
positively correlated in subcutaneous fat, expression of each was negatively correlated with 
plasma cholesterol levels. This is suggestive of disruption of the clock as a result of high fat 
intake. Furthermore, in the omental visceral depot, no association was found between BMAL1 
and PER2. Here, PER2 expression was found to negatively correlate with waist 
circumference, suggestive of a clock link with central obesity and metabolic syndrome 
(Gomez-Abelian et a l, 2008). Differences between fat depots have also been discovered in 
obese women, where there were phase and amplitude differences in clock gene expressions 
between subcutaneous and visceral WAT (increased amplitude PER2, but
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Figure 1.7: Clock gene expression profiles in liver and white and brown adipose tissue. Expression 
of clock genes is rhythmic in the liver, BAT and epididymal and inguinal adipose tissue (eWAT and 
iWAT) (Zvonic et a i, 2006).
reduced amplitude BMAL1 and CRY1 in subcutaneous compared to visceral fat) (Gomez- 
Santos et a l, 2009). Additionally, visceral adipose tissue has been found to have higher 
amplitude oscillations in clock genes (Bmall, Cryl-2, Perl-3, Rev-erba and Dbp) compared 
to subcutaneous fat in Svlmj mice housed in a 12L:12D schedule (Bray and Young, 2007).
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Figure 1.8: Comparison of clock gene expression in lean, and obese/diabetic mice. Daily mRNA expression 
profiles of the clock genes (A and B) and adipokines (C) in C57BL/6J, KK and KK-Ay mice visceral adipose 
tissues with (clear dots) and without (solid dots) 0.02% pioglitazone for two weeks (Ando et al., 2005).
1.5.4 Effect of high-fat diet on clock genes and rhythmic 
behaviour
The Ando et al (2005) study was extended by Kohsaka et al. (2007) in C57BL/6J murine 
epididymal adipose tissue to show that high-fat diet induces obesity and altered behavioural, 
as well as molecular, rhythms. After 6 weeks exposure to high-fat diet, some nuclear receptor 
genes (Rora, Rxra and Ppary) exhibited decreased expression, resulting in suppressed diurnal 
rhythmicity. This was also true of other metabolic genes, such as suppressed peak expression
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and rhythmicity of Srebplc. Similarly, there was lower Per2 expression in fat tissue from 
animals maintained on a high-fat diet compared to those fed regular chow.
In comparison to controls, mice exposed to a high-fat diet exhibited increased period length 
under free-running conditions, and also increased feeding during light periods under 12L:12D 
conditions, even before a significant overweight state was reached (Kohsaka et a i, 2007). 
This suggests that the high-fat diet itself and not obesity per se is responsible for some 
components of the obese clock phenotype.
1.5.5 Clock gene mutations alter metabolic physiology
Numerous clock gene mutations in both specific target tissues or ubiquitously across the 
organism have been used to assess the role of the clock in metabolism. Turek et al. (2005) 
examined effects of the homozygous Clock?119 mutation on metabolism in mice with a 
C57BL/6J background. The Clock?119 mutation, resulting from an A to T transversion and 
resulting deletion of exon 19 (King et a l, 1997), encodes a dominant-negative CLOCKA19 
protein that competes with wild-type CLOCK in heterozygous animals. CLOCKA19 is able to 
bind to E-boxes, but not activate transcription (DeBruyne et a l, 2006; Gekakis et a l, 1998; 
Kondratov et a l, 2006). As a result, the molecular clock mechanism is attenuated.
Compared to wild-type mice, Clock?119 mutants exhibit hyperphagia, abnormal feeding 
rhythms, and reduced activity, resulting in 10% decreased energy expenditure. Consequent 
adipocyte hypertrophy causes obesity and other factors characteristic of metabolic syndrome, 
such as hypercholesterolemia, hyperglycaemia, hypoinsulinaemia and increased serum leptin 
levels (Turek et a l, 2005).
In contrast to Turek et al (2005), Oishi et a l (2006) and Kudo et a l (2007b) showed that 
Clock?119 mutant mice with an JcklCR background were protected against high fat diet- 
induced obesity. Oishi et a l (2006) found that Clock419 mutants had defective dietary fat 
absorption, possibly due to a decrease in the pancreatic expression of cholecystokinin-A 
(CCK-A) receptor, a key hormone in this process. Conversely, Kudo et a l (2007b) showed 
that the Clock419 mutation had no effect on dietary fat absorption, possibly due to the different 
techniques used to study the process. However, both studies show a reduction in key hepatic 
lipogenic genes, such as Srebpl, Fas, and Fatty acid binding protein 1 (Fabpl) that transports
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FFA into liver tissue, and there was a significant accumulation of serum FFA in the Kudo et 
al. (2007b) study in animals fed a high-fat diet.
Additionally, microarray analysis of Clock?19 mutant compared to wild type mice revealed 
that CLOCK regulates genes involved in metabolism in liver, including those involved in de 
novo fatty acid synthesis (Oishi et a l, 2003). Additionally, experiments performed by 
Kennaway et a l (2007) reported disruption of Pepck and Glucokinase (Gck) that are involved 
in gluconeogenesis and glycolysis, respectively, in the liver of Clock?19+Mel mice, which 
have had melatonin re-introduced. Therefore, although difference in mouse breeding 
background is likely to account for the different results between Turek et a l (2005), Oishi et 
al (2006) and Kudo et a l  (2007b), all experiments clearly establish a link between the 
molecular clock and metabolism.
Mice with a specific liver disruption of Bmall lost circadian rhythmicity in genes associated 
with metabolism (such as Gck) and exhibited hypoglycaemia restricted to the fasting phase of 
the circadian cycle (Lamia et a l, 2008). The latter was likely the result of losing Glut-2 
rhythmicity. GLUT-2 is a glucose transporter that normally peaks during the fasting phase to 
export glucose into the plasma and thus avoid fasting hypoglycaemia. In liver-specific Bmall 
mutant mice, the rhythm is annulled and Glut-2 mRNA expression remains constitutively low. 
Therefore, the circadian clock in the liver is essential for hepatic glucose homeostasis (Lamia 
et a l, 2008).
In contrast, Rev-erba mutation or disruption in hepatocytes has been linked to elevated plasma 
triglyceride levels through apolipoprotein C-III (ApoC-III) (Raspe et a l, 2002). ApoC-III is a 
glycoprotein synthesised in the liver and intestine that delays catabolism of triglyceride-rich 
lipoprotein remnants (TRL). RORcc has been shown to positively regulate the ApoC-III 
promoter, whereas REV-ERBa suppresses ApoC-III production and subsequently suppresses 
plasma triglyceride concentrations (Raspe et a l, 2002). Therefore, a Rev-erba, Bmall knock­
out, or Clock419 mutation will reduce REV-ERBa protein, resulting in increased ApoC-III and 
triglyceride levels. Elevated triglyceride is a risk factor for atherosclerosis and may result in 
increased lipid uptake by adipocytes, and might therefore partially explain the adipocyte 
hypertrophic phenotype found in C/ocA^79mutant mice (Turek et a l, 2005).
Interestingly, there is also evidence that CCGs, such as Nocturnin, play a role in mediating the 
effects of the circadian oscillator on metabolism. Nocturnin is a circadian deadenylase that is
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transcriptionally regulated by BMALI/CLOCK through an E box promoter region (Li et a l,
2008). N o c a  mice possess a targeted disruption of the Nocturnin gene such that the entire 
region of exon 3, which possesses the protein catalytic domain, is missing. While Noc^ mice 
exhibit normal circadian behaviour and hepatic clock gene expression, compared to wild-type 
mice the knock-out animals are resistant to high fat diet-induced weight gain (Green et a l,
2007). Additionally, liver and epididymal fat pads accumulate significantly less lipid, which 
is likely the result of reduced expression of the lipogenic genes Ppary, Srebplc, and Fabp 
observed in the liver of Noc^ mice (Green et a l, 2007). This suggests that Nocturnin, and 
possibly other CCGs, control circadian pathways related to lipid uptake and/or utilisation.
1.5.6 Clock gene polymorphisms associate with metabolic 
dysfunction
Recently, whole population studies have been implemented to look at prevalence of various 
clock gene haplotypes and polymorphisms in different disease states. For example, familial 
studies and in vitro cell culture systems have shown that BMAL1 haplotypes are linked to type 
2 diabetes (Woon et a l, 2007). However, most evidence to date comes from studies in 
CLOCK polymorphisms.
Various clock gene single nucleotide polymorphisms (SNPs) have been found to associate 
with obesity (Sookoian et a l, 2008). Sookoian et a l (2007) reported that CLOCK 
polymorphisms in human subjects are associated with susceptibility to non-alcoholic fatty 
liver disease, a common abnormality observed in obese patients, including fatty liver and 
steatohepatitis. CLOCK haplotypes have also been linked to the protection from, or presence 
of metabolic syndrome, respectively, in a cohort of white European subjects, with one 
haplotype associated with lower hip and waist circumference, lower BMI, and lower leptin 
levels, and with reduced prevalence in subjects suffering from metabolic syndrome (Scott et 
a l, 2007).
A study was also conducted to examine frequencies of 3111T/C CLOCK gene SNP in 
overweight/obese Caucasians with or without binge eating disorder (BED). It was discovered 
that, while genotype and allele frequencies did not vary between normal weight and 
overweight/obese individuals with or without BED, overweight/obese individuals carrying the 
CC genotype were prone to higher BMI compared to CT and TT genotypes (Monteleone et 
a l, 2008).
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1.5.7 Role of clock genes in metabolism and interaction with
metabolic factors
There is now increasing evidence that nuclear receptors are involved in linking metabolism 
with the circadian oscillator. In mouse WAT, 19 of the 49 nuclear receptors found in the 
murine system are rhythmically expressed, including Ppara, Ppary and Rev-erba (Yang et a i, 
2006).
PPARa is a nuclear receptor that is involved in lipid metabolism. The BMAL 1/CLOCK 
complex transactivates Ppara expression via an E-box-rich region located in the second intron 
(Oishi et a l, 2005). Interestingly, a more recent study has shown that livers from Ppara'A 
mice show reduced amplitude Bmall expression. Likewise, in Rat-1 fibroblasts, fenofibrate 
treatment, which upregulates Ppara expression, also upregulates Bmall and Rev-erba in the 
liver (Canaple et a l, 2006). In 2008, it was discovered that there is dose-dependent activity 
of PPARo/RXRa-mediated transcription by the Bmall/Clock gene in HEK293T cells 
(Nakamura et a l, 2008). However, whether this is due to direct binding of BMAL1/CLOCK 
to the PPRE promoter, or via binding to PPAR/RXR remains unclear. Nevertheless, taken 
together these results suggest a reciprocal regulatory role between PPARa and the circadian 
clock (Figure 1.9). This could be one mechanism whereby the peripheral clocks can be 
affected by food provision and other metabolic parameters.
It appears that clock genes exhibit pleiotropy as they affect physiological parameters outside 
the clock mechanism, including roles in adipocyte physiology. For example, the nuclear 
receptor REV-ERBa, which plays a role in a secondary clock feedback loop is now proposed 
to be involved in metabolism (Laitinen et a l, 2005). Rev-erba overexpression in vitro 
upregulates inflammatory markers, such as cyclooxygenase 2 (COX-2) and IL-6 (Migita et 
a l, 2004). Elevated plasma levels of inflammatory markers are characteristic of obesity and 
glucose intolerance as described in Sections 1.4.3.1.1-1.4.3.1.2. Therefore, dysregulation of 
Rev-erba could have implications for metabolic disorders (Laitinen et a l, 2005).
A more recent link discovered between the clock and metabolism involves the inducible 
transcriptional coactivator, PPARy co-activator la  (PGC-la), which regulates adaptive 
energy metabolism in multiple tissues, and is expressed in WAT (Liu et a l, 2007a). PGC-la 
exhibits circadian rhythms in the murine liver, with peak protein levels coinciding with 
activation of Bmall transcription. Using a Bmall reporter promoter in hepatocytes, PGC-la
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has been shown to augment transcriptional up-regulation of Bmall expression via the action 
of RORa on the RORE element. As expected for negative regulatory action of REV-ERBa in 
the core clock mechanism, REV-ERBa inhibits PG C-la stimulatory effects on Bmall 
transcription. In vivo, Pgc-la  null mice exhibit a longer free-running period, and diurnal 
expression of metabolic genes, such as Fabp3, is disrupted in skeletal muscle (Liu et a i, 
2007a). These findings suggest that PG C-la is a component of the molecular clock, and may 
itself be regulated by the clock oscillator. Importantly, PG C-la may provide a link between 
metabolic regulation and the core clock oscillator.
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Figure 1.9: Interaction between BMAL 1/CLOCK and PPARa. BMAL 1/CLOCK binds to E boxes to drive 
Ppara expression. PPARa feeds back to inhibit BMAL 1 /CLOCK-mediated transcription.
1.5.8 Role of clock genes in adipocyte differentiation
To date, Rev-erba and Bmall have been implicated in adipocyte differentiation. Treatment 
with a Ppary agonist (rosiglitazone) induces Rev-erba expression in rat adipocytes in vivo,
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and in 3T3-L1 cells in vitro (Laitinen et a l, 2005). Additionally, Rev-erba is transcriptionally 
up-regulated during adipocyte differentiation, increasing expression of PPARy target genes, 
such as aP2 and C/Ebpa (Laitinen et a l, 2005).
A more recent study of 3T3-L1 cells has shown that Rev-erba has a biphasic role in adipocyte 
differentiation, exhibiting low expression during early adipogenesis, but high protein levels, 
followed by reduced protein levels after mitotic clonal expansion and increased mRNA 
(Wang and Lazar, 2008). Glycerol synthase kinase 3(3 (GSK3(3) has been shown to stabilise 
REV-ERBa, and is itself downregulated during adipogenesis, likely accounting for the 
degradation of REV-ERBa observed. Subsequent removal of REV-ERBa-mediated 
inhibition of its own gene leads to increased Rev-erba expression observed later in 
differentiation (Wang and Lazar, 2008).
Interestingly, Rev-erba knock-down prevents mitotic clonal expansion, while introduction of 
a REV-ERBa protein that is resistant to degradation impairs progress of later adipocyte 
differentiation by suppressing Ppary induction (Wang and Lazar, 2008). Therefore, REV­
ERB a is critical for initial clonal expansion, but requires subsequent degradation for 
adipogenesis to progress to full term (Wang and Lazar, 2008). Taken together, these data 
support a role for Rev-erba in adipocyte differentiation.
Similarly, Bmall knock-down 3T3-L1 cells, created by siRNA delivery, failed to differentiate 
into adipocytes (Shimba et a l, 2005). Cells over expressing Bmall, or knock-out and re- 
introduction of Bmall, stimulated cellular lipid accumulation and induction of adipocyte- 
related genes, such as Pparyanà. aP2. BMAL-1 is believed to mediate these lipogenic actions 
through enhanced expression of Rev-erba and Srebpl a. SREBPla regulates transcription of 
several lipogenic factors, such as Fas, which are required for lipid synthesis and accumulation 
in 3T3-L1 cells. SREBPla also activates genes that produce a PPARy ligand (Shimba et a l, 
2005) (Figure 1.10).
1.6 SUMMARY
Studies of circadian biology to date have provided evidence of functional molecular clocks in 
peripheral tissues. These are synchronised by the SCN, but capable of being dissociated from 
the SCN by feeding stimuli. Circadian rhythms in adipose tissue are blunted in mice 
exhibiting components of the metabolic syndrome, and likewise, attenuating clock function
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can lead to obesity and metabolic disorders. Unfortunately, no studies suggesting a 
relationship between adipocyte physiology and the molecular clock are free of entrainment 
via the SCN, or humoral and neuronal influences. For example, adipose tissue analysed in 
Zvonic et al (2006), Ando et a l (2005), and Gômez-Abelian et a l (2007) were obtained from 
subjects maintained on a light-dark schedule prior to obtaining samples. Therefore, the caveat 
when interpreting these diurnal rhythms is that an animal in an entrained state may have 
rhythmicity driven by the changing environment, a phenomenon termed ‘masking’, or by 
rhythmic neuronal and/or humoral input to the tissue. Additionally, there is a confounding 
effect of numerous adipose cell types. As such, circadian regulation of clock genes and 
adipokines cannot be directly attributed to an adipose specific oscillator.
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Figure 1.10: Interaction of clock components, PPARa and SREBP1 in adipogenesis.
Thus, functionality of the adipocyte internal molecular clock has not yet been fully 
characterised in disease states, such as obesity. In order to model circadian rhythms in 
obesity, a key initial question to answer is whether the adipocyte itself possesses an 
endogenous clock. Clearly, analysing such parameters in vivo is difficult based on the large 
number of humoral and neuronal factors that govern both circadian and adipose function.
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Therefore, an in vitro approach will be an important tool to establish a link between metabolic 
syndrome and circadian biology at the adipocyte level, and begin teasing apart the 
mechanisms governing such a relationship. The research can then be used to look at the 
molecular clock in both human adipocytes and WAT in various disease states, such as obesity 
and diabetes.
This work would provide novel insight into aetiology of metabolic syndrome exhibited by 
individuals exposed to altered sleep/wake cycles and altered feeding rhythms, for example in 
shift workers, and individuals suffering from sleep disorders. Information gleaned from such 
studies would be invaluable in elucidating targets for therapy to treat a wide range of 
metabolic abnormalities, and may also reveal further genetic markers for pre-disposition to 
the metabolic syndrome.
1.7 HYPOTHESES AND OBJECTIVES
1.7.1 Central hypotheses to be tested
Hypothesis 1: Adipocytes possess an endogenous circadian clock, which drives rhythmic 
gene expression and adipokine secretion.
Hypothesis 2: Rhythmic gene expression and adipokine secretion is disrupted in individuals
with obesity or type 2 diabetes mellitus.
1.7.2 Objectives
Objective 1: Develop an in vitro pre-adipocyte and adipocyte model.
Objective 2: Examine circadian clock gene and adipokine expression in serum pulsed pre­
adipocytes and adipocytes.
Objective 3: Assess whether the rhythmic expression of adipose clock and adipokine genes, 
and adipokine secretion, is disrupted in patients with obesity or type 2 diabetes.
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CHAPTER 2:
Methods
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2.1 MANUFACTURERS
Table 2.1 lists the manufacturers of items and products described herein, with their 
headquarters:
Manufacturer Address
Abgene Abgene, Portsmouth, USA
Alfa Wassermann Alfa Wassermann, Bologna, Italy
ATCC-LGC LGC, Middlesex, UK
B&K Universal Ltd. B&K Universal Ltd., Hull, UK
BioVision BioVision, California, USA
Fisher Thermo Fisher Scientific, Massachusetts, USA
GIB CO Life Technologies Inc. GIB CO, California, USA
Molnlycke Health Care Molnlycke Health Care, Gothenburg, Sweden
Nutricia Nutricia, Schiphol, Netherlands
Promega Promega, Madison, USA
R&D Systems R&D Systems, Minneapolis, USA
Sigma Sigma-Aldrich Corporation, Missouri, USA
Teklab Teklab, Illinois, USA
Table 2.1: Manufacturers of reagents and products described herein.
2.2 REAGENT DISSOLUTION
2.2.1 Dexamethasone
Dexamethasone (Sigma) stock solution of 20ug/ml was made by adding 1ml absolute ethanol 
to Img dexamethasone powder, gently agitating, and adding 49ml sterile DMEM. This 
provided a 50pM solution, which was aliquoted into 1ml supplies and stored at -20°C.
2.2.2 Insulin
1 mg/ml insulin stock solution was made by taking 250pi of 4mg/ml insulin (human 
recombinant, plus zinc) (Fisher) adding 750pl DMEM, and storing 250pi aliquots at -20°C.
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2.2.3 3-isobutvImethvlxanthine
0.5M 3-isobutylmethylxanthine (IB MX) was made by dissolving lOOmg IB MX (Sigma) in 
900|xl dimethyl sulphoxide (DMSO) (Sigma), and aliquots of 100pi were stored at -20°C.
2.2.4 Sodium dodecvl sulphate solution
0.1M sodium dodecyl sulphate (SDS) solution was made by dissolving SDS powder (Sigma) 
in distilled water and heating to 50°C to fully dissolve.
2.3 CELL CULTURE
For all cell culture work, sterile techniques and materials were used, and work was conducted 
in a type 2 laminar flow cabinet. All solutions added to the cell culture were pre-warmed to 
37°C in a water bath, unless otherwise stated, and experimental cells were stored in an 
incubator at 37°C with 5% CO2. Normal growth medium consisted of DMEM containing L- 
glutamine and D-glucose (GIBCO) supplemented with 10% foetal bovine serum (FBS) 
(Fisher), 1% antibiotic/antimycotic (Fisher), and 1% sodium pyruvate (Sigma). Ix phosphate 
buffered saline (PBS) was made by dissolving PBS tablets (GIBCO) in nuclease-free sterile 
water. Unless otherwise stated, in all methods nuclease-free water was made by adding 1ml 
diethyl pyrocarbonate (DEPC) (Sigma) to 11 MilliQ water, leaving to stand overnight and then 
autoclaving the following day.
2.3.1 Beginning a fresh cell culture and cell splitting
A cryovial of 1.5ml murine 3T3-L1 pre-adipocyte (ATCC-LGC) cell suspension was quick
thawed for approximately 1 minute, from liquid nitrogen storage, in a water bath pre-warmed 
to 37°C. 10ml of medium was added drop wise to the cell suspension in a 50ml Falcon tube. 
This was then centrifuged at 150 x g for 10 minutes, followed by disposal of supernatant, 
which contained any cryoprotectants. The resulting cell pellet was resuspended in 10ml 
DMEM, the whole suspension then being transferred to a T25 flask, and incubated at 37°C 
with 5% CO2.
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Cells were permitted to reach approximately 70-80% confluence, at which point they were 
split 1:3 into a T75 flask. This was achieved by discarding cell medium, and washing once 
with 10ml IxPBS solution. 1ml trypsin/ethylenediaminetetraacetic acid (trypsin/EDTA) 
solution (Fisher) was added to the T25 flask, which was gently agitated and then returned to 
the incubator for approximately 3 minutes, or until all cells were detached from the bottom of 
the flask. 10ml DMEM was added to the flask, and the resulting cell suspension was 
transferred to a 50ml Falcon tube and centrifuged at 200 x g for 10 minutes.
Following centrifugation, the medium was aspirated and the cell pellet resuspended in the 
appropriate volume of medium. In this case all cells were transferred to a T75 and DMEM 
was added to a total flask volume of 30ml. Cells were allowed to grow until 70-80% 
confluent, at which point they were split either 1:6 or 1:8 into T75 flasks using 3ml of 
trypsin/EDTA solution per T75 flask. Medium was changed every two days. Cells to be used 
for differentiation were not allowed to exceed passage 7; beyond P7, cells became easily 
detached from the base of plates when exposed to experimental conditions.
2.3.2 Freezing down new 3T3-L1 cells
A cryovial of 1ml 3T3-L1 pre-adipocytes was placed in liquid nitrogen upon delivery. This 
was then quick thawed and split into a T75 flask as described in Section 2.3.1, which was 
counted as passage 1. When the cells reached approximately 80% confluence, they were split 
1:10 into 10 x T75 flasks (passage 2). When these reached approximately 80% confluence, 9 
flasks were trypsinised and centrifuged as described in Section 2.3.1, but they were 
resuspended in cell culture freezing medium (Sigma). 1.5ml aliquots were made such that 
each T75 flask made 3 cryovials (each cryovial was therefore a 1:3 split). These were then 
frozen down to -80°C in isopropanol containers overnight and transferred to liquid nitrogen 
for long term storage the next day (passage 2 vials). The tenth T75 flask was split 1:10 into 
10 x T75 flasks (passage 3), which were frozen down in the same manner upon reaching 
approximately 80% confluence (passage 3 vials).
2.3.3 Differentiation
Trypan blue exclusion method was used to assess cell viability and aid cell counting. Briefly, 
following resuspension of the cell pellet as described in Section 2.3.1, 80pl of IxPBS was 
added to 20pi of cell suspension, and 20pl of this was mixed with Trypan Blue (Sigma) to
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provide a 1:10 dilution of the cell suspension. Cells were then counted under a microscope 
using a haemocytometer and 3T3-L1 pre-adipocytes were seeded out in 6 well plates at a 
density of 200,000 cells per well. Cells were maintained in pre-warmed 2ml normal growth 
medium per well, which was replaced every two days. Cells were cultured until two days 
post-confluence to enable growth arrest prior to the experiment.
At two days post-confluence (Day 0), differentiation of 3T3-L1 pre-adipocytes was induced 
by adding 0.5mM IBMX, IpM dexamethasone and lOpg/ml insulin to the culture medium 
made according to Sections 2.2.5 - 2.2.7. After 48 hours the medium was exchanged for 
medium containing 10pg/ml insulin (Day 2). 48 hours later, this medium was exchanged for 
normal medium (Day 4) (Figure 2.1). Cells were then allowed to grow until required for 
experiments, with medium replaced every two days.
Grow to 2 
days post­
confluence 
 A a  r
Insulin, DEX, 
IBMX
 A _ "a r
Insulin
 A ___
Normal growth medium
Time (days)
Figure 2.1: Protocol for differentiation of 3T3-L1 pre-adipocytes into mature adipocytes. Differentiation was 
induced at two days post-confluence with IpM  dexamethasone (DEX), 10pg/ml insulin and 0.5mM IBMX. Two 
days later, medium was exchanged to that containing 10pg/ml insulin. After a further two days, normal medium 
was added and refreshed every two days for the remainder of the experiment.
2.3.4 Serum pulse
Serum pulse is a method whereby the molecular clocks in individual cells (Nagoshi et a l, 
2004; Welsh et a l, 2004) can be induced to synchronise across a cell culture by provision of 
high serum concentrations (Balsalobre et a l, 1998). 3T3-L1 cells were seeded in 6 well 
plates in DMEM and grown to the stage of adipocyte differentiation as described in individual 
experiments in Chapters 3 and 4. At timepoint 0, medium was exchanged for that containing
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50% horse serum (Fisher). After 2 hours, medium was exchanged for serum free DMEM, in 
which the cells were maintained without medium change for the remainder of the experiment. 
Figure 2.2 illustrates the protocol for 48-hour 3T3-L1 pre-adipocyte and adipocyte serum 
pulse experiments.
| |
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Figure 2.2: Protocol for 48-hour serum pulse of pre-adipocytes and adipocytes. 3T3-L1 pre-adipocytes 
were grown to 2 days post-confluence, and mature adipocytes to day 8 post-differentiation induction. At 
this point, the cells were treated with 50% horse serum for 2 hours, followed by serum-free medium for 
the remainder of the experiment.
2.4 ADIPOKINE ASSAYS
After collecting the DMEM samples taken from 6 wells plates of 3T3-L1 adipocyte cultures, 
samples were centrifuged at 200 x g for 10 minutes to precipitate any cells. Leptin or 
adiponectin concentration in the medium was then measured using commercial Quantikine 
ELISA kits (R&D Systems). Intra-assay coefficient of variance was 2.2% and 6.5%, 
respectively.
2.5 TRIGLYCERIDE MEASUREMENTS
2.5.1 Triglyceride staining using oil red O
Firstly, 0.3% saturated oil red O stock solution was made by adding 0.3g oil red O (Sigma) to 
100ml isopropanol. The working oil red solution was prepared from this by adding 6ml stock
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red oil solution to 4ml distilled water. This was allowed to stand for 20 minutes, and then 
filtered through a 0.45 micronfilter.
Medium was first removed from the 6 well plate, and 2.4ml of 10% formalin in IxPBS was 
added to each well. This was immediately discarded, the same volume of 10% formalin in
IxPBS added again, and the plates incubated for 1 hour at room temperature. At this stage,
some plates were wrapped in parafilm, covered with silver foil and stored at room temperature 
for no longer than two days in formalin solution (this enabled mass processing later). After 
the incubation period, formalin was removed, and wells were washed twice with 60% ethanol, 
and twice with distilled water. Pictures of morphology were then taken using a digital camera 
(Nikon, COOLPIX990) attached to a microscope (Nikon, TMS-F) prior to staining. For the 
staining, 1ml of the filtered oil red O working solution was added to each well for 10 minutes. 
Oil red O was then removed, and the wells washed carefully three times with distilled water. 
1ml distilled water was then added to each well and the cells were photographed as above.
2.5.2 Triglyceride extraction using solvents
2.5.2.1 Chloroform: methanol extraction
A common method for total triglyceride extraction involves the use of non-polar solvents 
(Christie, 1973; Hamilton, 1992). A modification of the Folch method, which uses the 
solvents chloroform and methanol (Folch et a l, 1951), is described below.
Medium was removed from the wells of 3T3-L1 adipocytes, and the cells washed twice with 
IxPBS pre-warmed to 37°C. Cells were then gently scraped into 700pi of pre-warmed IxPBS 
and transferred to a capped 10ml glass bottle. Any residual cells in the well were rinsed with 
500pl pre-warmed IxPBS and added to the glass bottle. 5ml of chloroform: methanol (2:1, by 
volume) was added to the 1200pi of cell suspension in the glass bottle (3.4ml chloroform, 
1.6ml methanol), and the bottles mechanically shaken for 10 minutes. Following this, the 
suspension was centrifuged at 2000 x g for 10 minutes. The resulting solution contained two 
phases (the lower methanol, the upper chloroform) separated by an interphase of cell debris. 
The top chloroform phase containing the triglycerides was removed to a glass test tube using a 
glass pipette, and dried at room temperature under a continuous stream of nitrogen (N- 
EVAP™ 111 Nitrogen Evaporator, Organomation Associates, Inc.). This resulted in the 
formation of a white triglyceride pellet, which could then be re-dissolved.
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2.S.2.2 Hexane: ethanol extraction
The extraction was carried out as above (Section 2.5.2.1) but with chloroform and methanol 
substituted with hexane and ethanol, respectively. Following centrifugation, the upper hexane 
phase containing the triglycerides was removed to a glass test tube using a glass pipette, and 
dried at room temperature under a continuous stream of nitrogen. This resulted in the 
formation of a white triglyceride pellet, which could then be re-dissolved.
2.5.3 Triglyceride extraction using SDS
Medium was removed from the 6 well plate and cells rinsed twice with pre-warmed IxPBS. 
Cells were then gently scraped into 1ml 0.1M SDS solution (made according to Section 2.2.8) 
using a cell scraper. The resulting cell suspension was transferred to a 1.5ml Eppendorf tube, 
and the well rinsed with 200pi 0.1M SDS solution to obtain and remaining cells. This was 
also transferred to the Eppendorf (for a total volume of 1.2ml), and the Eppendorf briefly 
vortexed. Next, the sample was sonicated using a sonic probe (LABSONIC M, B. Braun 
Biotech International, Melsungen, Germany) on maximum power for 30 seconds. This 
achieved lysis of cells and a uniform suspension of triglyceride and total cell protein. 6pl of 
the suspension was transferred to the triglyceride quantification assay (Section 2.5.4) and the 
remainder used for normalising the triglyceride concentration between samples using a 
genomic DNA assay (Section 2.5.5). Triglyceride recovery was approximately 90% 
irrespective of the amount of triglyceride in the well (Section 3.4.1).
2.5.4 Triglyceride quantification assay
A colorimetric one-step triglyceride reagent kit (Alfa Wassermann) was used in a 96 wells 
plate, where the triglyceride is hydrolysed and glycerol measured by assay. The resulting 
absorbance is directly proportional to the glycerol concentration in the sample, as described in 
the manufacturer’s datasheet. As free glycerol is not stored in the adipocyte (Rasmussen and 
Wolfe, 1999), and medium is removed and cells washed twice with IxPBS prior to 
triglyceride extraction, only glycerol obtained by the enzymatic degradation of intracellular 
triglyceride stores was recognised in this assay.
Final working reagent was made up with reagent A: reagent B 30:1 (by volume) according to 
manufacturer’s instructions. 3pl of sample or standard (2.7mM, Alfa Wassermann) was
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added to 225|il of triglyceride final working reagent. 3(il of 0.1M SDS was added to 225pi 
reagent to make the blank. The absorbance of the resulting quinoneimine dye was measured 
for 0.1 sec after 20 minutes at a wavelength of 540nm (VICTOR3 1420 Multilabel Counter, 
PerkinElmer, Massachusetts, USA). The absorbance is directly proportional to the glycerol 
concentration in the sample. Concentration of triglyceride was then measured using the 
following calculation (FA = final absorbance):
Total triglyceride = FA sample -  FA blank x concentration of standard
FA standard -  FA blank
In order to calculate intra- and interassay coefficient of variance, two controls (Alfa 
Wassermann) of known concentration were also run twice per plate in the assay. Control 
level 1 was 1.16mM/l, and control level 2 was 2.71mM/l.
2.5.5 Triglyceride normalisation to DNA
As the triglyceride samples had been treated with 0.1M SDS and sonicated, a homogeneous 
sample had already been created. Therefore, DNA was extracted from 420pi (volume based 
on that recommended in the manufacturer’s protocol, if using their method of extraction from 
cell culture) of cell suspension (from Section 2.5.3) using the GenElute Mammalian Genomic 
DNA Miniprep Kit (Sigma), according to the manufacturer’s protocol, from step 4 onwards. 
Following extraction, DNA was stored short term at 4°C until quantified using the NanoDrop 
spectrophotometer (ND-1000, NanoDrop, USA). The typical concentration of DNA was 
13ng/pl and triglyceride was expressed as ng/ng DNA.
2.6 CELL VIABILITY ASSAY
As adipocytes were difficult to trypsinise and therefore trypan blue staining and counting on a 
haemocytometer to establish viability was not practical, the presence of lactate dehydrogenase 
(LDH) in culture medium was measured. LDH is frequently used as a measure of 
cytotoxicity, as it is a stable enzyme rapidly released into the cell culture medium upon 
damage to the cell plasma membrane. A colorimetric LDH-Cytotoxicity Assay Kitll 
(BioVision) was used, which follows the principle that LDH oxidises lactate to generate 
NADH, which then reacts with a tétrazolium salt to generate a yellow dye which correlates 
with the number of cells lysed. Briefly, 3055.5pi of 0.1% Triton X-100 in PBS was added to
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each well of cells in a 6-well plate, cells gently scraped and transferred to a universal bottle. 
Medium was centrifuged at 600 x g for 10 minutes to precipitate any cells. lOpl of 
supernatant or control cell suspension was transferred to the LDH cytotoxicity assay and the 
assay was carried out according to manufacturer’s instructions from step 3 onwards. Optical 
density was measured using a spectrophotometer (VICTOR3 1420 Multilabel Counter, 
PerkinElmer) at 450nm, with reference 620nm. Cytotoxicity was then calculated using the 
manufacturer’s following equation, and normalised to DNA using the GenElute Mammalian 
Genomic DNA Miniprep Kit (Sigma) as described previously (Section 2.5.5):
Cytotoxicity (%) = Test sample -  Low control x 100
High control -  Low control
2.7 WHOLE CELL RNA EXTRACTION
All solutions and plasticware used were DNase/RNase free and plasticware was autoclaved 
prior to use.
2.7.1 RNA extraction from TRIzoI lysate
Whole cell RNA collection was achieved using 1ml TRIzol (Fisher) per well in a 6 well plate 
for cell culture. For human adipose biopsies, samples were homogenized in 1ml TRIzol in a 
1.5ml Eppendorf tube. All lysates were stored at -80°C in 1.5ml Eppendorf tubes for later 
analysis. All work with TRIzol was carried out in a fume hood. Once RNA was collected 
according to the manufacturer’s instructions, aliquots of lOpl were stored at -80°C.
2.7.2 RNA quantification and quality
RNA samples were defrosted on ice and RNA concentration in each tube was quantified using 
a NanoDrop spectrophotometer (ND-1000, NanoDrop, USA). The concentration of total 
RNA per well was typically between 1600ng/pl (pre-adipocytes) and 1900ng/pl (mature 
adipocytes), or between approximately 500ng/pl and ISOOng/pl per approximately 0.5g 
human subcutaneous WAT biopsy. The quality of RNA in all samples was determined by 
analyzing the 260/280 ratio from the Nanodrop reading and also by running a 1% agarose gel
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(Sigma) at 120V for 30 minutes in 1 x Tris Borate-EDTA (TBE) (Sigma) buffer in nuclease 
free water with 0.25g of 5% ethidium bromide in a 100ml agarose gel. 260/280 readings were 
typically 1.80 for murine liver, murine WAT and cell culture extracts, and 1.50 for human 
WAT biopsies. Example gel pictures are shown in Figure 2.3. The samples were diluted to 
50ng/(il in nuclease free water, and lOpl was mixed with 2(J,1 blue/orange loading dye 
(Promega). lOjil of this was loaded per well and bands visualised under UV light. The 
remainder of the diluted RNA was stored in 10pl aliquots at -80°C.
2.8 cDNA SYNTHESIS
All solutions and plasticware used were DNase/RNase free and plasticware was autoclaved 
prior to use. All reagents for cDNA synthesis were from Promega unless otherwise stated.
2.8.1 DNase treatment
Ipg RNA was DNase treated with 2.5jil lOx DNasel buffer (400nM Tris-HCl [pH8.0], 
lOOmM MgSC>4, lOmM CaClz), 2pi DNasel (lU/pl) and 0.5pl nuclease free water. This 
solution was incubated at 37°C for 40 minutes followed by addition of 2pl stop solution 
(20mM EDTA [pH8.0]). After a further incubation at 65°C for 10 minutes, DNase-treated 
RNA was stored at -80°C in 5pi aliquots, keeping one for cDNA synthesis.
2.8.2 cDNA synthesis step 1
2.5pl DNase-treated RNA was added to a mixture of Ipl random primers (0.5pg/pl) and 1.5pl 
nuclease-free water in a 0.6ml Eppendorf tube. A non-template control sample was included 
to assess any reaction contamination, consisting of Ipl random primers and 4pl nuclease-free 
water. The Eppendorfs were then heated at 70°C for 5 minutes.
2.8.3 cDNA synthesis step 2
A mixture of 4pl 5X buffer (20mM Tris-HCl [pH8.0], 200mM NaCl, 0.1 mM EDTA), 2pl 
MgCH (25mM), Ipl PCR nucleotide mix (40mM), 0.5pl RNasin inhibitor (40U/pl), Ipl 
reverse transcriptase (200U/pl), and 11.5pl nuclease free water was made. 15pl of this was 
added to 5pl of the mixture prepared in step 1 (Section 2.8.2). The Eppendorfs were
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incubated at room temperature for 5 minutes (annealing), followed by 42°C for 60 minutes 
(extension), and 70°C for 15 minutes (inactivation of reverse transcriptase). The cDNA end 
product was stored at -80°C.
Murine Murine Human 3T3-L1 3T3-L1 pre-
Liver WAT WAT adipocyte adipocyte
Figure 2.3: RNA run on agarose gel. Examples of RNA run on an agarose gel to highlight the 28S (top band) 
and 18S (lower band) ribosomal subunits.
2.8.4 Generation of RT- samples
In order to ascertain whether there was genomic DNA contamination in samples to be run in 
real-time quantitative reverse transcriptase PCR using primers/probe sets designed to amplify 
cDNA within an exon, reverse transcriptase negative (RT-) samples were run. These were 
generated using the methods in Sections 2.8.1 -  2.8.3, but in Section 2.8.3, reverse 
transcriptase and RNasin inhibitor were replaced with nuclease free water.
2.9 POLYMERASE CHAIN REACTION (PCR)
All solutions and plasticware used were DNase/RNase free and plasticware was autoclaved 
prior to use. All reagents for semi-quantitative and real-time quantitative PCR were from 
Promega unless otherwise stated.
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2.9.1 Semi-quantitative reverse-transcriptase PCR
The prepared cDNA (or control) was allowed to thaw on ice. 5pl cDNA (or control) was then 
mixed with 12.5|il GoTaq Green Master Mix (buffer [pH8.5], 400pM dATP, 400pM dGTP, 
400pM dCTP, 400pM cTTP, 3mM MgClz), and the 0.5pi of lOpM/pl forward and reverse 
primers (see Appendix A) added. Primers were designed using Lasergene software, checked 
for specificity through a BLAST search, ordered from Eurofins MWG Operon, and optimised 
in-house (see Section 2.9.2). The total PCR reaction volume was then made to 25pl volume 
with nuclease free water.
The reactions were run on a PCR machine (2720 Thermal Cycler, Applied Biosystems) using 
a cycling protocol of 95°C for 3 minutes, followed by ‘x’ cycles (95°C for 30 seconds, 
followed by ‘y’°C for 30 seconds) and then 72 °C for 30 seconds (where ‘x’ cycles and y  °C 
vary according to cycle number and optimal temperature of the primer sets). The PCR end 
product was run on a 1% agarose (Sigma) gel at 120V for approximately 60 minutes. A 100- 
base-pair ladder was used as a standard to estimate the size of the DNA product.
2.9.2 Primer optimisation for semi-quantitative reverse- 
transcriptase PCR
Many of the semi-quantitative primers designed exhibited non-specific binding, failed to 
anneal at the recommended temperatures, or formed primer dimers. As such, time was spent 
optimising PCR reactions before utilising primers experimentally (shown in the examples 
below). This involved altering one or more of the following parameters:
■ Primer concentration
■ Annealing temperature (by performing temperature gradients)
■ Sample (cDNA) concentration
■ Other reaction reagents (e.g. MgCL, DMSO)
Example 1: Temperature gradient for Dtp
Primers to Dbp mRNA were tested for 40 cycles against 3T3-L1 pre-adipocyte cDNA on a 
temperature gradient spanning either side of the recommended annealing temperature as
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calculated by the primer design software. The resulting gel (Figure 2.4) shows that 62°C is 
the best temperature at which to run the Dbp PCR.
Example 2: Optimisation of cycle number
Primers to fi-actin showed good product yield in cDNA synthesised from 3T3-L1 pre­
adipocyte mRNA, but the fragments were too strong to ascertain any differences between 
samples at 40 cycles. There is also a small amount of non-specific binding at 67°C annealing 
temperature with 40 cycles (Figure 2.5). Although increasing temperature is a method of 
reducing non-specific binding, this would take fi-actin primers above melting temperature. 
Therefore, cycle number was reduced from 40 to 35, 30 and 25 to remove non-specific 
binding and reduce fragment intensity. Figure 2.5 clearly shows weaker fragment intensity at 
a lower cycle number of 25, removing non-specfic binding. At this intensity, it is also 
possible to see variance between fragments of experimental repeats, which is beneficial 
during semi-quantitative experiments. Therefore, for experiments requiring an indication of 
quantity of p-actin expression, 25 cycles were used for fi-actin PCR.
2.9.3 TaqMan Real-time PCR
The prepared cDNA (or control) was allowed to thaw on ice. Nanodrop quantification was 
then carried out and the samples diluted to the concentration of the least concentrated sample 
using nuclease free water. This was further diluted 35x for use with the murine adiponectin 
primer-probe set. All primer-probe sets were designed in-house within exons using the 
Primer Express software, diluted in IxTE buffer (Sigma) and ordered online from Eurofins 
MWG Operon (see Appendix A for primer/probe details) following specificity check using a 
BLAST search. 5pl of diluted cDNA (or control) was mixed with Ipl of forward primer 
(10pmol/pl stock), Ipl reverse primer (10pmol/pl stock), 0.5pi probe (5pmol/pl stock), 5pi 
nuclease-free water and 12.5pl ABsolute™ QPCR ROX Mix (Abgene). The reactions were 
run on white Thermo-Fast ® 96 PCR detection plates (Abgene) covered with an adhesive 
AB solute™ QPCR seal (Abgene). A standard curve was made by serial dilution of genomic 
DNA in IxTE buffer at concentrations of 101, 102, 103, 104, and 105 copies per well (see 
Appendix B for calculations). This was then run on every plate and used to calculate the 
concentration of the expressed gene of interest. The TaqMan PCR reactions were carried out 
on a AB7500 machine, and the cycling protocol was 2 minutes at 50°C, 15 minutes at 95°C,
15 seconds at 95°C (45 cycles), and 1 minute at 60°C. Standard curve R2 values were 
between 0.997 and 0.999.
Annealing temperature (°C)
Figure 2.4: Agarose gel showing Dbp primer optimisation using cDNA, synthesised from 3T3-L1 
pre-adipocyte mRNA, on a temperature gradient for 40 cycles. The brightest fragment suggests 
that 62°C is the optimal temperature.
'Non-specific bindin;
Figure 2.5: Agarose gel showing [1-act in primer optimisation using cDNA, synthesised from 
3T3-L1 pre-adipocyte mRNA. Primers showed non-specific binding and low resolution 
between fragments at 67°C annealing temperature and 40 cycles. Non-specific binding was 
removed by reducing cycle number down a gradient to 25 cycles, and 25 cycles for fi-actin 
primers also shows greater resolution between repeats.
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2.10 MOUSE EXPERIMENTS
Male C57B1/6J mice were housed under a 12L:12D cycle (approximately 250 lux during the 
day) for 14 days and fed transgenic mouse diet (B&K Universal Ltd.) ad libitum. At the time 
of culling (schedule 1 cull; cervical dislocation after 3 minutes in increasing CO2), mice were 
aged 71 days old (SD= 16 days). Animal care, culling and tissue collection were carried out 
by Dr van der Veen, University of Surrey.
2.11 HUMAN DIABETES AND ADIPOSE STUDY
All methods used in this study were standard procedures previously employed for human 
chronobiology work (Professor Skene’s research group), or routinely used within the Division 
of Nutritional Science, Faculty of Health and Medical Science, University of Surrey. All the 
procedures had previously had a favourable ethical opinion from the University of Surrey 
Ethics Committee. Samples were processed according to the procedures approved under the 
University of Surrey Ethical Guidelines for Teaching and Research, and the Revised
Guidance Note for the Policy on the Donation and Use of Human Specimens in Teaching and
Research in the University of Surrey.
2.11.1 Recruitment
Participants were recruited via advertising on posters (Appendix C), in local newspapers 
(Figure 2.6) and via Dr Wright’s clinic and his links with local GPs. In addition, recruits were 
obtained following outreach talks to Rotary Clubs and diabetes support groups. Posters were 
placed in areas frequented by type 2 diabetics, such as the Guildford and South West Surrey 
Voluntary Group, and also in public areas such as bus stops, cafes and supermarkets. 
Advertisements were also distributed via email within the University of Surrey and a press 
release issued to raise awareness of the study, with an article subsequently published in the 
Surrey Advertiser (Appendix D).
2.11.2 Participants
Based upon power calculations and estimated drop-out rates (see Appendix E) nine subjects 
per experimental group were required. Only males were recruited for this study, because the
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menstrual cycle, oral contraceptives, and menopause are possible confounding variables in 
circadian measurements. Therefore, male subjects, age range 40 - 65 were recruited into one 
of three age-matched groups (lean and healthy, overweight or type 2 diabetic) (see Sections
2.11.2.1 -  2.11.2.3) and paid £250 for inconvenience upon finishing the trial, in addition to 
travelling expenses. All participants were included based on the inclusion/exclusion criteria 
described in Section 2.11.2.4.
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Figure 2.6: Example of an advert posted with the Surrey Advertiser to aid recruitment.
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2.11.2.1 Group 1: Patients with type 2 diabetes
The effects of drag regimes on circadian physiology are unknown. Therefore as many diet 
and exercise controlled type 2 diabetic patients (not taking medication) were recruited as 
possible. However, due to recruitment issues such as local practices prescribing some 
medications as standard practise for diabetic patients, some individuals were taking drags. 
These were limited to metformin, statins and some blood pressure medications not known to 
influence the circadian system or any of the parameters under study (see Table 5.1 for drag 
information). None of the drags were known to directly influence plasma insulin levels. 
Diabetics had a BMI in the range of 25 -  35 kg/m2, with no evidence of hypoglycaemic 
episodes, and a haemoglobin A le (HbAlc) < 8.5 %. Recruits also had no evidence of 
hepatic, cardiac or kidney disease based on information obtained from both the participant 
and their GP. In total, 8 participants were recruited into this cohort.
2.11.2.2 Group 2: Overweight subjects
Overweight subjects were recruited based on having a BMI in the range of 27 -  35kg/m2. 
Secondary to this, subjects were included based on insulin resistance defined by the European 
Group for Study of Insulin Resistance (EGIR) criteria (Fasting insulin > 60 pmol/1) with at 
least 2 of the following co-factors; fasting hyperglycaemia (> 6 mmol/1), hypertension 
(130/85 or treated), or central adiposity (waist >102 cm). Recruits also had no evidence of 
hepatic, cardiac or kidney disease based on information obtained from both the participant 
and their GP. In total, 11 participants were recruited into this cohort.
2.11.2.3 Group 3: Lean insulin sensitive subjects
Lean and healthy individuals were recruited based on having a BMI in the range of 19 -  25 
kg/m2. Participants were free from any of the EGIR criteria as described in Section 2.11.2.2, 
and were free from any disease or other medications, although high blood pressure did not 
form part of the exclusion criteria for this group, due to the possible stressful situation of new 
surroundings during pre-screening. Recruits also had no evidence of hepatic, cardiac or 
kidney disease based on information obtained from both the participant and their GP. In total, 
8 participants were recruited into this cohort.
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2.11.2.4 Inclusion and exclusion criteria
Inclusion and exclusion criteria applied to this study.
Participants were required to:
a) be between 40-65 years of age,
b) be male,
c) be able and willing to give informed oral and written consent,
d) have no reason, according to their medical practitioner, why they were unable to 
participate
e) complete and meet the defined criteria of pre-study questionnaires and screens,
f) have a regular sleep/wake cycle with a sleep duration between 6 and 8 hours,
g) not exhibit extreme morning or evening preference (Home and Ostberg, 1976)
h) agree to keep a constant sleep/wake cycle (awakening at 06.30 and going to bed at 22.30) 
for one week prior to the laboratory study,
i) obtain 15 minutes of sunlight within 1.5 hours of waking and agree to nap, where 
required, only within a 4 h designated nap window for one week prior to the lab study,
j) allow confirmation of compliance to these instructions by reporting wake and sleep times 
to the lab voicemail, wearing Actiwatches (AWL) continuously and completing daily 
sleep diaries for one week before the study session,
k) agree to refrain from smoking, alcohol, caffeine, heavy exercise and food components 
high in fat or sugar for one week prior to the study session,
1) complete a daily diet diary one week prior to the lab study to document food and drink 
consumed,
m) agree to eat specially provided meals for three days prior to the study,
n) agree to refrain from prescribed and ‘over the counter’ medication (other than that 
previously discussed with the team for the type 2 diabetic group) and food/vitamin 
supplements for a wash-out period two weeks before and during the study.
Participants were excluded if they:
a) were taking regular medication or food supplements (e.g vitamins, minerals, fish oil, 
antioxidant tablets) from which it was not possible to refrain, known to influence:
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1) sleep/alertness/the circadian timing system (e.g (3-blockers, barbiturates, 
antidepressants, benzodiazepines, melatonin, ritalin, modafinil, soporifics, St John’s 
Wort),
2) any of the metabolic functions (e.g. affecting thyroid, kidney, liver or gastrointestinal 
function)
3) any of the inflammatory markers (e.g. aspirin, ibuprofen, antiobiotics, hay fever 
medication, medication for sore throats and colds)
4) and/or many of the endothelial markers (e.g. angiotensin (receptor) blockers, diuretics, 
(3-blockers, anti-thrombosis medication),
b) had a history of any circadian or sleep disorder or metabolic (excluding type 2 diabetic 
patients), cardiovascular or chronic infectious / inflammatory disease as confirmed by the 
GP or the pre-study questionnaires,
c) had a history of psychiatric or neurological disease or drug and alcohol abuse,
d) had donated over 400 ml of blood in the three months preceding the study,
e) were anaemic, confirmed by a haematology screen,
f) had participated in shift work or have travelled across more than two time zones within 
one month of the study,
g) did not keep a regular sleep-wake cycle,
h) did not refrain from alcohol, caffeine containing drinks (e.g. coffee, coke, tea, redbull), 
heavy exercise and certain foods (e.g. those high in fat or sugar) one week before the 
laboratory session,
i) did not refrain from smoking one week prior to the lab study.
2.11.3 Ethical procedures
After a favourable ethical opinion was obtained from the Surrey Research Ethics Committee 
and University of Surrey Ethics Committee, participants were recruited according to Section 
2.11.2. After participants had passed pre-screens (described in Section 2.11.4), participants’ 
medical practitioners were informed of the study and asked whether their patients had any 
medical conditions, or were taking any medication, which may preclude them from 
participating (Appendix F). Written informed consent (Appendix G) was obtained from the 
participants before the study, after they had read the participant information sheet (Appendix 
H). Medical insurance for the study was provided by the University of Surrey. Participants 
were reimbursed for their time and inconvenience with a maximum payment of £250 for
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completion of the study, in addition to any traveling expenses incurred. Participants were free 
to leave the study at any time without giving reason.
Any abnormalities detected during pre-screening or during the study session were discussed 
with the participants by Dr John Wright and the suitability for participation was assessed by 
the research team. All volunteer information was coded and held in the strictest confidence in 
compliance with the Data Protection Act (1998).
2.11.4 Prescreening
Experimental subjects were selected following completion of a number of questionnaires and 
screens.
2.11.4.1 Questionnaires
As part of the pre-screening procedure, all participants were asked to complete a series of 
questionnaires, which included the General Health Questionnaire, General Sleep 
Questionnaire, Home-Ostberg (HO) Questionnaire (in order to exclude extreme morning or 
evening types from the study), Pittsburgh Sleep Quality Index (PSQI), Beck Depression 
Inventory, and the Epworth Sleepiness Scale. If participants scored within the range required 
for this study (i.e. 30 < HO < 70, PSQI < 9, Beck Depression Inventory <21,  and Epworth 
Sleepiness Scale < 13) they were asked to provide a blood sample at the Univeristy of Surrey.
2.11.4.2 Blood samples
All blood tubes were ordered from Teklab. To monitor the metabolic status of subjects, a 
single fasting blood sample of 13ml was taken either at the Surrey Clinical Research Centre 
(CRC) or Clinical Investigation Unit (CIU), University of Surrey, to measure HbAlc, insulin, 
and glucose. To ensure participants were not anaemic, plasma iron was also measured. 
Blood was collected into a serum tube (10ml blood) or dipotassium-EDTA tubes (1ml in the 
first tube and 2ml in the second). The dipotassium-EDTA tube containing 2ml whole blood 
was centrifuged at 3000 x g for 10 minutes and the plasma collected and stored at -80°C for 
future analysis of plasma triglyceride and cholesterol concentration. The second (1ml whole 
blood) dipotassium-EDTA tube was not centrifuged, but used to measure glucose (YSI 2300
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STAT Plus, YSI Incorporated, YSI Life Sciences, Fleet, Hampshire, UK) and iron (GEM 
OPL Oxygenation Portable Lab, Instrumentation Laboratory, Warrington, Cheshire, UK). 
This tube was then sent, together with the serum tube, to the Clinical Biochemistry 
Department at the Royal Surrey County Hospital, Guildford, for analysis of HbAlc and 
insulin, respectively. Pre-screens occurred within 1 month of the laboratory study session, 
except where study sessions were rescheduled and one type 2 diabetic patient was pre­
screened within 3 months and an overweight participant within 2 months of the study session.
2.11.4.3 Other measurements
Other measurements were also taken during pre-screening blood sampling. These included 
height and weight (for calculation of BMI), waist circumference and blood pressure (OMRON 
MX3 Plus Digital Automatic Pressure Monitor, Omron Automotive Electronics UK Ltd., 
Kingswinford, West Midlands, UK).
2.11.5 Pre-study
To synchronise daily behaviour before the subjects arrived at the CRC, participants were 
required to maintain a prescribed daily activity routine for 7 days prior to the study. This 
included:
a) precisely 8 hours in bed, in the dark trying to sleep and not deviating from their 
prescribed sleep onset (22:30) and offset (06:30) times by more than 15 minutes. 
Participants were given a three hour window in the afternoon (centered 12 hours away 
from the midpoint of their night-time sleep) in which they were permitted to nap if 
they chose. It has been demonstrated that naps during the afternoon do not shift the 
phase of the circadian rhythm (Buxton et a l, 2000). This sleep behaviour was 
confirmed by participants wearing Actiwatches for analysis of activity, telephoning 
the laboratory voicemail and completing daily sleep diaries.
b) obtaining at least 15 minutes of natural outdoor light exposure within 1.5 hours of 
waking each morning and avoiding excessive exercise
c) avoiding alcohol and caffeine, which are known confounders of circadian rhythms, 
one week prior to the study
d) consuming provided food 3 days prior to the study, which contained neither alcohol 
nor caffeine and was low in fat
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Meals
Subjects chose their meals for the 3 days prior to lab admittance from a selection provided 
(Tesco Light Choice range) and could select different foods from each other. However, this 
inter-individual variation was minimised by offering meals with similar macronutrient 
content. Subjects were also provided with yoghurts (Danone Shape fruit yoghurts), cereal 
(Kellogg’s Cornflakes), and snack bars (Kellogg’s Nutrition Soft Bake), the latter of which 
could be eaten at any time of day. Subjects were required to consume meals within time 
windows (breakfast 07:00-09:00, lunch 12:00-14:00 and dinner 17:30-19:30) for one week 
prior to the study session. These time windows were chosen to minimise impact on 
participants’ daily routines.
2.11.5.2 Sleep and activity monitoring
Sleep behaviour was confirmed by wearing of an Actiwatch (AWL, Cambridge 
Neurotechnology Ltd., UK), completion of daily sleep diaries (Appendix I), and calling into 
the laboratory voicemail. Participants were asked to wear the Actiwatch on their wrist, which 
measured motor activity for the 7 days prior to the study. Instructions on how to wear the 
monitor were supplied (Appendix J). Daily sleep diaries recorded the following:
a) Date (date woke up on)
b) Time of retiring to bed (e.g. 2305 hours)
c) Time of trying to sleep (e.g. 2315 hours)
d) How long it took to fall asleep (minutes)
e) Number of night awakenings, including time and duration
f) Time of waking
g) Time of getting up
h) Sleep quality rated on a scale of 1-9 (l=best ever sleep, 9=worst ever sleep)
i) Number and duration of daytime naps
2.11.6 Laboratory study
Figure 2.7 provides an overview protocol of the study session.
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2.11.6.2 Body position
Since body position is known to affect hormonal parameters measured in the study (Deacon 
and Arendt, 1994), careful control of posture was required. Throughout the entire study, 
subjects remained in a semi-recumbent position. During circadian day, subjects were allowed 
to go to the bathroom following a blood sample but were required to be back in bed at least 30 
minutes before the next blood sample. During the waking periods, when in the semi- 
recumbent position, participants were asked to move their legs and perform basic stretching 
exercises every two hours to minimise the risk of deep vein thrombosis.
2.11.6.3 Meals
Throughout the study, water was provided ad libitum. During lights on, participants were 
provided with a liquid Fortisip isocaloric diet (Nutricia) with total nutrient and caloric intake 
divided over the day into 16 equal hourly feedings to minimise inter-individual variation and 
effects of post-prandial insulin surges on peripheral clocks. Meals were provided hourly from 
ZTO, with the final feed at ZT15. All subjects had identical meals, which were approximately 
30% fat and formulated based on calculated energy requirements using the Schofield 
Equation. This equation estimates the basal metabolic rate (BMR) in calories and therefore 
calculates daily caloric intake required to maintain current body mass as follows (where W is 
the participant’s weight in kg):
BMR males 30-59 years = 11.5 x W + 873
2.11.6.4 Blood samnlinff
Regular blood samples were collected from the participants throughout the experiment at the 
times indicated in Figure 2.7. Following one adaptation night (day 0), at ZTO (06:30) on day 
1 an indwelling cannula was inserted into the forearm vein by a qualified nurse. At ZT0.5, 
and then every hour for a total of 25 hours (final collection at ZT0.5 on day 2), 12ml blood 
was collected to assay hormones, such as melatonin and adipokines. This sampling protocol 
enabled the first and last samples, both collected at the same external clock time, to be 
compared for consistency. As up to 6 people were included per study session, blood sampling 
was staggered such that two subjects would be sampled 10 minutes before the hour, two 
subjects on the hour and two subjects 10 minutes past the hour. The blood collection protocol 
resulted in a maximum of 320ml of blood taken from each participant during the entire study.
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In the event that a blood sample could not be obtained through the cannula, a venapuncture 
was performed by a trained phlebotomist after permission was obtained from the participant.
Blood was collected in lithium-heparin (for melatonin and cortisol assays), or potassium 
EDTA tubes (for insulin, leptin or adiponectin assays) (Teklab) and the plasma separated by 
centrifugation at 3000 x g for 10 minutes at 4°C several minutes after collection. Plasma was 
then aliquoted and stored at -80°C until assayed in the future for hormone measurement.
2.11.6.5 Adipose biopsies
Four small biopsies were taken from the upper buttock subcutaneous adipose depot by a 
trained medical doctor at ZT4.5, ZT10.5, ZT16.5 and ZT22.5. As up to 6 people were 
included per study session, biopsy sampling was staggered such that two subjects would be 
sampled 30 minutes before the hour, two subjects on the hour and two subjects 30 minutes 
past the hour. Prior to collection, the site was injected with a local anaesthetic (lidocaine) and 
after the site numbed it was cleaned with Unisept antiseptic solution (Molnlycke Health 
Care). An open adipose biopsy was taken by making an incision (approximately 1.5cm long) 
and cutting a small pea-sized section of adipose tissue approximately 0.5g in mass. The 
wound was then closed with stitches and the site covered with a dressing. Dressings were 
changed every two days, and participants received a stitch cutter to remove stitches one week 
later. Alternatively, they were given the option to return to the CRC or their local GP to have 
the stitches removed. Subjects were provided with an information sheet detailing care of the 
biopsy sites (Appendix K).
Following collection, biopsy samples were cleaned with saline to remove any blood and 
connective tissue, and snap frozen in liquid nitrogen. Biopsies were then stored at -80°C for 
later RNA extraction and the analysis of adipokine and clock gene expression by quantitative 
reverse transcriptase PCR (Sections 2.7 -  2.9).
2.12 STATISTICAL ANALYSIS
Significant differences between experimental groups was defined as P < 0.05. All statistical 
analyses for triglyceride data described in Chapter 3 were performed using SPSS. 
Triglyceride accumulation was statistically analysed using One-way ANOVA with Tukey 
post-hoc for more than two groups, or independent samples t-test where only two groups
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existed. Time course data was analysed using a Two-way ANOVA with Tukey post-hoc. An 
independent samples t-test was used to analyse the LDH assay used in Chapter 3.
In Chapter 4, data obtained from serum pulse or animal tissue was analysed using One-way 
(SPSS) or Two-way ANOVA (Sigma Stat for Two-way-ANOVA) with Fisher’s Least 
Significant Difference (LSD) post-hoc test, and variation in rate of adipokine secretion was 
measured by testing the departure of leptin and adiponectin accumulation from linearity, using 
a runs test.
In Chapter 5, participant pre-screen data was analysed using One-way ANOVA with Tukey 
post-hoc (Prism). Repeated measures ANOVA with Tukey post-hoc was used to analyse the 
data obtained from gene expression analysis using Statistica, and correlation analyses 
performed using Prism.
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CHAPTER 3:
3T3-L1 adipocyte triglyceride
manipulation
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3.1 INTRODUCTION
Rhythmic clock gene expression has been measured in WAT from animals on a 12L:12D 
schedule. Large-scale microarray experiments have since shown that the expression of at 
least 7% to 21% of active genes in WAT, including core clock genes and many involved in 
metabolism and adipose function, follow a daily oscillatory pattern (Ptitsyn et a l, 2006; 
Zvonic et a l, 2006). Additionally, Ando et a l (2005) have shown that rhythmic adipokine 
and clock gene expression is attenuated in adipose tissue from a murine model of obesity and 
type 2 diabetes. In order to test the hypothesis that reported diurnal rhythms in clock gene 
and adipokine expression described in the Ando et a l (2005) and Zvonic et a l (2006) studies 
are generated by an adipocyte-specific oscillator, it is necessary to create an in vitro model 
that is free from rhythmic input signals that WAT is exposed to in vivo.
Murine 3T3-L1 cells are an in vitro immortalised pre-adipocyte cell line readily differentiated 
into mature adipocytes. To date, 3T3-L1 cells have been widely used to study adipogenesis 
from onset through to terminal differentiation (lessen and Stevens, 2002; Lin and Lane, 
1992). Additionally, 3T3-L1 adipocytes are used to examine mature adipocyte function, for 
example analysis of downstream effects following lipolytic stimulation of adipocytes 
(Brasaemle et a l, 2000), and effects of various dietary components on triglyceride 
accumulation (Brown et a l, 2001; Granlund et a l, 2003; Granlund et a l, 2005). Clock gene 
expression has also been reported in 3T3-L1 cells (Aoyagi et a l, 2005), rendering them a 
useful model for adipocyte circadian studies.
In this chapter, 3T3-L1 adipocytes are treated with various pharmacological agents in an 
attempt to manipulate triglyceride content and generate in vitro models that mimic a lean 
versus obese phenotype in vivo. Although nobody has yet tried to specifically create lean and 
obese phenotypes, many agents have been previously reported to alter triglyceride contents of 
adipocytes either during terminal differentiation (Granlund et a l, 2005; Long and Pekala, 
1996) or in mature adipocytes (Usui et a l, 1999). These agents include certain hormones, 
such as insulin and dexamethasone, and also many fatty acids.
Insulin potently inhibits lipolysis by inhibiting adipose triglyceride lipase (ATGL) synthesis 
in 3T3-L1 adipocytes in vitro (Kralisch et a l, 2005), and by binding to insulin receptors, 
causing downstream phosphorylation-mediated activation of phosphodiesterase-3A. 
Phosphodiesterase-3A is responsible for breakdown of cAMP, and thus reduced
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phosphorylation and activity of hormone-sensitive lipase (HSL) (Amer, 2005), the primary 
catalytic enzyme in triglyceride breakdown (Brasaemle et a l, 2000).
In contrast, the synthetic glucocorticoid dexamethasone promotes lipolysis in primary cultures 
of rat adipocytes by increasing HSL mRNA levels (Slavin et a l, 1994) and also through 
removal of inhibitory G-protein (GO subunit interactions with adenylate cyclase, with 
increasing cAMP (Yip and Goodman, 1999). Dexamethasone has also been found to impair 
insulin signalling and glucose transport capacity in isolated rat adipocytes through reduced 
cellular content of insulin receptor substrate-1 (IRS-1), a protein that transduces the insulin 
signal (Buren et a l, 2002).
As with hormones, dietary fatty acids also have diverse effects on adiposity. Saturated animal 
fats, such as palmitic acid (PA), promote hypertrophy and hyperplasia of adipose tissue 
(Madsen et a l, 2005; Trujillo and Scherer, 2006). Studies, conducted using adipocytes 
isolated from epididymal WAT of male Sprague-Dawley rats and 3T3-L1 adipocytes, showed 
that PA increased both basal and insulin-stimulated glucose incorporation into adipocytes 
(Thode et a l, 1989; Usui et a l, 1999) by promoting GLUT-4 (the insulin sensitive glucose 
transporter) translocation to the plasma membrane (Usui et a l, 1999).
In contrast, poly-unsaturated fatty acids (PUFAs), such as docosahexaenoic acid (DHA) and 
arachidonic acid (AA), are widely reported to reduce adipocyte size, for example by 
repression of de novo fatty acid synthesis as observed in 3T3-L1 cells (Awad et a l, 2000; 
Petersen et a l, 2003), and number in vitro (Awad et a l, 2000; Azain, 2004; Granlund et a l, 
2005; Madsen et a l, 2005; Moon et a l, 2002; Pegorier et a l, 2004; Rosen et a l, 2000). AA 
also decreases glucose uptake by disrupting binding of PPARy to the peroxisome proliferator 
response element (PPRE) and subsequent PPARy-mediated Glut-4 transcription, and by 
decreasing membrane localisation of GLUT-4 (Long and Pekala, 1996). AA also inhibits 
adipocyte differentiation and diacylglycerol acetyltransferase (DGAT1) activity (the rate- 
limiting enzyme in triglyceride synthesis), reducing triglyceride accumulation (Petersen et a l, 
2003). In contrast, DHA increases basal lipolysis in 3T3-L1 cells (Kim et a l, 2006), and 
mediates triglyceride reduction in WAT through activation of PPARa-driven fatty acid 
oxidation, coupled with suppression of fatty acid synthesis via reduction of hepatic SREBP 
content (Delarue et a l, 2004; Kim et a l, 2006). Therefore, these fatty acids may be able to 
manipulate the amount of triglyceride accumulated in 3T3-L1 adipocytes.
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In order to create a hypertrophic phenotype in 3T3-L1 adipocytes for later circadian studies, a 
minimal two-fold increase in intracellular triglyceride stores is required, as reported for lean 
compared to obese adipocytes in both humans (Salans et a l, 1973; Tchoukalova et a l, 2003) 
and rats (Cushman and Salans, 1978).
3.2 OBJECTIVES
Objective 1: Create and characterise a model of mature adipocytes:
• Develop a quantitative method for measuring triglyceride.
• Characterise the differentiation of immortalised 3T3-L1 murine pre-adipocyte cells 
into mature adipocytes by measuring mRNA expression of differentiation markers and 
analysing triglyceride accumulation.
Objective 2: Create a ‘lean’ versus ‘hypertrophic’ adipocyte model.
• Grow 3T3-L1 adipocytes in serum, insulin, or dexamethasone to alter triglyceride
content.
3.3 METHODS
Details for dissolution of reagents can be found in Section 2.2. 3T3-L1 cells were grown and 
differentiated as described in Section 2.3, and oil red O staining was carried out according to 
Section 2.5.1. Unless otherwise stated, triglyceride concentration per well was calculated as 
described in Sections 2.5.3 - 2.5.5 and all statistical analysis was performed using SPSS 
statistical software.
3.3.1 Primer design and development
Examples of primer design and optimisation can be seen in Section 2.9.2.
3.3.2 Development of quantitative triglyceride assay
Measurement of triglyceride from cell culture is widely utilised as a marker of adipocyte 
differentiation and adiposity. However, at the University of Surrey, the process had not
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previously been carried out and numerous methods were therefore attempted to calculate 
intracellular triglyceride concentration.
3.3.2.1 Quantification of Oil Red O staining
After staining cells with oil red O, it is possible to elute the stain using isopropanol, and 
quantify triglyceride content by measuring the optical density of the sample. However, oil red 
O adhered to plastic and glassware when transferred from the 6 wells cell culture plate to a 96 
wells plate, resulting in reduced oil red O stain in the 96 wells plate and, therefore, artificially 
low signals in all groups.
3.3.2.2 Triglyceride extraction using solvents
3.3.2.2.1 Triglyceride extraction using non-polar solvents
A modification of the Folch method, which uses the non-polar solvents chloroform and 
methanol (Folch et a l, 1951), was originally implemented as described in Section 2.5.2.1 to 
attempt total triglyceride extraction from adipocytes at day 8 post-differentiation induction. 
However, chloroform: methanol (2:1, by volume) caused a pink discoloration within the 
triglyceride pellet. Therefore, the method was abandoned as it was deemed likely that the 
discoloration would give false readings in any colorimetric triglyceride assay once the pellet 
was re-dissolved. Instead, the extraction was carried out using hexane and ethanol as 
described in Section 2.5.2.2. This resulted in the formation of a white triglyceride pellet, 
which was then re-dissolved.
3.3.2.2.2 Triglyceride dissolution
Five different solutions were compared for their ability to dissolve the resulting white 
triglyceride pellet from Section 3.3.2.2.1: IxPBS, methanol, ethanol, butanol, and 
isopropanol. Solutions were added in increments of 900pl, the tubes sonicated for 10 
minutes, and the resulting solution observed to see if triglyceride had fully dissolved. If not 
fully dissolved, a further 900pl was added followed by 10 minutes sonication, and so forth.
Triglyceride was found to completely dissolve in 900pl of butanol or isopropanol, after being 
sonicated in a sonic bath for 10 minutes to ensure full dissolution, but failed to dissolve in
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2700|il methanol, ethanol or IxPBS. Therefore, butanol and isopropanol were considered to 
be the best solvents. This supports previous observations that the longer the chain of the 
organic solvent, the greater the triglyceride solubility (Christie, 1973; Hamilton, 1992). 
However, although triglyceride fully dissolved in butanol and isopropanol, the solvents were 
later found to react with the colorimetric quantitative triglyceride kit, creating artificially high 
signal, and the method was discarded.
3.3.2.3 Triglyceride extraction using 0.1M SDS
3T3-L1 adipocytes were grown to day 8 post-differentiation induction, at which time medium 
was removed from the 6 well plate and triglyceride extracted using 0.1M SDS according to 
Section 2.5.3. 0.1M SDS was found not to react with the triglyceride reagent in the
quantification assay after 20 or 80 minutes incubation.
3.3.2.4 Triglyceride quantification assay
A colorimetric one-step triglyceride reagent kit designed for measuring glycerol using clinical 
chemistry automated systems was adapted for manual assays in a 96 well plate according to 
Section 2.5.4.
3.3.2.5 Normalisation of triglyceride to cell number
Originally, triglyceride normalisation to cell number was attempted. However, even with a 
bigger counting chamber to accommodate large size of differentiated adipocytes, cells were 
extremely fragile and either lysed, or adhered to each other. Pre-incubation with trypsin to 
loosen the cells did not resolve this problem. Therefore, total genomic DNA was used for 
normalising triglyceride data according to Section 2.5.5.
3.3.2.6 SDS extraction: triglyceride percentage recovery
Triglyceride recovery for the technique and assay was assessed by performing SDS 
extraction, triglyceride quantification and normalisation (see Sections 2.5.3 - 2.5.5) on 3 wells 
of 3T3-L1 cells at either day 4 or day 10 post-differentiation induction. However, after 
removal of the first 1200pl SDS and cell suspension, the process was repeated a further three 
times for a total of four extractions per well, to enable calculation of percentage recovery of
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total triglyceride from the first extraction. An Independent samples t-test was used to analyse 
the data.
3.3.3 3T3-L1 differentiation
To characterize the 3T3-L1 differentiation timecourse, 3T3-L1 pre-adipocytes were 
differentiated using insulin, dexamethasone and IBMX according to previous publications 
(Green and Kehinde, 1975; Rubin et a l, 1978; Russell and Ho, 1976; Student et a l, 1980) 
and as described in Section 2.3.3. Extractions for RNA or triglyceride analysis were taken at 
0, 2, 4, 6, 8, and 10 days post-differentiation induction. RNA was extracted (see Section 2.7), 
cDNA synthesised (see Section 2.8), and semi-quantitative reverse-transcriptase PCR carried 
out against primers for Leptin, Ppary and Glut-4 (see Section 2.9.1). Triglyceride 
accumulation was analysed by visualising cells with oil red O staining, and triglyceride 
concentration per well was calculated and the data analysed using a One-way ANOVA with 
Tukey post-hoc. For this experiment, n=3 wells of cells.
3.3.4 Dexamethasone and insulin timecourse
In order to establish the optimal time of hormone treatment to create the maximal triglyceride 
difference, 3T3-L1 adipocytes from day 6 post-differentiation induction (treatment day 0) 
were treated for 9 days with lOOnM insulin or lOOOnM dexamethasone (n=3 wells of cells). 
Medium was changed 1, 3, 5, and 7 days following onset of hormone treatment. Triglyceride 
samples were taken on treatment days 1, 3, 5, 7, and 9, stored at -80°C, and thawed for mass 
processing, when triglyceride was assayed.
To assess any cytotoxic effect of dexamethasone, separate plates were set up and day 6 
adipocytes were treated with either lOOOnM dexamethasone or normal growth medium 
(control) for 9 days. On day 9, medium was collected and stored at 4°C. Next, a cytotoxicity 
assay was carried out according to Section 2.6. Ethanol was the diluent for dexamethasone 
and therefore also run to ensure no assay interference. Total genomic DNA was extracted 
from the cell suspension, according to Section 2.5.5, and used to normalise the data. 
Timecourse data from both experiments was analysed using a Two-way ANOVA with Tukey 
post-hoc, and an Independent samples t-test was used to analyse the LDH assay.
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3.3.5 Different dexamethasone concentrations
In order to establish whether a lower concentration of dexamethasone could be used, 
adipocytes at day 6 or day 10 post-differentiation induction were treated with vehicle or either 
40nM, 200nM, or lOOOnM dexamethasone for 9 days followed by triglyceride quantification 
(n=3 wells of cells). The effect of dexamethasone treatment on triglyceride content was 
statistically analysed using a One-way ANOVA with Tukey post-hoc. Oil red O stains were 
made at the end of the experiment to visualise triglyceride content of the adipocytes and a 
representative photograph was taken.
3.3.6 Different serum concentrations
3T3-L1 pre-adipocytes were differentiated up to day 6 post-differentiation induction, at which 
point they were treated with either 2.5%, 5%, 10% or 20% FBS for 9 days (n=3 wells of 
cells). At the end of 9 days, triglyceride was quantified or oil red O staining carried out and a 
representative well photographed. One-way ANOVA with Tukey post-hoc was used to 
statistically analyse the data.
3.4 RESULTS
3.4.1 SDS extraction method: Triglyceride percentage recovery
Percentage recovery was consistently above 90% for extractions from both stages of 
differentiation. Figure 3.1 A illustrates a representative recovery from one well over four 
successive extractions. After the first extraction, subsequent recoveries were extremely low, 
reaching Ojig/ml after the third extraction. There was no significant difference in percentage 
recovery between the wells containing 3T3-L1 cells from either day 4 or day 10 of 
differentiation (P > 0.05, Independent samples t-test, Figure 3.IB).
3.4.2 3T3-L1 Differentiation
As differentiation proceeded, the fibroblastic 3T3-L1 pre-adipocytes became more spherical 
and began to accumulate small triglyceride droplets by approximately day 4 post­
differentiation induction (Figure 3.2A). By day 10, many of the cells possessed the
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characteristic large triglyceride droplets of mature adipocytes and, in some cells, these were 
already unilocular. There was a significant progressive accumulation of intracellular 
triglyceride after day 4 post-differentiation induction (Figure 3.2B, P < 0.001, One-way 
ANOVA). Significant differences in triglyceride concentration occurred between days 0, 2, 
and 4 compared with days 6, 8, and 10, and also between days 6, 8, and 10 (Tukey post-hoc, 
PcO.OO).
Ppary was already present at low concentrations in undifferentiated pre-adipocytes (day 0). 
Ppary was then expressed at high levels throughout the remainder of the differentiation 
timecourse. In contrast, Glut-4 was absent at day 0, expressed at low levels by day 2, and 
expressed at high levels from day 4 onwards. The adipocyte marker, Leptin, was first 
detected at day 4, but levels increased by day 8 (Figure 3.2C). From day 8, all three markers 
of differentiation were expressed at high levels. In contrast, there were no obvious changes in 
fl-actin expression (Figure 3.2C).
Extraction Differentiation
Figure 3.1: Percentage triglyceride recovery from 3T3-L1 cells. (A) Representative recovery from four 
successive extractions of triglyceride from one well of a 6 well plate. (B) % recovery from 3T3-L1 cells 
differentiated up to day 4 or day 10 (P > 0.05, Independent samples t-test) (n=3 wells of cells ± SEM).
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Figure 3.2: 3T3-L1 pre-adipocyte differentiation ten day timecourse following induction of differentiation (day 
0). Cells were assessed for triglyceride accumulation and differentiation marker gene expression on days 0, 2, 4, 
6, 8, and 10. (A) Cells were fixed in formalin and photographs taken with or without oil red O staining; (B) 
Triglyceride quantification over the ten day timecourse per well of a 6 well plate (n=3 wells of cells ± SEM); (C) 
RNA was extracted using TRIzol and semi-quantitative reverse transcriptase PCR carried out for analysis of 
markers of adipocyte differentiation.
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3.4.3 Dexamethasone and insulin timecourse
There was a significant effect of treatment time on triglyceride concentration (P < 0.001, 
Two-way ANOVA, Figure 3.3). There was also a significant interaction between type of 
treatment and duration on triglyceride concentration (P < 0.05, Two-way ANOVA, Figure 
3.3), but no significant effect of treatment on triglyceride concentration (P > 0.05, Two-way 
ANOVA, Figure 3.3). Significant effects on triglyceride concentration occurred between 
treatment day 1 compared to days 5, 7 and 9, and treatment day 3 compared to day 9 (P < 
0.01, Tukey post-hoc, Figure 3.3). Interestingly, dexamethasone increased triglyceride 
content of adipocytes for the first 5 days of treatment, after which it decreased triglyceride 
concentrations, with dexamethasone-treated cultures showing greater than a two-fold 
reduction in triglyceride concentration by day 9 when compared with the control.
The cytotoxicity assay showed that there was only 2.2% toxicity when treating cells with 
lOOOnM dexamethasone, which was not significantly different to vehicle treated wells (P > 
0.05, Independent samples t-test).
3.4.4 Different Dexamethasone concentrations
Figure 3.4A shows a representative graph based on the results from two duplicate 
experiments. There was a significant reducing effect of dexamethasone treatment on 
triglyceride content in cells treated at day 6 post-differentiation induction (P <0.01, One-way 
ANOVA), which again showed a two- to three- fold reduction in triglyceride concentration. 
However, although there was a significant difference between vehicle control versus 40nM, 
200nM or lOOOnM dexamethasone on triglyceride accumulation (P <0.01, Tukey post-hoc), 
there was no significant difference in triglyceride concentration between different 
dexamethasone treatments in cells treated at day 6 post-differentiation induction (P > 0.05, 
Tukey post-hoc). Therefore, 40nM dexamethasone had a similar effect on triglyceride 
concentration to lOOOnM dexamethasone.
However, oil red O photographs of cells that had been treated at day 6 post-differentiation 
induction with 40nM dexamethasone showed that there were still a large percentage of pre­
adipocytes in the adipocyte culture (Figure 3.4B). Similarly, those adipocytes present did not 
appear to have reduced triglyceride droplet size and some were unilocular.
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Figure 3.3: 3T3-L1 adipocyte treatment with insulin or dexamethasone. 3T3-L1 adipocytes were differentiated 
up to day 6 at which point they were treated for 9 days with vehicle (blue), lOOnM insulin (black) or lOOOnM 
dexamethasone (pink). Medium was changed 1, 3, 5, and 7 days following onset of hormone treatment at day 6 
of adipocyte differentiation (treatment day 0). Culture samples were extracted every 2 days following onset of 
treatment (triglyceride assayed from treatment days 1, 3, 5, 7, and 9) and assayed for triglyceride. There was a 
significant effect of time on triglyceride concentration (P < 0.001, Two-way ANOVA) and treatment versus time 
(P < 0.05, Two-way ANOVA) (n=3 wells of cells ± SEM).
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Figure 3.4: 3T3-L1 treatment with dexamethasone at day 6 post-differentiation induction. 3T3-L1 pre­
adipocytes were grown to day 6 of differentiation and then treated for 9 days with 40nM, 200nM or lOOOnM 
dexamethasone. After the 9 days, triglyceride was quantified or cells were stained with oil red O. (A) 
Dexamethasone significantly reduced well triglyceride content (P = 0.001, One-way ANOVA), but there was no 
difference between different dexamethasone concentrations (P > 0.05, Tukey post-hoc) (n=3 wells of ± SEM). 
(B) Representative oil red O stains. Note the larger number of pre-adipocytes in the dexamethasone-treated 
plate.
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Figure 3.5: 3T3-L1 treatment with dexamethasone at day 10 post-differentiation induction. 3T3-L1 pre­
adipocytes were grown to day 10 of differentiation and then treated for 9 days with 40nM, 200nM or lOOOnM 
dexamethasone. After the 9 days, triglyceride was quantified or cells were stained with oil red O. (A) 
Dexamethasone did not significantly alter well triglyceride content (P > 0.05, One-way ANOVA) (n=3 wells of 
cells ± SEM). (B) Representative Oil red O stains. Note the larger number of pre-adipocytes in dexamethasone- 
treated plates.
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Figure 3.6: 3T3-L1 treatment with serum. 3T3-L1 pre-adipocytes were differentiated up to day 6 at which 
point they were treated with 2.5%, 5%, 10% or 20% FBS for 9 days. On treatment day 9, cellular extracts were 
assayed for triglyceride (n=3 wells of cells ± SEM) or oil red O stains were carried out. (A) The first experiment 
showed a significant dose-dependent increase in triglyceride as a result of serum treatment (P < 0.05, One-way 
ANOVA). (B) The second experiment showed no significant change in triglyceride as a result of serum 
treatment (P > 0.05, One-way ANOVA). (C) Representative oil red O stains.
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In contrast to day 6 treated adipocytes, dexamethasone showed no significant dose-dependent 
effect on triglyceride content of adipocytes treated at day 10 post-differentiation induction (P 
> 0.05, One-way ANOVA), although there was a tendency towards a dose-dependent increase 
in triglyceride concentrations (Figure 3.5A). Similarly to day 6 treated adipocytes, oil red O 
stained wells from day 10 dexamethasone treated cultures also showed an observable increase 
in the number of non-differentiated pre-adipocytes (Figure 3.5B).
3.4.7 Different serum concentrations
From two independent experiments, results were inconclusive. The first experiment showed a 
significant dose dependent increase in triglyceride content of the cells as a result of serum 
treatment (P < 0.05, One-way ANOVA) with an approximate 2-fold increase in triglyceride 
when comparing 2.5% with 20% FBS treatments (P < 0.05, Tukey post-hoc) (Figure 3.6A). 
In comparison, the second experiment showed no significant effect of FBS treatment on 
triglyceride accumulation (P > 0.05, One-way ANOVA) (Figure 3.6B), although the highest 
concentrations of triglyceride obtained for both experiments were similar (approximately 
450ng/ng DNA). There were no obvious changes in triglyceride droplet size between the 
treatments (Figure 3.6C).
3.5 DISCUSSION
In order to test the hypothesis that increased lipid content in adipocytes disrupts clock gene 
expression in the absence of confounding factors, it is first essential to establish a model of 
adipocyte hypertrophy. To this end, 3T3-L1 pre-adipocytes were successfully differentiated 
into mature adipocytes, and the differentiation process characterised by analysing triglyceride 
accumulation, and expression of key adipogénie markers. Next, attempts were made to 
modify the lipid content of the mature adipocytes in order to create the ‘hypertrophic’ versus 
‘lean’ model. To my knowledge, no other studies have been conducted to specifically alter 
triglyceride content within differentiated 3T3-L1 adipocytes, so the protocols required 
development and optimisation.
3.5.1 3T3-L1 differentiation
In the 3T3-L1 differentiation timecourse experiment, oil red O staining and triglyceride 
quantification clearly showed a significant increase in lipid content as differentiation of pre-
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adipocytes to adipocytes progressed. Concentrations of triglyceride obtained are comparable 
to those in other studies (Granlund et a l, 2005; Rubin et a l, 1978).
Molecular mRNA markers of differentiation studied encode proteins important for 
maintaining the mature adipocyte phenotype. For example, GLUT-4 is a key glucose 
transporter (Bimbaum, 1989), PPARy is important in insulin sensitisation and adipocyte 
metabolism (Gumell, 2005), and leptin is a satiety hormone promoting negative energy 
balance (Klok et a l, 2007). Here, Ppary is expressed at low levels at day 0, and then 
increases by day 2, whereas Glut-4 begins to be detected at day 2, and then increases by day 
4. While this supports some previous observations (Fu et a l, 2005), expression of both genes 
is approximately 2 days earlier than reported in other studies (Prusty et a l, 2002; Reginato et 
a l, 1998). These differences could be due to 1) pre-adipocyte confluence at differentiation 
day 0 stimulating 3T3-L1 pre-adipocytes to begin differentiating. This would account for the 
low levels of Ppary observed and subsequent upregulation of Glut-4 expression (Laitinen et 
a l, 2005); 2) the use of different techniques to measure adipogénie markers, as mRNA levels 
measured here do not directly correlate with protein levels reported elsewhere (Prusty et a l,
2002); 3) the high number of PCR cycles used here to detect low levels of Ppary mRNA that 
may otherwise be below detection threshold. Despite these differences, Leptin begins to be 
detected at approximately day 4, and increases to peak levels by days 6-8, consistent with 
previous studies (Kallen and Lazar, 1996). As leptin production only occurs in adipocytes 
and not pre-adipocytes (Langendonk et a l, 1998; Meier and Gressner, 2004), it is used as a 
marker of adipocyte presence within the cell culture system. Therefore, for my adipocyte 
experiments, 3T3-L1 cells can be used at days 6-10 post-differentiation induction, as in other 
studies using 3T3-L1 adipocytes (Kralisch et a l, 2005; Nugent et a l, 2001; Usui et a l, 1999).
3.5.2 3T3-L1 adipocyte intra cellular triglyceride manipulation
Although previous studies have manipulated triglyceride content in 3T3-L1 cells during 
differentiation, none have manipulated triglyceride in differentiated 3T3-L1 adipocytes. 
Mature 3T3-L1 adipocytes were treated with either the hormones dexamethasone or insulin, 
or different serum concentrations.
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3.5.2.1 Hormone treatment
Triglyceride accumulation was measured following treatment with insulin or dexamethasone. 
In order to ascertain whether insulin or dexamethasone could alter adipocyte triglyceride 
content, a treatment timecourse of 9 days, with triglyceride analysis on days 1, 3, 5, 7, and 9, 
was carried out. Day 6 adipocytes instead of day 8 were also used, the former having 
accumulated less triglyceride based on findings from the 3T3-L1 differentiation timecourse 
experiment (Section 3.4.2).
Although I have not specifically tested insulin sensitivity in this cell population, my 3T3-L1 
pre-adipocytes differentiate following provision of a ‘cocktail’ that includes insulin, and 
insulin sensitive genes Glut-4 and Ppary are both upregulated thereafter. It has also been 
demonstrated by others that 3T3-L1 cells are insulin responsive both in the pre-adipocyte and 
adipocyte stage (Rudich et a l, 1997). Therefore, we might expect to see an effect of the 
insulin treatment. However, although there was a significant effect of time on treatment, 
triglyceride analysis over a 9 day insulin treatment timecourse showed no difference between 
insulin treated versus control wells.
Lack of insulin responsiveness was unlikely to be due to intracellular triglyceride saturation as 
day 6 adipocyte cultures contain less than 50% of the triglyceride measured in day 10 cultures 
(see Figure 3.2). However, it is also possible that chronic exposure to high concentrations of 
insulin renders the adipocyte insulin resistant, as would be seen in type 2 diabetes. 3T3-L1 
adipocyte insulin resistance, including downregulation of GLUT-4 availability at the cell 
surface membrane, has been shown following 24-hour exposure to higher doses (500nM) of 
insulin (Kozka et a l, 1991). It is therefore possible that the insulin treatment time used here 
should be reduced in order to see the large changes in adipocyte triglyceride content required 
for creation of ‘hypertrophic’ compared with ‘lean’ adipocytes.
In contrast to insulin, dexamethasone has previously been shown to decrease adipocyte lipid 
stores under normal conditions by both increasing lipolysis (Slavin et a l, 1994; Wang, 2005), 
and translocating glucose transporters from the plasma membrane to an intracellular 
membrane fraction (Homer et a l, 1987; Olefsky, 1975), rendering cells incapable of substrate 
uptake for lipogenesis. Dexamethasone treatment of 3T3-L1 adipocytes from day 6 post­
differentiation induction, over a 9 day timecourse resulted in increased adipocyte culture
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triglyceride content up to day 5 of treatment, followed at day 7 by a 2-fold reduction in 
triglyceride levels compared to control and insulin-treated wells.
A 9 day dose response (40nM, 200nM and lOOOnM dexamethasone) was then carried out to 
establish whether a lower concentration of dexamethasone could be used to achieve the 2- or 
3-fold triglyceride reduction observed for lOOOnM of hormone. While dexamethasone 
compared to vehicle treated wells again produced a significant 3-fold reduction in triglyceride 
concentrations in day 6 post-differentiation adipocyte cultures, this was not in a dose- 
dependent manner. Interestingly, oil red O staining of dexamethasone treated cultures 
revealed a large proportion of undifferentiated pre-adipocytes, suggesting that the reduction in 
triglyceride observed in this and the timecourse experiment may not be due to a 
dexamethasone induced decrease in intracellular triglyceride stores, but to fewer cells 
undergoing adipogenesis. These are novel findings and could, if substantiated by quantitative 
analysis, suggest that dexamethasone is 1) inhibiting the differentiation process when 
provided chronically beyond the initial induction of differentiation, or 2) causing de­
differentiation of mature adipocytes. The latter phenomenon has been reported previously as 
a result of chronic (>72hr) TNFa administration to 3T3-L1 adipocytes, causing cells to revert 
to a fibroblastic morphology and lose lipid (Engelman et a l, 2000).
In order to address these two possibilities and potentially eradicate the former explanation of 
dexamethasone-induced inhibition of differentiation, adipocytes at day 10 post-differentiation 
induction, which possess all the markers of mature adipocytes, were treated for 9 days with 
40nM, 200nM or lOOOnM dexamethasone. Interestingly, although dexamethasone treatment 
of day 10 post-differentiation induction cells did not result in a significant change in 
triglyceride accumulation, oil red O pictures showed no obvious differences between cells 
treated with or without dexamethasone. This suggests that dexamethasone is not de­
differentiating mature cells in cultures treated at day 6 post-differentiation, but rather 
inhibiting their differentiation into mature adipocytes. Therefore, dexamethasone is pro- 
adipogenic when used as an acute stimulator of adipogenesis, as has been shown many times 
(Brasaemle et a l, 2000; lessen and Stevens, 2002; Smas et a l, 1999) including in this 
experiment, but appears to be anti-adipogenic with chronic administration.
Although beyond the scope of this work, it would be interesting to compare expression of 
characteristic markers of different stages of differentiation, such as lipogenic factors, and 
Glut-4, in an attempt to elucidate where the anti-adipogenic dexamethasone effect is
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mediated. Also, it is known that inducers of differentiation may have inhibitory effects later 
in the adipogénie programme. For example, the clock gene Rev-erba has a biphasic role in 
adipocyte differentiation (Wang and Lazar, 2008). During adipogenesis, Rev-erba initially 
exhibits low mRNA expression, which subsequently increases. In contrast, REV-ERBa 
protein levels are elevated in early adipogenesis and then, following mitotic clonal expansion, 
decline as a result of proteasomal degradation. However, production of a REV-ERBa protein 
that is resistant to degradation impairs adipocyte differentiation. Therefore, it is plausible that 
a dexamethasone target required early during differentiation, but re-introduced mid­
differentiation as a result of chronic dexamethasone treatment, could exert inhibitory effects 
on mid to late adipogenesis.
The observation that 9 day dexamethasone treatment of day 10 post-differentiation adipocytes 
did not affect adipocyte culture triglyceride content suggests that chronic glucocorticoid 
exposure does not result in the lipolytic effects observed under normal conditions (Wang, 
2005). Indeed, antilipolytic responses have been reported previously. Treatment of human 
bone marrow explants with lOOnM dexamethasone for 5 days has been shown to result in 
adipocytes that are 1-1.5 times larger than control cells (Kitajima et a l, 2007). Additionally, 
the endogenous overproduction of, and chronic exposure of tissues, including adipose depots, 
to glucocorticoid hormones observed in Cushings Syndrome (Wang, 2005) causes a 
redistribution of fat. While this results in a reduction in subcutaneous triglyceride depots, 
there is increased intra-abdominal storage, leading to visceral adiposity (Garrapa et a l, 2001; 
Wajchenberg et a l, 1995). 3T3-L1 cells have an embryonic origin (Kim et a l, 2007) and 
therefore it is uncertain which adipose depot they would best represent. Despite this, none of 
the dexamethasone experiments carried out yielded the lean versus overweight adipocyte 
phenotype required.
3.S.2.2 Serum treatment
The final experiment used different concentrations of FBS in the culture medium of day 6 
adipocytes over a 9 day program. Increasing the lipid content in the culture medium through 
increased serum provision was expected to promote adipocyte triglyceride accumulation. 
However, while oil red O stains showed that the cells differentiated normally, duplicate 
experiments yielded different changes in triglyceride concentration. These ranged from a 
significant dose dependent increase in triglyceride content to no significant effect of serum. 
Previous literature has also shown that acute incubation of adipocytes with serum can be
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lipolytic. For example isolated rat adipocytes incubated with rat- (Curtis-Prior, 1973) or 
human-derived serum (Rumberger et a l, 2004) for 90 or 30 minutes, respectively, released 
approximately 10-fold more glycerol compared to control cells. Therefore, although serum 
type, coupled with cell type and treatment time, may influence resulting changes in 
intracellular triglyceride accumulation, results from my experiments were inconclusive, and 
the method was abandoned.
3.5.3 Summary
None of the experiments described herein have yielded the minimal two-fold increase in 
intracellular triglyceride stores required to compare lean with obese adipocyte phenotypes 
(Cushman and Salans, 1978; Salans et a l, 1973; Tchoukalova et a l, 2003). However, these 
studies have revealed a diverse effect of different treatments on adipocytes depending on type, 
time of onset and length of treatment, and also the phenotype of the 3T3-L1 cell used. These 
data also suggest that 3T3-L1 adipocytes may be more resistant to changes in intracellular 
triglyceride stores compared to primary cells. Not only do the results described herein 
support observations of the diversity and complexity of adipocyte responses to various 
stimuli, they also illustrate the importance of further studies into understanding the effects of 
hormones and dietary components on adipocyte triglyceride storage, and provide possible 
avenues for future work. However, as the focus of this thesis was to investigate adipocyte 
clocks, it was decided not to pursue this line of experimentation.
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CHAPTER 4;
Identification of a circadian 
clock in 3T3-L1 adipocytes
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4.1 INTRODUCTION
As well as storing energy in the form of triglycerides, white adipose tissue (WAT) acts as an 
active endocrine tissue, via the secretion of hormones termed adipokines (Trujillo and 
Scherer, 2006). The secretion of adipokines varies with changes in metabolic state, and these 
hormones regulate a wide range of distal target tissues, such as the brain, liver and skeletal 
muscle.
Many aspects of endocrine physiology and metabolism are under the control of endogenous 
circadian clocks. Analysis of transgenic mouse models shows that mutation of clock-related 
genes consistently results in metabolic dysregulation, such as dyslipidemia, and 
hypoinsulinaemia, although the phenotype depends on genetic background (Kondratov et a l, 
2006; Oishi et a i, 2006; Turek et a l, 2005). Similarly, clock gene polymorphisms in humans 
have been found to associate with components of the metabolic syndrome, such as obesity 
and type 2 diabetes (Monteleone et a l, 2008; Scott et a l, 2007; Woon et a l, 2007). 
Supporting these data, there is now increasing evidence for the circadian regulation of adipose 
function (Bray and Young, 2007; Zvonic et a l, 2007).
It is now known that approximately 20% of the murine WAT transcriptome exhibits circadian 
variation (Ptitsyn et a l, 2006), consistent with similar findings from other tissues (Duffield,
2003). Furthermore, studies of both rodents and humans have revealed diurnal changes of 
circulating adipokine concentration (Kalsbeek et a l, 2001; Saad et a l, 1998) and this 
rhythmicity may have a transcriptional basis, as adipokine mRNA is subject to diurnal 
variation in murine WAT (Ando et a l, 2005; Bray and Young, 2007).
Despite increasing evidence for a role of the circadian clock in governing adipose tissue 
rhythmicity, there are several caveats when interpreting these rhythms: 1) animals were 
maintained on a light-dark schedule prior to obtaining adipose tissue samples, so rhythmicity 
may be driven by the changing environment, a phenomenon termed ‘masking’ (Mrosovsky, 
1999); 2) adipose tissue is subject to both rhythmic endocrine and neural input (Balsalobre et 
a l, 2000a; Bartness et a l, 2001; Kreier et a l, 2006; Pevet et a l, 2006), so rhythmic clock 
gene and adipokine expression cannot be directly attributed to an adipose-specific oscillator; 
3) adipose tissue is extremely heterogeneous, meaning that circadian gene expression may be 
generated by cells other than the key metabolic adipocytes and many of these cells have been 
shown to possess endogenous clocks (Table 4.1). Therefore, in order to show that there is an
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adipocyte-specific circadian oscillator that controls various metabolic outputs, it is necessary 
to create an in vitro model that is free from masking by environmentally and systemically 
driven diurnal rhythms.
Cell type References
Fibroblast Balsalobre et a l (1998); Nagoshi et a l (2004); Welsh et a l (2004)
Macrophage Hayashi et a l (2007)
Vascular 
endothelial cell
Wang et a l (2006); Takeda et a l (2007); Schoenhard et a l (2003); 
Viswambharan et a l (2007); Westgate et a l (2008)
Leukocytes Archer et a l (2008); Boivin et a l (2003); Kusanagi et a l (2004); Takata et a l (2002)
Pre-adipocytes Wu et a l (2007); Aoyagi et a l (2005)
Table 4.1: References supporting the presence of endogenous clocks in adipose-related cell types.
There is evidence to suggest that every cell in a cell culture system possesses an intrinsic 
circadian clock (Nagoshi et al., 2004; Welsh et a l, 1995; Welsh et a l, 2004). However, as 
the circadian period of the cells will vary between cells across the culture, for example x 
values between 20 and 27 hours in Rat-1 fibroblast cultures (Balsalobre et a l, 1998), 
oscillations between the cells run out of phase and the circadian rhythm across the population 
of cells is desynchronised. It is now known that application of a pharmacological stimulus, 
such as glucose or glucocorticoid (Balsalobre et a l, 2000a; Hirota et a l, 2002), or application 
of a serum stimulus such as 50% horse serum (Balsalobre et a l, 1998) is capable of resetting 
the intracellular circadian clock mechanism. This results in synchronisation of clock gene 
expression across the culture such that the population of cells oscillates in phase (Figure 4.1).
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Figure 4.1: Synchronisation of circadian docks in cell culture. Application of a pharmacological stimulus (blue 
arrow), such as a serum pulse, to a previously oscillatory but desynchronised cell population causes resetting of 
the circadian clock mechanism. This results in synchronisation of clock gene expression across the cell culture 
such that proceeding circadian oscillations occur in phase.
4.2 HYPOTHESIS
This chapter tests the hypothesis that 3T3-L1 adipocytes possess a circadian clock that drives 
rhythmic gene expression and adipokine secretion.
4.3 OBJECTIVES
Objective 1: Design and optimise primers for clock genes, metabolic genes and adipokines.
Objective 2: Use semi-quantitative reverse transcriptase PCR to confirm the expression of 
clock genes in 3T3-L1 pre-adipocytes and adipocytes.
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Objective 3: Use serum pulse methodology to synchronise the molecular clock across the 
cell culture, and measure metabolic and clock gene mRNA expression using real-time 
quantitative PCR in 3T3-L1 pre-adipocytes and adipocytes, and adipokine mRNA expression 
in 3T3-L1 adipocytes.
Objective 4: Measure adipokine secretion from 3T3-L1 adipocytes.
4.4 METHODS
For all experiments, 3T3-L1 pre-adipocytes were grown to 2 days post-confluence and 
differentiated adipocytes were grown to day 8 post-differentiation induction as described in 
Section 2.3.3. Serum pulses were carried out according to Section 2.3.4. All RNA 
extractions were performed and cDNA synthesised according to Sections 2.7 and 2.8, 
respectively. Semi-quantitative reverse transcriptase PCR was carried out and the product run 
on an agarose gel as described in Section 2.9.1, and real-time quantitative PCR was performed 
according to Section 2.9.3.
4.4.1 Clock gene expression in 3T3-L1 pre-adipocvtes and adipocytes
To ascertain whether clock genes were expressed in 3T3-L1 pre-adipocytes and adipocytes, 
RNA was extracted from un-pulsed 3T3-L1 pre-adipocytes and adipocytes, and cDNA 
synthesised. Semi-quantitative reverse transcriptase PCR was then carried out and the 
products run on an agarose gel to look at mRNA expression of Perl, Clock, Cryl, Rev-erba 
and Dbp.
4.4.2 Acute induction of clock genes following a serum pulse
In order to establish acute effects of serum treatment on core clock gene expression, 3T3-L1 
pre-adipocytes and adipocytes were treated with a serum pulse. Following onset of the serum 
pulse (time 0), RNA was extracted after 0, 30, 60 and 120 minutes and cDNA synthesised. 
Semi-quantitative reverse transcriptase PCR was then carried out to study expression of Perl 
and Perl, with P-actin used as a house-keeping gene, and the products run on an agarose gel.
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4.4.3 Circadian gene expression in 3T3-L1 pre-adipocvtes and
adipocytes
3T3-L1 pre-adipocytes and adipocytes were serum pulsed. RNA was extracted every 4 hours 
from initiation of the serum pulse (0 hours) up to 48 hours and cDNA synthesised. Real-time 
quantitative PCR was then carried out for mRNA expression analysis of the clock genes Perl, 
Perl, Cryl, Rev-erba, Small and Dbp, the nuclear receptors Ppara and Ppary, the 
transcription factor Srebpl, and the adipokines Leptin and Adiponectin (see Appendix A for 
primer and probe details). Each timepoint is the mean ± SEM of triplicate samples. Reverse 
transcriptase negative samples were also run to assess any DNA contamination from the RNA 
extraction phase. Data was statistically analysed using One-way ANOVA (SPSS) with LSD 
post-hoc, or Two-way ANOVA with LSD post-hoc (Statistica).
4.4.4 Temporal differences in adipokine secretion from 3T3-L1 
adipocytes
From the 48 hour adipocyte serum pulse experiments described in Section 4.4.3, medium was 
collected every 4 hours from the onset of the serum pulse and stored at -80°C until thawing on 
ice to assay concentration of the adipokines leptin and adiponectin in the medium according 
to Section 2.4. Variation in the rate of adipokine secretion was measured by testing the 
departure of leptin and adiponectin accumulation from linearity, using a runs test.
4.4.5 Rhythmic gene expression in murine liver and adipose tissue
Mice were housed according to Section 2.10. After 14 days entrainment, male C57B1/6J mice 
were sacrificed at ZTO, ZT4, ZT8, ZT12, ZT16 and ZT20 (ZT = zeitgeber time, where ZTO = 
lights-on), and liver and epididymal white adipose tissue (eWAT) were collected and 
immediately frozen in liquid nitrogen for storage at -80°C until analysis. Each time point is 
the average of three animals, excepting ZTO, where there were two animals.
Liver and eWAT were thawed, homogenised in TRIzol, and RNA extracted. cDNA was then 
synthesised and real-time quantitative reverse transcriptase PCR carried out to analyse 
circadian expression of Perl, Small, Cryl, Ppara, Ppary and Srebpl, in liver and eWAT. 
Leptin and Adiponectin mRNA expression was also analysed in eWAT. Expression was then
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normalised to GAPDH and data statistically analysed using One-way ANOVA (SPSS) with 
LSD post-hoc.
4.5 RESULTS
4.5.1 Clock gene expression in 3T3-L1 pre-adipocytes and adipocytes
Amplicons were at the size predicted for each set of primers, suggesting that products were 
specific, and the core clock genes Perl, Clock, Rev-erba, Cryl and the clock-controlled gene, 
Dbp, were expressed in both 3T3-L1 mature and pre-adipocytes (Figure 4.2). There were no 
obvious differences in expression between the two cell types for any of the genes examined.
Perl Clock Rev-erba
Figure 4.2: Agarose gel showing expression of core clock components {Perl, Clock, Rev-erba, C ryl) and a 
clock output gene, Dbp, using cDNA synthesised from 3T3-L1 pre- and mature adipocyte mRNA. RNA 
was extracted from two days post-confluent pre-adipocytes, and adipocytes from day 8 post-differentiation 
induction. L = 100 base pair ladder.
4.5.2 Acute induction of clock genes following a serum pulse
Following a serum pulse, expression of Perl and Perl was induced by 2 hours in 3T3-L1 pre­
adipocytes (Figure 4.3). In contrast, fl-actin did not show any obvious changes in expression 
following a serum pulse.
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Perl
p-actin
Figure 4.3: Agarose gel of P erl and P erl expression over two hours following a serum pulse. 3T3- 
L1 pre-adipocytes were grown to 2 days post-confluence at which point, the cells were treated with 
50% horse serum for 2 hours. RNA was then extracted at 0, 30, 60 and 120 minutes post-pulse 
induction, cDNA synthesised, and gene expression estimated by semi-quantitative reverse- 
transcriptase PCR. L = 100 base pair ladder.
4.5.3 Clock gene mRNA expression in 3T3-L1 pre-adipocvtes and
adipocytes
Following a serum pulse of pre-adipocyte cells, significant (P < 0.001, One-way ANOVA) 
temporal variation of clock gene mRNA expression, as measured by quantitative real-time 
PCR, was observed for all genes examined with the exception of Perl, which did not exhibit 
significant temporal variation (P > 0.05, One-way ANOVA) (Figure 4.4 left panel). 
Expression of Per2 was significantly elevated at 4 hours compared to 0 hours post-pulse (P < 
0.001, LSD post-hoc) and then followed a circadian pattern, with the second peak occurring 
around 24-hours post-pulse and a tertiary rise in expression by 48 hours (Figure 4.4 left 
panel). Expression of Dbp was significantly lower at 4 hours compared to 0 hours post-pulse 
(P < 0.001, LSD post-hoc), but then followed a circadian rhythm, in phase with Per2 with a 
tertiary rise in expression by 48 hours (Figure 4.4 left panel). Rev-erba was not significantly 
different between 0 and 4 hours post-pulse (P > 0.05, LSD post-hoc), but exhibited 2 peaks 
approximately 24-hours apart at 20- and 44-hours post-pulse. Per2, Dbp and Rev-erba, 
rhythms were robust, with approximately 6-fold difference in expression between peak and 
trough values for Per2 and Dbp, and 3-fold changes for Rev-erba.
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Similarly to pre-adipocytes, treatment of differentiated 3T3-L1 adipocytes with a serum pulse 
induced significant (P < 0.001, One-way ANOVA) temporal variation in Per2, Rev-erba and 
Dbp expression (Figure 4.4 right panel). Expression profiles were similar to those observed 
in the pre-adipocytes, with elevated Perl expression and reduced Dbp expression at 4 hours 
compared to 0 hours post-pulse (P < 0.001, LSD post-hoc). Similarly to pre-adipocytes, there 
was a peak of expression occurring approximately 24-hours post-pulse for Perl and Dbp and 
a tertiary rise in expression by 48 hours post-pulse. Interestingly, the amplitude of Perl and 
Dbp circadian rhythmicity in adipocytes was greatly attenuated compared to pre-adipocytes 
(compare Figure 4.4 left panel to right panel for Perl and Dbp). Replotting the data 
surrounding the peak (defined as first peak after acute serum effects, and therefore 24 hours 
post-pulse), showed that Perl and Dbp expression was significantly affected by cell type and 
time separately, and there was also a significant interaction of cell type and time (cell type P < 
0.001, time P < 0.001, cell type x time P < 0.001, Two-way ANOVA) (Figure 4.5). 
Expression of both Perl and Dbp was significantly lower in adipocytes compared to pre­
adipocytes (comparison between cell types at individual timepoints for Perl P < 0.001 at 20, 
24 and 28, and P <0.01 at 32 hours post-pulse; and for Dbp P < 0.001 at 20, 24 and 28 hours 
post-pulse, LSD post-hoc).
Rev-erba also followed a similar profile to that observed in pre-adipocytes with a peak at 20- 
hours post-pulse and a secondary rise in expression approximately 24 hours later at 44 hours 
post-pulse. However, in comparison to pre-adipocytes, Rev-erba expression was significantly 
higher at 4 hours compared to 0 hours post-pulse (P < 0.001, LSD post-hoc).
By contrast, although expression of Cryl and Email exhibited significant temporal variation 
in pre-adipocytes (P < 0.05, One-way ANOVA), with significantly elevated expression at 4 
hours compared to 0 hours post-pulse (P < 0.001, LSD post-hoc), expression of these genes 
then settled to a constant level of expression, with no clear circadian variation (Figure 4.4 left 
panel). In comparison, pre-adipocyte Perl expression did not exhibit significant temporal 
variation (P > 0.05, One-way ANOVA). Unlike in pre-adipocytes, in serum pulsed 
adipocytes significant temporal Perl expression was observed in addition to Cryl and Email 
temporal variation (P < 0.001, One-way ANOVA) (Figure 4.4 right panel). In all three genes, 
significant differences between 0 and 4 hours post-pulse (P < 0.001, LSD post-hoc) was 
followed by a constant level of expression.
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Figure 4.4: Temporal profiles of clock gene expression following a serum pulse of 3T3-L1 pre-adipocytes and 
adipocytes. Pre-adipocyte cells were grown to 2 days post-confluence at which point they were treated with a 
serum pulse. Mature adipocytes were serum pulsed 8 days after the onset of differentiation. Following the serum 
pulse, total RNA was extracted every 4-hours over a 48-hour period and gene expression measured by 
quantitative real-time PCR. For both pre-adipocyte and adipocyte serum pulses, there was significant (P < 0.05, 
One-way ANOVA) temporal variation of expression of each gene measured, except P erl in pre-adipocytes. 
Values are mean ± SEM of n=3 wells of cells from a representative experiment.
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Figure 4.5: Replotted peak from temporal profiles of clock gene expression in Figure 4.4. Pre-adipocyte cells 
were grown to 2 days post-confluence at which point they were treated with a serum pulse. Mature adipocytes 
were serum pulsed 8 days after the onset of differentiation. Following the serum pulse, total RNA was extracted 
every 4-hours over a 48-hour period and gene expression measured by quantitative real-time PCR. There was a 
significant effect of time, cell type and interaction of time x cell type on pre-adipocyte and adipocyte gene 
expression (P < 0.001, Two-way ANOVA). Values are mean ± SEM of n=3 wells of cells from a representative 
experiment. ** P < 0.0P, *** P < 0.001
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4.5.4 Clock gene mRNA expression in murine eWAT and liver
Expression of Perl and Bmall mRNA in murine eWAT showed significant diurnal variation 
(P < 0.05 and 0.001, respectively, One-way ANOVA) (Figure 4.6 left panel). Whereas Perl 
showed a peak in expression at ZT16, Bmall showed a 2- to 3-fold change in gene 
expression, with the zenith occurring at approximately ZTO and a nadir occurring in antiphase 
to Perl at ZT16. Cryl also showed significant temporal change in expression (P < 0.01, One­
way ANOVA) with the primary peak occurring at ZT20 (Figure 4.6 left panel). However, 
there was also a secondary peak in Cryl expression at ZT8 (ZTO compared to ZT4 and ZT4 
compared to ZT8 P < 0.05, LSD post-hoc).
Significant circadian gene expression of Perl, Cryl and Bmall was also observed in the liver 
(P < 0.001, One-way ANOVA) (Figure 4.6 right panel). There was a highly significant 
difference in peak to trough expression of both Bmall and Perl. Phasing in gene expression 
was similar in both eWAT and liver tissue and, similarly to adipose tissue, the biphasic peak 
of Cryl mRNA expression was also observed in the liver (ZTO compared to ZT4 and ZT4 
compared to ZT8 P < 0.01 and P < 0.001, respectively, LSD post-hoc). However, Perl, Cryl 
and Bmall showed approximately 10-fold larger changes in expression when compared to 
eWAT.
4.5.5 Metabolic gene mRNA expression in 3T3-L1 pre-adipocytes 
and adipocytes
Following a serum pulse of pre-adipocytes, significant (P < 0.05, One-way ANOVA) 
temporal variation in Ppara, Ppary and Srebpl mRNA expression was observed, as measured 
by quantitative real-time PCR (Figure 4.7 left panel). Whereas Srebpl and Ppary (Figure 4.7 
left panel) expression gradually decreased following a serum pulse, Ppara expression 
exhibited transient suppression (Figure 4.7 left panel). Expression of all three genes then 
remained constant, with no evidence of circadian variation.
As with pre-adipocytes, 3T3-L1 adipocytes exposed to a serum pulse showed significant (P < 
0.05, One-way ANOVA) temporal variation in Ppara, Ppary and Srebpl mRNA expression 
following a serum pulse (Figure 4.7 right panel). In contrast to pre-adipocytes, expression of 
Srebpl and Ppara (Figure 4.7 right panel) gradually increased, with expression of Ppara
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decreasing again by 44-hours post-pulse, but remaining constant in Srebpl. However, in none 
of the metabolic genes examined was there circadian variation of expression patterns.
4.5.6 Metabolic gene mRNA expression in murine eWAT and liver
Figure 4.8 (left panel) shows Ppara, Ppary and Srebpl expression in C57B1/6J murine 
eWAT. In eWAT, Srebpl, Ppara and Ppary failed to exhibit significant temporal variation 
(P > 0.05, One-way ANOVA). Ppara also failed to show significant temporal variation in 
liver (P > 0.05, One-way ANOVA) (Figure 4.8 right panel). In contrast, liver Srebpl and 
Ppary mRNA expression exhibited a significant 2 to 3-fold diurnal variation (P < 0.05, One­
way ANOVA) with a peak at ZT16 or ZT12 for Srebpl and Ppary, respectively (Figure 4.8 
right panel).
4.5.7 Temporal variation of leptin mRNA expression and hormone 
secretion
Temporal changes in leptin secretion were assessed by measurement of leptin accumulation in 
the culture medium. Following a serum pulse, leptin concentration increased in the culture 
medium, but in a non-linear fashion (P < 0.05, runs test) (Figure 4.9A). In order to estimate 
rate of leptin secretion, the data were re-plotted as the difference in mean leptin concentration 
between 4-hourly time-points. These data revealed that leptin secretion was markedly 
attenuated between 8-12 hours post-pulse and then appeared to exhibit circadian rhythmicity, 
with a second nadir of leptin secretion after 32-36 hours (Figure 4.9B).
Following a serum pulse of differentiated 3T3-L1 adipocytes, expression of Leptin mRNA 
exhibited significant temporal variation (P < 0.001, One-way ANOVA) (Figure 4.9C). 
However, there was no evidence of circadian rhythmicity. In contrast, there were no 
significant temporal changes in Leptin mRNA expression in C57B1/6J murine adipose tissue 
(P > 0.05, One-way ANOVA) (Figure 4.9D).
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4.5.8 Temporal variation of adiponectin mRNA expression and
hormone secretion
Following a serum puise, adiponectin concentration increased in the culture medium, but in a 
non-linear fashion (P < 0.05, runs test) (Figure 4.10A). The data were re-plotted as the 
difference in mean adiponectin concentration between 4-hourly time-points (Figure 4.10B). 
However, there were no obvious circadian variations in adiponectin secretion.
Following a serum pulse of differentiated 3T3-L1 adipocytes, expression of Adiponectin 
mRNA exhibited significant temporal variation (P < 0.001, One-way ANOVA) (Figure 
4 .10C). However, there was no evidence of circadian rhythmicity. In contrast, temporal 
dynamics of Adiponectin mRNA expression in C57B1/6J murine adipose tissue failed to reach 
significance (P > 0.05, One-way ANOVA) (Figure 4.10D).
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Figure 4.6: Temporal profiles of clock gene expression in murine eWAT and liver from animals housed on a 
12L:12D (white bar: black bar) cycle. There was significant (P < 0.05, One-way ANOVA) temporal variation of 
expression for all genes in liver and eWAT. Values are mean ± SEM of n=3 animals, except ZT0 where n=2.
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Figure 4.7: Temporal profiles of metabolic gene expression following a serum pulse of 3T3-L1 pre-adipocytes 
and adipocytes. Pre-adipocyte cells grown to 2 days post-confluence, and mature adipocytes 8 days post­
differentiation induction, were treated with a serum pulse. Total RNA was then extracted every 4-hours over a 
48-hour period and gene expression measured by quantitative real-time PCR. For both pre-adipocyte and 
adipocyte serum pulses, there was significant (P < 0.05, One-way ANOVA) temporal variation of expression of 
each gene measured. All values are mean ± SEM of n=3 wells of cells from a representative experiment.
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Figure 4.8: Temporal profiles of metabolic gene expression in murine eWAT and liver from animals housed on 
a 12L:12D (white bar: black bar) cycle. Temporal changes in tissue metabolic gene expression only reached 
significance (P < 0.05, One-way ANOVA) for Srebpl and Ppary in liver. Values are mean ± SEM of n=3 
animals, except ZT0 where n=2.
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Figure 4.9: Temporal expression and secretion of leptin following a serum pulse of differentiated 3T3-L1 
adipocytes or from murine eWAT of animals housed on a 12L:12D cycle. Mature adipocytes were serum pulsed 
8 days after the onset of differentiation. Culture medium and total RNA was then collected every 4 hours over a 
48-hour period. Leptin concentration was then measured using commercial quantitative ELISA assays, and gene 
expression measured by quantitative real-time PCR. (A) Concentration of leptin in culture medium accumulated 
in a non-linear manner (P < 0.05, runs test). The dashed line shows the linear regression for the adipokine 
concentration data. (B) Rate of secretion over the 48-hour period was estimated by plotting the difference in 
mean adipokine concentration between consecutive time points from (A). (C) Leptin mRNA from 3T3-L1 
adipocytes exhibited significant (P < 0.001, One-way ANOVA) temporal non-circadian variation. (D) There 
was no significant (P > 0.05, One-way ANOVA) variation of Leptin mRNA in murine adipose tissue. Values 
are mean ± SEM of n=3 (A-C) wells of cells from a representative experiment or (D) animals (except ZT0 where 
n=2).
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Figure 4.10: Temporal expression and secretion of adiponectin following a serum pulse of differentiated 3T3- 
L1 adipocytes or from murine eWAT of animals housed on a 12L:12D cycle. Mature adipocytes were serum 
pulsed 8 days after the onset of differentiation. Culture medium and total RNA was then collected every 4 hours 
over a 48-hour period. Adiponectin concentration was then measured using commercial quantitative ELISA 
assays, and gene expression measured by quantitative real-time PCR. (A) Concentration of adiponectin in culture 
medium accumulated in a non-linear manner (P  < 0.05, runs test). The dashed line shows the linear regression 
foi the adipokine concentration data. (B) Rate of secretion over the 48-hour period was estimated by plotting the 
difference in mean adipokine concentration between consecutive time points from (A). (C) Adiponectin mRNA 
from 3T3-L1 adipocytes exhibited significant (P < 0.001, One-way ANOVA) temporal but non-circadian 
variation. (D) There was no significant (P > 0.05, One-way ANOVA) variation of Adiponectin mRNA in 
murine adipose tissue. Values are mean + SEM of n=3 (A-C) wells of cells from a representative experiment or 
(D) animals (except ZT0 where n=2).
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4.6 DISCUSSION
Circadian docks are involved in many aspects of mammalian metabolism (Bray and Young, 
2007; Hastings et a l, 2007; Ramsey et a l, 2007), and microarrays have demonstrated that 
approximately 20% of the WAT transciiptome exhibits circadian rhythmicity (Ptitsyn et a l, 
2006; Zvonic et a l, 2006). However, due to cellular heterogeneity, the occurrence of 
rhythmical WAT input signals in vivo, and masking in previous animals studies, it is still 
unclear whether murine adipocytes themselves possess an endogenous circadian clock.
In order to address this question, it was necessary to create an in vitro adipocyte culture. 3T3- 
L1 cells were employed as they are a well-characterised murine cell line commonly used to 
examine adipocyte physiology. Although these cells are known to express clock genes 
(Aoyagi et a l, 2005; Shimba et a l, 2005), there are no published data describing temporal 
changes in their physiology using quantifiable assays.
In this study, circadian rhythmicity within murine 3T3-L1 pre-adipocyte and adipocyte cells 
has been comprehensively characterised, by quantifying both clock and metabolic gene 
mRNA, as well as adipokine gene expression and secretion. 3T3-L1 pre- and mature 
adipocytes have been shown to express the clock genes Perl, Per2, Cryl, Rev-erba, Bmall, 
Clock and the CCG Dbp. However, only Perl, Rev-erba and Dbp exhibit circadian 
rhythmicity following a serum pulse. Additionally, after a serum pulse, both pre-adipocytes 
and adipocytes express the metabolic genes Ppary, Ppara and Srebpl in a non-circadian 
manner. Mature adipocytes are also shown here to secrete leptin, but not adiponectin, in a 
circadian manner in the absence of circadian Leptin and Adiponectin mRNA expression. This 
is the first time that a quantifiable method has established the presence of an endogenous 
circadian clock in 3T3-L1 pre- and mature adipocytes, and the first study to report rhythmic 
secretion of leptin from adipocytes.
4.6.1 Clock genes are expressed in 3T3-L1 pre-adipocytes and 
adipocytes
In order to confirm that my population of cells express clock genes and are responsive to a 
serum pulse, semi-quantitative reverse-transcriptase PCR was used. Perl, Perl, Rev-erba, 
Clock and the CCG Dbp, were expressed in both cell types as has been described previously 
in 3T3-L1 mature adipocytes (Aoyagi et a l, 2005; Shimba et a l, 2005). However, for the
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first time, Cryl mRNA expression has been shown in both pre- and mature 3T3-L1 
adipocytes. Additionally, Perl and Per2 are acutely induced within two hours of a serum 
pulse, showing that the serum pulse is capable of upregulating clock gene expression in these 
cells in a manner similar to that previously reported in multiple cell lines, including Rat-1 
fibroblasts (Balsalobre et a l, 1998).
By extending the sampling period to 48 hours and using quantitative reverse-transcriptase 
PCR, circadian variation of Per2, Rev-erba and Dbp expression was observed in both 3T3-L1 
pre-adipocytes and differentiated adipocytes following a serum pulse. This is consistent with 
the recently reported circadian rhythms in human adipose-derived stem cells (Huang et a l, 
2009; Wu et a l, 2007), and provides evidence for an endogenous circadian clock in 3T3-L1 
adipocytes. However, Perl, Cryl, and Bmall mRNA failed to exhibit circadian rhythmicity, 
despite having previously been shown to oscillate in murine WAT (Ando et a l, 2005; Bray 
and Young, 2007; Zvonic et a l, 2006). The arrhythmicity of Perl, Cryl and Bmall mRNA 
expression in 3T3-L1 cells was unlikely to be an artefact of primer-probe design as 24-hour 
rhythms of all these genes in C57B1/6J murine adipose and liver tissue were detected as 
described previously (Ando et a l, 2006; Ando et a l, 2005; Yang et a l, 2006; Zvonic et a l,
2006). Lack of a robust circadian rhythm in some of the clock genes reported here is 
consistent with other studies. For example, Perl expression exhibits extremely low (less than 
two-fold) amplitude changes in adipose-derived stem cells following a serum pulse (Huang et 
a l, 2009), while Cryl fails to exhibit circadian expression after a serum pulse of murine GT1- 
7 neurons (Gillespie et a l, 2003). Human peripheral leukocytes derived from blood also 
exhibit less than two-fold changes in BMAL1 expression (Ando et a l, 2009), and BMAL1 
protein fails to oscillate in ex vivo murine cerebellum (Siepka et a l, 2007), both of which 
suggest that lack of clock gene rhythmicity is not an artefact of using a cell culture system. 
BMAL1 and CRY1 have also been found to be arrhythmic in other cell types, including human 
bone marrow CD34+ cells (Tsinkalovsky et a l, 2007), in the presence of rhythmic PER2.
It is surprising that Perl is not rhythmic while Per2 mRNA expression oscillates in a 
circadian manner in both 3T3-L1 pre-adipocytes and adipocytes, as both possess E box 
promoter elements that are transcriptionally activated by the BMAL 1/CLOCK complex 
(Gekakis et a l, 1998). However, failure of Perl to oscillate in the presence of rhythmic Per2 
expression has been observed previously in NIH3T3 cells (Akashi et a l, 2006), and following 
a 50% horse serum pulse in H35 hepatoma cells (Balsalobre et a l, 1998). Perl expression 
has also been found to be arrhythmic in adipose derived stem cells (Huang et a l, 2009). It
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has been suggested that there may be differential promoter activity between the two genes. 
Indeed, is has been shown that Perl has a classical circadian E box sequence (CTCGTG), 
whereas Perl has a different E box motif (CTCGTT). While both of these promoter 
sequences facilitate BMALI/CLOCK binding, when the CTCGTT E box is replaced by the 
classical circadian E box in the Perl promoter (Akashi et a l, 2006), Perl showed lower 
amplitude expression comparable to Perl. Therefore, Perl rhythmicity may be partially 
dependent on humoral or neural signals to drive circadian expression in some cell types, 
whereas Perl is primarily cell autonomous. This is supported by findings in 
Perl:Luciferease knock-in mice, where tissue explants exhibit robust self-sustained rhythms 
for more than 20 cycles (Yoo et a l, 2004), and may explain why Perl in my study showed 
acute induction following the serum pulse, but no rhythmicity thereafter. However, it is also 
been found that hepatic protein rhythms do not necessarily reflect temporal mRNA expression 
(Reddy et a l, 2006). Therefore, Western blotting of PERI, BMAL1 and CRY1 is necessary 
to establish whether the protein is rhythmic in 3T3-L1 pre- and mature adipocytes.
In this study, Perl, Rev-erba and Dbp exhibited circadian rhythms in both pre- and mature 
3T3-L1 adipocytes. As has been reported previously, Perl and Dbp show a similar temporal 
zenith of expression (Siepka et a l, 2007) with Rev-erba reaching peak expression four hours 
earlier (Zvonic et a l, 2007). However, the amplitude of Perl and Dbp rhythms was 
dramatically reduced in adipocytes compared to pre-adipocytes, a phenomenon that has also 
been observed in human subcutaneous adipocytes compared to pre-adipocytes that were 
synchronised with either a dexamethasone or serum pulse (Wu et a l, 2007). The reason for 
this is currently unknown, but may be due to either attenuated intra-cellular rhythm amplitude 
or a decreased ability of the serum pulse to synchronise rhythmicity in the cell population.
Analysis of neuronal firing and reporter gene expression has demonstrated that circadian 
clocks reside within individual cells that require adequate synchronisation to provide coherent 
output rhythms (Nagoshi et a l, 2004; Welsh et a l, 1995; Welsh et a l, 2004). As it is known 
that circadian rhythms persist in differentiated human adipocytes (Wu et a l, 2007), reduced 
adipocyte rhythmicity in the 3T3-L1 cell population may derive from poorer inter-cellular 
synchronisation following a serum pulse. Alternatively, intra-cellular triglyceride 
accumulation in mature adipocytes may directly or indirectly (such as through altered 
cytokine production) inhibit the molecular clock mechanism, and therefore result in the 
reduced amplitude of clock gene rhythms observed here (Ando et a l, 2005; Kohsaka et a l,
2007). Hypertrophic adipocytes are known to secrete higher concentrations of TNFa due to
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higher expression and reduced turnover (Xu et a l, 2002). TNFa is capable of suppressing the 
rhythm of E box regulated clock genes (Cavadini et a l, 2007), thereby providing a putative 
link between triglyceride content of adipocytes, inflammation during obesity and subsequent 
suppression of amplitude in the molecular clock rhythm.
4.6.2 Circadian metabolic gene expression
In this study, Ppara, Ppary and Srebpl mRNA expression did not oscillate in a circadian 
fashion in murine adipose tissue, or in 3T3-L1 pre- and mature adipocytes. However, both 
Srebpl and Ppary mRNA expression exhibited a significant 2- to 3-fold diurnal variation in 
murine liver tissue. To date, there is evidence linking PPARs to the molecular clock in liver 
and other tissues. BMALI/CLOCK transactivates PPARa target genes in the murine small 
intestine by binding to the PPRE (Inoue et a l, 2005), consistent with results shown for 
PPARy in human kidney 293T cells (Nakamura et a l, 2008). An E-box rich region in intron 
2 of the Ppara gene has been discovered, suggesting that BMAL1/CLOCK upregulates Ppara 
expression, which subsequently increases expression of PPARa target genes, such as 
Lipoprotein lipase (Lpl) (Oishi et a l, 2005). Oishi et a l (2005) also found that ClockA19 
mutation, leads to loss of Ppara rhythmicity both in vivo and in vitro in murine liver. 
Conversely, there is evidence for reciprocal regulation between the molecular oscillator and 
Ppara, as Ppara'A mice failed to show phase shifts in Bmall mRNA expression under a 
restricted feeding paradigm (Canaple et a l, 2006). This suggests that Bmall is under PPARa 
regulation, supported by the discovery of a peroxisome proliferator response element (PPRE) 
site in the Bmall promoter to which PPARs bind (Canaple et a l, 2006). SREBP1 is also 
capable of binding to E-boxes, and can be entrained by restricted feeding. This may provide a 
further link between the molecular clock and metabolism (Brewer et a l, 2005).
Interestingly, in this study, Ppara was not rhythmic in murine liver or eWAT despite Bmall 
oscillations in both tissues. Although this discrepancy with previous studies could be due to 
different mouse genetic background or experimental procedures, Yang et a l (2006) report 
that Ppara and y expression is rhythmic in C57BL/6J mice maintained on a 12L:12D cycle. 
However, rhythm amplitude is extremely low (approximately 2-fold in eWAT and liver for 
Ppara), suggesting that circadian rhythms in Ppara and Ppary expression may have been too 
low to detect in my eWAT samples. Alternatively, lack of diurnal variation of eWAT and 
liver Ppar expression in the presence of Bmall circadian rhythmicity may suggest that Bmall 
rhythmicity is insufficient to drive rhythmic Ppar expression.
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To date no studies have shown that a functional intracellular clock mechanism is required for 
circadian Ppar or Srebpl expression, and vice versa. Therefore, results from the previous 
studies coupled with current findings suggest that reciprocal regulation between Ppars and 
Bmall is not sufficient to drive circadian regulation, but acts merely as a fine tuning 
mechanism. For example, the shifts in Ppara expression observed during the restricted 
feeding paradigm (Canaple et a l, 2006) feed back into the molecular oscillator to enable 
Bmall expression to entrain to the new feeding schedule, but do not cause Bmall circadian 
expression per se. This would also provide a mechanism whereby the molecular oscillator in 
peripheral tissues can be entrained to feeding. Therefore, these results suggest that rhythmic 
input is required to drive diurnal rhythmicity of Bmall and Ppar expression in pre-adipocytes 
and adipocytes in vivo, supported by the failure of Ppara, Ppary and Bmall to oscillate in 
3T3-L1 pre- and mature adipocytes.
If diurnal expression of Ppar and Srebpl is driven by rhythmic input from neural or humoral 
cues and not by the intracellular clock, loss of circadian Ppara mRNA expression in 
ClockA19 mutant mice may be explained by abnormal circulating hormone concentrations, 
such as hypoinsulinaemia, observed in these mutants (Turek et a l, 2005).
4.6.3 Circadian adipokine gene expression and secretion
As well as failing to exhibit rhythmic metabolic gene expression, 3T3-L1 adipocytes also 
failed to show clear circadian variation in the expression of the adipokines Leptin and 
Adiponectin. Murine eWAT also failed to exhibit significant temporal variation in Leptin and 
Adiponectin mRNA, unlike the low amplitude circadian expression reported previously (Ando 
et a l, 2005; Kalsbeek et a l, 2001). In contrast, reduction of leptin secretion into culture 
medium between eight and twelve hours post-pulse suggests that leptin, but not adiponectin, 
secretion is controlled by the adipocyte molecular clock following a serum pulse.
In vivo, plasma leptin and adiponectin concentrations are known to exhibit circulating 
rhythmicity in humans (Gavrila et a l, 2003; Shea et a l, 2005; Sinha et a l, 1996; Spiegel et 
a l, 2004a; Spiegel et a l, 2004b) and rodents (Kalsbeek et a l, 2001), and there is evidence for 
diurnal adipokine gene transcription in adipose tissue (Ando et a l, 2005). Interestingly, 
circadian leptin secretion from 3T3-L1 adipocytes occurred in the absence of clear rhythmic 
changes in leptin mRNA expression. Similar findings have been described by previous
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studies of the liver proteome, in which hepatic protein rhythms do not necessarily reflect 
temporal mRNA expression patterns (Reddy et a i, 2006).
Results from 3T3-L1 adipocytes may shed further light on an experiment conducted by 
Kalsbeek et a l (2001), who claimed, via analysis of lesion experiments in rats, that the SCN 
was required to drive diurnal changes in plasma leptin levels. If the adipocyte molecular 
clock does govern the diurnal leptin secretion, and subsequently plasma rhythms, it may be 
that the SCN is required to maintain synchrony of this rhythm between adipocytes rather than 
generate de novo circadian hormone release. Although no experiments have been published 
assessing desynchrony of cells within a tissue in the absence of a synchronising stimulus, 
studies of Per2\Luciferase transgenic mice showed that SCN lesions caused phase 
dyssynchrony between tissues, such as the liver, pituitary and lung (Yoo et a l, 2004). 
Additionally, the observation that the intrinsic molecular oscillator persists in all cells of a 
culture system, but is desynchronised between cells suggests the necessity for a synchronising 
stimulus (Nagoshi et a l, 2004; Welsh et a l, 2004).
In contrast to leptin data, while adiponectin secretion exhibited clear temporal variation, no 
circadian periodicity was observed. However, ultradian rhythms in adiponectin plasma 
concentrations have also been observed in humans (Gavrila et a l, 2003), so the possibility 
cannot be ruled out that ultradian adiponectin release from 3T3-L1 adipocytes in this study 
masks any circadian secretory patterns. Indeed, while plasma leptin concentration exhibits 
approximately 4 ultradian peaks over 24 hours, occurring approximately 3 hours post- 
prandially (Saad et a l, 1998), adiponectin has approximately 10 peaks of a higher percentage 
increase (Gavrila et a l, 2003). Therefore, a greater temporal resolution would be required to 
establish temporal ultradian versus circadian secretory dynamics. A more accurate way of 
measuring temporal changes in secretory dynamics would also be beneficial. While this study 
uses a static culture system, flow cultures of adipocytes would increase temporal resolution of 
culture medium sampling. Further work should also be carried out to establish a direct 
connection between the adipocyte molecular clock and leptin release, such as through 
measuring adipokine release from cells in which the molecular oscillator has been ablated. It 
will also be essential to study the mechanism linking the clock to secretion in adipocytes.
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4.6.4 Rhythmical input versus an endogenous adipocyte circadian
clock
Temporal variation in the expression of Perl, Rev-erba and Dbp mRNA, coupled with 
secretion of leptin from adipocytes, indicates that 3T3-L1 pre- and mature adipocytes contain 
elements of an endogenous circadian clock. This study also provides the first indication of an 
adipocyte-based mechanism driving plasma leptin concentration, as opposed to other possible 
contributory factors, such as changes in hormonal half life or rhythmical stimulation of WAT 
hormone secretion by input pathway(s).
In contrast, the lack of circadian mRNA expression of Perl, Cryl, Bmall, Ppara, Ppary, 
Srebpl, Leptin and Adiponectin suggests that the reported rhythmic expression of these genes 
in ex vivo murine adipose tissue (Bray and Young, 2007; Ptitsyn et a i, 2006; Zvonic et a l, 
2006) results from external factors, such as non-adipocyte cell type(s) or rhythmical input 
signals, rather than the endogenous pre-adipocyte/adipocyte clock.
Adipose tissue is comprised of numerous cell types, including fibroblasts, macrophages, and 
vascular cells. Fibroblasts, such as NIH3T3 cells and Rat-1 fibroblasts, have been widely 
reported to exhibit circadian rhythms in clock gene expression (Balsalobre et a l, 1998; 
Nagoshi et a l, 2004; Welsh et a i, 2004; Yamanaka et al., 2007). Vascular endothelial cells 
and macrophages also exhibit robust circadian oscillations in clock gene expression (Hayashi 
et a l, 2007; Schoenhard et a l, 2003). However, although rhythms of Perl, Cryl, and Bmall 
mRNA reported here in murine eWAT may derive from clocks present in the non-adipocyte 
fraction of WAT, adipokine mRNA is localised to adipocyte cells. This suggests that, 
although murine adipocytes and pre-adipocytes do contain an endogenous circadian clock, 
some of the rhythmicity reported in adipose tissue derives from rhythmical input to the tissue. 
This is supported by a study in which rhythmic expression of some genes in the liver, 
including Perl, persisted in the presence of a disrupted hepatocyte circadian clock (Kommann 
et a l, 2007).
WAT is highly vascularised and adipocytes are therefore exposed to, and possesses receptors 
for, a milieu of humoral agents that possess circadian dynamics in blood concentration, such 
as glucocorticoids, insulin (Bost et a l, 2005; Feve, 2005) atrial natriuretic peptide (ANP) 
(Portaluppi et a l, 1989) and melatonin (Brydon et a l, 2001). Glucocorticoids and insulin 
have been implicated in various aspects of adipocyte biology, including differentiation,
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lipolysis and lipogenesis. Indeed, insulin is a negative regulator, and glucocorticoids are a 
positive regulator of Ppara expression in vivo, with exogenously applied insulin or 
glucocorticoids affecting expression levels of Ppara (Lemberger et a l, 1994). In contrast, 
ANP is involved in exercise related lipid mobilisation from adipocyte triglyceride stores 
(Mora et a l, 2004a). Interestingly, the melatonin MT2 receptor has been found on adipocytes 
(Brydon et a l, 2001), although the role is currently unknown, it has been suggested that 
melatonin controls adipokine expression (Alonso-Vale et a l, 2006; Alonso-Vale et a l, 2008; 
Alonso-Vale et a l, 2005) and may also aid in the entraining of peripheral clocks (von Gall et 
a l, 2002).
As well as circadian exposure to humoral agents, adipose tissue is subject to circadian 
sympathetic input, with increased sympathetic activity occurring during the day. Studies 
using transneuronal tract tracers reveal sympathetic innervation of adipose tissue from the 
brain, and that approximately three percent of adipocytes possess direct neural connections 
(Turtzo et a l, 2001). Adipocytes also express P1.3- and (^-adrenoceptors, rendering them 
sensitive to noradrenaline and adrenaline (Carmen and Victor, 2006). Therefore, future 
studies will be required to explore which of these rhythmic inputs might be important for 
synchronising the molecular oscillator in adipocytes.
4.6.5 Summary
In summary, this study provides evidence for an endogenous adipocyte clock that controls not 
only gene expression but also endocrine activity. Lack of rhythmicity of some clock and all 
metabolic genes examined suggests that rhythmical input to adipocytes and WAT is also 
essential for normal WAT circadian function. These data therefore strengthen the view that 
circadian rhythms have functional relevance to adipose biology, lipid metabolism and related 
pathophysiology.
Data from Chapter 4 is published as Otway, D. T., Frost, G., and Johnston, 
J. D. (2009). Circadian rhythmicity in murine pre-adipocyte and adipocyte 
cells. Chronobiol Int 26(7): 1340-1354 (see Appendix L)
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CHAPTER 5:
Circadian rhythms in human 
adipose tissue
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5.1 INTRODUCTION
There are multiple lines of evidence that provide a compelling link between circadian 
disruption, metabolic diseases and diabetes. These include an increased incidence of 
metabolic syndrome and diabetes in shift workers (Knutsson, 2003), and the presence of 
metabolic abnormalities in transgenic mice that bear mutated genes associated with circadian 
clock function (Kudo et al., 2007b; Oishi et ah, 2006; Turek et al., 2005). This genetic link 
between clocks and metabolism has also been observed in humans, with reported associations 
between clock gene haplotypes and type 2 diabetes (Woon et a l, 2007). However, the 
clearest physiological link between circadian timing and diabetes arguably comes from 
studies of rhythmicity in adipose tissue and its hormonal products, termed adipokines.
Adipokines provide an important physiological link between adipose physiology and glucose 
metabolism, and act via multiple pathways including regulation of insulin sensitivity (Trujillo 
and Scherer, 2006). In many studies, the best studied adipokines, leptin and adiponectin, 
exhibited daily rhythms in human plasma (Gavrila et a l, 2003). Moreover, there appears to 
be a transcriptional basis for these rhythms. Microarray data of samples collected over a 24- 
hour cycle revealed widespread rhythmicity of mRNA expression within mouse white adipose 
tissue (WAT) that encompasses up to 20% of the entire WAT transciiptome, including 
multiple adipokine genes (Ptitsyn et a l, 2006; Zvonic et a l, 2006). Chapter 4 also provides 
compelling evidence for an adipocyte role in diurnal leptin secretion from these cells (Otway 
et a l, 2009). However, molecular rhythms in human adipose tissue from type 2 diabetic 
patients have not been studied.
Obesity is recognised as one of the major risk factors for the development of type 2 diabetes. 
At the tissue level, obesity is associated with increased adipocyte differentiation and also 
hypertrophy, an increase in cell size caused by excess triglyceride accumulation (Trujillo and 
Scherer, 2006). In addition, the occurrence of obesity exhibits a clear correlation with 
attenuation of adipose and adipokine rhythmicity. For example high-fat diet induces lower 
Perl expression in epididymal WAT from C57BL/6J mice compared to those fed regular 
chow (Kohsaka and Bass, 2007). Additionally, obese mice exhibiting symptoms of diabetes 
show daily rhythms of both adipokine and clock gene mRNA that are severely attenuated in 
adipose depots (Ando et a l, 2005). Similar data have been obtained from studies of lean and 
obese human subjects; whereas lean subjects exhibited plasma adipokine rhythmicity, obese
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subjects did not (Calvani et a l, 2004; Matkovic et a l, 1997; Saad et a l, 1998). Although it 
has been proposed that abnormal rhythmic adipokine secretion may contribute to obesity 
(Matkovic et a l, 1997; Saad et a l, 1998), the relationship between adipokine rhythmicity and 
type 2 diabetes per se is not well studied.
Additionally, differences in metabolic factor gene expression have not been fully compared 
between lean and diabetic cohorts, although there are now links between these genes and the 
molecular oscillator. For example, PPARy co-activator 1“ (PGC-la) is a transcriptional co­
activator that is rhythmically expressed in murine liver and skeletal muscle. It upregulates 
adaptive energy metabolism in many tissues, and is involved in mitochondrial biogenesis 
(Leone et a l, 2005). PGC-la has been shown to induce expression of Clock and Bmall (Liu 
et a l, 2007a), and interact with nuclear receptors such as the PPARs, which have been shown 
to transactivate Clock and Bmall (Canaple et a l, 2006; Nakamura et a l, 2008; Oishi et a l, 
2005). Therefore, PGC-la may provide a link between the circadian clock and energy 
metabolism. In contrast, receptor interacting protein 140 (RIP 140) is a co-repressor 
responsible for repressing metabolic genes, including PGC-la, and upregulating lipogenic 
genes, such as fatty acid synthase in WAT (Leonardsson et a l, 2004). RIP140 is also capable 
of repressing the transcriptional activity of nuclear receptors such as the PPARs by direct 
binding (L'Horset et a l, 1996; Treuter et a l, 1998), again providing a putative link to the 
circadian oscillator.
5.2 HYPOTHESIS
Patients with type 2 diabetes exhibit attenuated clock gene and adipokine rhythmicity at the 
level of adipose transcription.
5.3 OBJECTIVES
Objective 1: Recruit study volunteers for three experimental groups, each matched for age 
and gender: patients with type 2 diabetes, overweight individuals without type 2 diabetes, and 
lean, healthy controls.
Objective 2: Collect serial samples of blood and subcutaneous abdominal adipose tissue 
from study volunteers across a 24-hour cycle, in experimentally controlled conditions.
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Objective 3: Analyse 24-hour rhythms of circadian clock gene and adipokine mRNA
expression in adipose biopsies by quantitative real-time PCR.
5.4 METHODS
Detailed methods for this chapter can be found in Section 2.11. This study received ethical 
approval from the Surrey Research Ethics Committee and University of Surrey Ethics 
Committee. Further information on ethical considerations can be found in Section 2.11.3.
5.4.1 Recruitment
Participants were recruited according to Section 2.11.1. 27 male participants aged 40-65 
years were recruited into one of three cohorts (8 type 2 diabetic patients, 11 overweight 
subjects, and 8 lean and healthy participants). Criteria for each of the cohorts as well as 
inclusion and exclusion criteria can be found in Section 2.11.2. From the type 2 diabetic 
patients recruited, 3 were diet and exercise controlled, while the remainder were taking 
medications, which are detailed in Table 5.1.
5.4.2 Pre-screening
Participants were recruited following completion of a number of questionnaires according to 
Section 2.11.4.1. Participants passing the questionnaire screen, were then asked to attend the 
university to have a fasting blood sample taken for analysis of HbAlC, insulin, glucose and 
iron (see Section 2.11.4.2). Height, weight, waist circumference and blood pressure were also 
measured (see Section 2.11.4.3). Pre-screening visits occurred within 1 month of the 
laboratory study session, except where study sessions were rescheduled and one type 2 
diabetic patient was pre-screened within 3 months and an overweight participant within 2 
months of the study session.
5.4.3 Pre-study
In order to synchronise daily behaviour before the subjects were brought into the Clinical 
Research Centre (CRC), participants were required to maintain a prescribed daily activity 
routine for 7 days prior to the study, waking at 06:30 and trying to sleep at 22:30. This was
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confirmed according to Section 2.11.5.2. Subjects were also required to consume meals 
within specified time windows for 7 days prior to laboratory admittance, and meals were 
provided 3 days prior to the study to minimise inter-individual variation in caloric intake (see 
Section 2.11.5.1).
5.4.4 Laboratory study
The study was conducted in the Surrey CRC where subjects spent one study period consisting 
of 1 adaptation night (day 0), and a 25-hour study session (days 1-2). For details of the CRC 
facility, participant supervision and light levels see Section 2.11.6.1. To match the sleep- 
wake patterns subjects maintained for one week prior to the study session, ZTO was 
designated lights on and was set at clock time 06:30, and lights off was at ZT16 (clock time 
22:30). Subjects were required to maintain a semi-recumbent posture (Section 2.11.6.2), and 
liquid Fortisip isocaloric meals were provided every hour from ZTO to ZT15 according to 
Section 2.11.6.3. Water was provided ad libitum.
5.4.4.1 Blood sampling and plasma assays
Blood sampling, plasma collection and storage was carried out according to Section 2.11.6.4 
for later analysis of melatonin, cortisol, adiponectin and leptin. Briefly, at ZTO (06:30) on day 
1 an indwelling cannula was inserted into the forearm vein. At ZT0.5, and then every hour 
for a total of 25 hours (final collection at ZT0.5 on day 2), 12ml blood was collected.
5.4.4.2 Adipose biopsies
One small biopsy was taken from the upper buttock subcutaneous adipose depot by a trained 
medical doctor at ZT4.5, ZT10.5, ZT16.5 and ZT22.5, according to Section 2.11.6.5 and 
stored at -80°C. RNA was extracted from the WAT using TRIzol (see Section 2.7), cDNA 
synthesized (see Section 2.8), and quantitative real-time reverse transcriptase PCR carried out 
(see Section 2.9.3). mRNA expression of genes involved in the molecular clock (PERI, 
PER2, PER3, BMAL1, CRY1, CRY2, DBP, REV-ERBa), adipokines LEPTIN and 
ADIPONECTIN, as well as the transcriptional factors PGC-la and RIP 140, were measured. 
Expression was normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
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5.4.5 Statistics
Pre-screen data was analysed using One-way ANOVA with Tukey post-hoc test (SPSS). 
Correlation analyses were conducted using Linear regression (Prism), and the gene expression 
timecourse from biopsies was performed using Two-way ANOVA with Tukey post-hoc test 
(Statistica).
5.5 RESULTS
5.5.1 Participant information
All pre-screen participant statistics can be seen in Table 5.1. None of the participants had 
taken part in shift work during the previous 5 years. The only participants who had taken part 
in long-term shift work were two overweight subjects (6 months or 2 years conducted more 
than 25 years ago) and one lean healthy control (2 years conducted more than 23 years ago). 
Only one lean participant was a smoker, but refrained from smoking for 7 days prior to the 
laboratory study. There was a significant difference in participant age between the three 
groups (P < 0.05, One-way ANOVA), with the overweight group being significantly younger 
than the type 2 diabetic group (P < 0.05, Tukey post-hoc).
5.5.1.1 Questionnaire scores
The Home Ostberg (HO) questionnaire is used to determine diurnal preference, while the 
Epworth questionnaire measures subjective sleepiness, and the Pittsburgh Sleep Quality Index 
(PSQI) is used to measure the quality and patterns of sleep in older adults. There was no 
significant difference in HO, Epworth, or PSQI scores between lean, overweight and type 2 
diabetic participants (P > 0.05, One-way ANOVA). However, there was a significant 
difference in the Becks Depression Inventory scoring between groups (P < 0.05, One-way 
ANOVA), which is used to diagnose clinical depression (Beck et a l, 1961). The type 2 
diabetic cohort had a significantly higher Becks score than the lean group (P < 0.05, Tukey 
post-hoc), but no significant difference was found between overweight versus type 2 diabetic, 
or lean versus overweight participants (P > 0.05, Tukey post-hoc). However, while the 
average Becks score for the type 2 diabetic patients was less than 9, and they were therefore 
not clinically depressed, two individuals scored for moderate depression (scores of 15 and 21) 
(Beck et a l, 1961).
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5.5.1.2 Physical measures
There was a significant difference in BMI (P < 0.0001, One-way ANOVA), with lean healthy 
control participants having an average BMI of 23.2 compared to a BMI of 30.2 and 31.2 for 
overweight and type 2 diabetic subjects, respectively. However, while lean healthy controls 
had a significantly lower BMI compared to overweight and diabetic subjects (P < 0.0001, 
Tukey post-hoc), there was no significant difference in BMI between overweight versus type 
2 diabetic subjects (P > 0.05, Tukey post-hoc). This was reflected in significantly lower 
weight and waist circumference (P < 0.0001, One-way ANOVA) in the lean healthy cohort 
when compared to type 2 diabetic or overweight subjects (P < 0.0001, Tukey post-hoc), but 
no significant difference in height (P > 0.05, One-way ANOVA).
5.5.1.3 Physiological measures
For information, one lean individual had insulin <10 pM/1, which was designated the value of 
9.9 pM/1 (the sensitivity limit of the assay, below which results become unreliable). There 
was a significant difference for all measures (fasting insulin, glucose and HbAlc) between 
groups (P < 0.05, One-way ANOVA), with type 2 diabetic patients showing significantly 
different results to lean and overweight groups (P < 0.05, One-way ANOVA), but no 
difference between lean and overweight cohorts (P > 0.05, Tukey post-hoc). Compared to 
lean and overweight groups, type 2 diabetic patients had significantly elevated insulin 
concentrations (over twice the concentration) (93.6 pM/1 versus 28.1 and 39.2 pM/1, 
respectively; P  < 0.05, Tukey post-hoc), higher glucose concentrations (6.7 mM/1 versus 4.2 
and 4.8 mM/1, respectively; P < 0.0001, Tukey post-hoc), and significantly elevated HbAlc 
concentrations (6.8 mM/1 versus 5.4 mM/1; P  < 0.0001, Tukey post-hoc).
However, there was no significant difference in iron concentrations between cohorts (P > 
0.05, One-way ANOVA), although all participants were within the normal range for an adult 
male (Davis et al., 1967). There was also no significant difference in diastolic blood pressure 
between groups (84-87.6 mmHg) (P > 0.05, One-way ANOVA), but there was a significant 
variation in systolic blood pressure (P < 0.05, One-way ANOVA), with type 2 diabetic 
patients having a significantly elevated systolic blood pressure compared to lean and 
overweight groups (146.3 mmHg versus 129.4 and 131.5 mmHg respectively; P  < 0.05, 
Tukey post-hoc). However, there was no significant difference between systolic blood 
pressure between lean and overweight groups (P > 0.05, Tukey post-hoc).
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Variable Lean Overweight Type 2 diabetic P  value
N 8 11 8
Age (years) 53.6 ± 6.0 49.9 + 7.5 58.0 + 4.5 *
Waist circumference (cm) 88.9 ± 6.5 105.7 + 4.3 110.9 + 10.6 * * *
Height (m) 1.7 ±0 .1 1.8+  0.1 1.7+  0.2 ns
Weight (kg) 69.7 ± 8.6 92.9 + 9.1 94.8 + 15.3 * * *
BMI (kg/m2) 23.2 ± 1.4 30.2 + 2.3 31.2 + 3.2 * * *
Glucose (mM/1) 4.2 ± 0.7 4.8 + 0.7 6.7 + 1.3 * * *
Insulin (pM/1) 28.1 + 16.8 39.2 + 17.4 93.6 + 78.7 *
Iron (g/dl) 17 .0+1 .3 16.4 + 1.1 17.0+1.1 ns
H bAlc (mM/1) 5.4 + 0.4 5.4 + 0.5 6.8 + 0.8 * * *
Systolic (mmHg) 129.4 + 9.7 131.5 + 14.4 146.3 + 9.5 *
Diastolic (mmHg) 84 .0+ 10 .2 84.2 + 11.4 87.6 + 9.6 ns
HO score 59.0 + 6.5 57.7 + 8.4 60 .0+  10.5 ns
Epworth score 3.0 + 2.3 5.0 + 2.0 5 .1 + 4 .0 ns
Becks score 2 .0 +  1.6 3 .2 +  2.3 7.5 + 6.8 *
PSQI score 3 .4 + 1 .5 4 .3 +  1.8 3 .4 +  1.9 ns
Smoker {N) 1 0 0
Blood pressure medication (AO N/A N/A 2
Statin (TV) N/A N/A 4
Metformin (AO N/A N/A 3
Diet and exercise controlled (AO N/A N/A 3
Table 5.1: Table showing mean participant data for each cohort (lean, overweight and type 2 diabetic) obtained 
during pre-screening (values ± SD). ns= not significant, P  > 0.05, * P < 0 .05 ,***  P < 0.0001.
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5.5.2 Actigraphy
Figure 5.1 shows a representative actigraphy plot for the week prior to the laboratory study in 
the CRC. The spike in activity at 06:30 and sudden drop in activity at 22:30 shows that 
subjects adhered to the sleep/wake patterns prescribed for the week prior to the study session. 
Activity during the lights-off period is minimal in comparison to the daytime activity patterns, 
suggesting that the subjects were in bed. Actigraphy data also matched with sleep/wake 
patterns recorded by participants in sleep diaries (information not shown), and also with 
messages left on the voicemail.
5.5.3 Gene expression in subcutaneous WAT biopsies
Due to adverse events, biopsies could not be obtained from one overweight subject at ZT4.5, 
and one lean volunteer at ZT22.5. Gene expression values for these participants were 
arbitrarily set as the average expression for the remainder of the subjects in the cohort for that 
timepoint (i.e. for ZT4.5 overweight missing data, the value was set as the average expression 
of all other overweight participants at ZT4.5). As there was no difference in the statistical 
outcome either with inclusion or exclusion of this data, the average data was included in the 
final graphs and also the statistical analyses.
5.5.3.1 Clock gene expression in subcutaneous WAT
Figure 5.2 shows the clock gene expression profiles for PERI, PER2, PER3, BMAL1, CRY1, 
CRY2, REV-ERBa and DBP. There was no temporal or cohort effect on CRY1 gene 
expression (P > 0.05, Two-way ANOVA). For all other clock genes examined, there was a 
significant effect of time on gene expression (P < 0.001, Two-way ANOVA), but no 
significant difference in mRNA expression between lean, overweight or type 2 diabetic 
cohorts (P > 0.05, Two-way ANOVA). Neither was there interaction between cohort and 
time (P > 0.05, Two-way ANOVA), with the exception of BMAL1, expression where there 
was a significant interaction of time and cohort (P < 0.01, Two-way ANOVA).
PERI, PER2 and PER3 exhibited a similar temporal pattern of gene expression with a trough 
at the beginning of the dark phase (Figure 5.2, left panel). PERI and PER2 mRNA 
expression decreased from ZT4.5, with lowest expression occurring at ZT16.5 (comparison of 
ZT4.5 with ZT10.5 and ZT16.5, P < 0.001, Tukey post-hoc) before increasing again by
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ZT22.5 (comparison of ZT16.5 with ZT22.5, P < 0.001, Tukey post-hoc). This resulted in 5- 
and 3-fold amplitude rhythms, respectively. Similarly, Per3 showed 5-fold amplitude 
changes in gene expression, which decreased from ZT4.5, to lowest expression between 
ZT10.5 and ZT16.5 (comparison of ZT4.5 with ZT10.5 and ZT16.5, P < 0.001, Tukey post- 
hoc) before increasing again by ZT22.5 (comparison ZT16.5 with ZT22.5, P < 0.001, Tukey 
post-hoc). In contrast, while REV-ERBa showed diurnal rhythmicity, with a 5-fold amplitude 
in gene expression, REV-ERBa mRNA levels exhibited lowest expression at ZT10.5 when 
compared to PER genes (comparison of ZT10.5 with ZT16.5, P < 0.001, Tukey post-hoc), 
and highest mRNA levels at ZT22.5, the end of the dark phase (comparison of ZT22.5 with 
ZT10.5 and ZT16.5, P < 0.001, Tukey post-hoc) (Figure 5.2, right panel). DBP mRNA also 
exhibited rhythmicity (Figure 5.2, right panel), with an approximate 3-fold amplitude of gene 
expression, which was highest at ZT22.5 (ZT22.5 compared to ZT4.5, ZT10.5 and ZT16.5, P 
< 0.001, Tukey post-hoc). However, DBP exhibited an intermediate mRNA expression 
pattern when compared to REV-ERBa and PER profiles, with no significant difference 
between ZT10.5 and ZT16.5 (P > 0.05, Tukey post-hoc).
In contrast, CRY1 did not exhibit temporal variation in gene expression, and there was no 
difference in mRNA levels between the 3 cohorts (P > 0.05, Two-way ANOVA). However, 
CRY2 showed temporal variation in gene expression resembling circadian rhythms (P < 
0.001, Two-way ANOVA), with elevated expression at ZT22.5 (comparison of ZT22.5 with 
ZT4.5, ZT10.5 and ZT16.5, P  < 0.001, Tukey post-hoc) (Figure 5.2, right panel). However, 
compared to PER, DBP and REV-ERBa, rhythm amplitude for CRY2 was lower, with 
approximately 2-fold changes, and there was no significant difference in expression between 
ZT4.5, ZT10.5 and ZT16.5 (P > 0.05, Tukey post-hoc).
In contrast BMAL1 showed a significant temporal mRNA expression profile (P < 0.001, Two- 
way ANOVA) that was anti-phasic to PERI, PER2, PER3, REV-ERBa, and DBP, with 
highest expression occurring at ZT16.5 at the start of the dark phase (comparison of ZT16.5 
with ZT4.5 and ZT22.5, P  < 0.001, Tukey post-hoc) (Figure 5.2). Interestingly, there was 
also a significant interaction between time and group (P < 0.01, Two-way ANOVA). While 
there was no significant difference between cohorts at ZT4.5 or ZT10.5 (P > 0.05, Tukey 
post-hoc), the overweight group exhibited significantly lower BMAL1 expression at ZT16.5 
compared to type 2 diabetic participants (P < 0.05, Tukey post-hoc), but not compared to lean 
subjects (P > 0.05, Tukey post-hoc). Indeed, amplitude of rhythm for BMAL1 in the
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overweight group was lower, with approximate 4-fold changes in gene expression compared 
to the 6-fold changes observed in lean and type 2 diabetic subjects.
As my groups showed significant differences in age (P < 0.05, One-way ANOVA), 
correlation analyses were carried out to see if there was an age effect on gene expression. 
None of the clock or clock-related genes examined showed a significant correlation with age 
for any of the zeitgeber times (P > 0.05, Linear regression) (representative example of 
BMAL1, Figure 5.3, left panel). Similarly, mRNA expression levels for PERI, PER2, PER3, 
CRY1, CRY2, REV-ERBa and DBP expression did not significantly correlate with BMI (P > 
0.05, Linear regression). However, BMAL1 expression at ZT10.5, but not ZT4.5, ZT16.5 or 
ZT22.5, correlated negatively with BMI (P < 0.05, R2 = 0.22, Linear regression) (Figure 5.3, 
right panel) (see Table 5.2 for R2 values).
5.5.3.1.1 Type 2 diabetic patients: medicated versus non-medicated
In order to provide preliminary information regarding the effects of medication on the 
biological rhythms of genes examined, diet and exercise controlled individuals were 
compared to those taking metformin, statins or blood pressure medication (n = 3 for diet and 
exercise controlled, and n = 5 for medicated type 2 diabetic patients). Figure 5.4 shows clock 
and clock-related gene expression profiles for type 2 diabetic patients. There was no cohort 
or temporal effect, or interaction, on CRY1 expression (P > 0.05, Two-way ANOVA) (Figure 
5.4, right panel). However, while there was a significant effect of time on gene expression for 
PERI, PER2, PER3, BMAL1, REV-ERBa, DBP (P < 0.001, Two-way ANOVA), and CRY2 
(P < 0.01, Two-way ANOVA) with similar circadian patterns of gene expression as described 
in Section 5.5.3.1, there was no significant effect of medication status of type 2 diabetic 
participants for any of the clock genes examined (P > 0.05, Two-way ANOVA). 
Interestingly, there was a significant interaction between time and group on PER2 expression 
(P < 0.01, Two-way ANOVA) (Figure 5.4, left panel), but not for any of the other clock or 
clock-related genes (P > 0.05, Two-way ANOVA). Although both groups exhibited a 
rhythmic profile of PER2 gene expression, with a trough at ZT16.5, there were lower 
amplitude rhythms observed in medicated compared to diet and exercise controlled type 2 
diabetic patients (3-fold compared to 10-fold changes in gene expression, respectively). This 
was due to significantly lower PER2 expression at ZT4.5 in the medicated compared to diet 
and exercise controlled cohort (P < 0.01, Tukey post-hoc). There was a similar pattern for 
PERI and PER3 gene expression, although this failed to reach significance.
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Figure 5.1: Representative actigraphy profile for the week prior to the CRC study session. Subjects were 
required to wake at 06:30 and go to bed trying to sleep at 22:30 for the week prior to the study session (Friday 
morning 06:30 through to the following Friday at 15:00 when they arrived in the CRC).
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Figure 5.2: Clock gene expression profiles for subcutaneous WAT. Subcutaneous WAT was collected from 
lean (blue), overweight (pink), and type 2 diabetic (green) subjects at ZT4.5, ZT10.5, ZT16.5 and ZT22.5, RNA 
was extracted, cDNA synthesised and qtPCR carried out. There was significant (P < 0.001, Two-way ANOVA) 
temporal variation in all genes examined except CRY1, but no difference between cohorts (P > 0.05, Two-way 
ANOVA). n = 8 for lean and type 2 diabetic cohorts, n = 11 for the overweight group ± SEM.
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Figure 5.3: Representative correlation analyses: BMALL Subcutaneous WAT was collected from lean,
overweight, and type 2 diabetic subjects at ZT4.5, ZT10.5, ZT16.5 and ZT22.5, RNA was extracted, cDNA 
synthesised and qtPCR carried out. There was no significant correlation of age with BMAL1 expression (P > 
0.05, Linear regression). However, at ZT10.5, but not ZT4.5, ZT16.5 or ZT22.5, BMAL1 expression correlated 
negatively with BMI (P < 0.05, Linear regression), n = 27 subjects.
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Gene
r 2 a g e r 2 b m i
ZT4.5 ZT10.5 ZT16.5 ZT22.5 ZT4.5 ZT10.5 ZT16.5 ZT22.5
PERI 0.0092 0.0328 0.0141 0.0018 0.0001 0.0301 0.1167 0.0437
PER2 0.0093 0.0073 0.0409 0.0061 0.0322 0.0998 0.0369 0.0267
PER3 0.0028 0.0175 0.0007 0.0711 0.0010 0.0407 0.0084 0.0347
REV-ERBa 0.0005 0.0209 0.0546 0.0312 0.0000 0.0000 0.0487 0.0356
DBP 0.0768 0.0788 0.0090 0.0171 0.0371 0.0151 0.0380 0.1296
BMAL1 0.0036 0.0795 0.0830 0.0833 0.0064 0.2243 0.0150 0.0066
CRY1 0.0000 0.0396 0.0190 0.0129 0.0029 0.0001 0.0111 0.0788
CRY2 0.0025 0.0071 0.0002 0.0232 0.0203 0.0059 0.0316 0.0414
PGC-la 0.0625 0.0068 0.0755 0.0002 0.0551 0.0079 0.1344 0.0917
RIP140 0.0029 0.0096 0.1474 0.0002 0.0185 0.0000 0.0036 0.0136
ADIPONECTIN 0.0012 0.0173 0.0770 0.0084 0.0065 0.0009 0.0047 0.0193
LEPTIN 0.0127 0.0179 0.0493 0.0490 0.1375 0.2377 0.1784 0.3081
Table 5.2: Table to show R2 values generated for correlation analyses o f all genes examined against participant 
age and BMI.
143
2.5 CRY1
2.0
0.5
0.0
242012 16840
2.5 PER1
2.0
0.5
0.0
24201612840
2.5
CRY2
2.0
0.5
0.0
20 2416124 80
2.5 PER2
2.0
C01
I
<
z
0.5
24201612840
E  2.5 0)
§ 2.0 
<ti
DC < c
PER3
0.5
0.0
24201612840
2.5
REV-ERBa
2.0
0.5
0.0
2420168 1240
2.5
DBP
2.0
0.5
0.0 20 24168 1240
2.5
BMAL1
2.0
0.5
0.0
24201612840
Zeitgeber Time (hours)
Figure 5.4: Clock gene expression profiles for subcutaneous WAT in medicated (full line) versus non­
medicated (dotted line) type 2 diabetic patients. Subcutaneous WAT was collected at ZT4.5, ZT10.5, ZT16.5 
and ZT22.5, RNA was extracted, cDNA synthesised and qtPCR carried out. There was no significant effect of 
medication status on expression for any of the clock genes examined (P > 0.05, Two-way ANOVA), but there 
was a significant interaction of time and group for PER2 expression (P < 0.01, Two-way ANOVA). n = 3 toi 
the non-medicated group, n = 5 for the medicated cohort ± SEM.
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5 .S .3 .2 Adipokine gene expression in subcutaneous WAT
There was significant temporal variation in adipokine gene expression, with both LEPTIN and 
ADIPONECTIN exhibiting a significant gradual decline in expression over the time course (P 
< 0.01 and P  < 0.001, respectively, Two-way ANOVA; ZT4.5 and ZT10.5 compared to 
ZT22.5, P < 0.01, and ZT4.5 compared to ZT16.5 and ZT22.5 P < 0.01, respectively, Tukey 
post-hoc) (Figure 5.5, left panel). However, there was no obvious diurnal pattern of gene 
expression for either lean or overweight groups, while type 2 diabetic patients appeared to 
exhibit a trough in ADIPONECTIN expression at ZT16.5 (Figure 5.5, left panel).
There was also no significant difference in either LEPTIN or ADIPONECTIN gene expression 
between lean, overweight or type 2 diabetic cohorts or interaction of group and time (P < 
0.05, Two-way ANOVA), although there was a significant positive correlation of BMI on 
LEPTIN gene expression at ZT10.5, ZT16.5 and ZT22.5 (P < 0.01 for ZT10.5 and ZT22.5, 
and P < 0.05 at ZT16.5, Linear regression) (Figure 5.6). There was no significant correlation 
between ADIPONECTIN and either age or BMI, nor did LEPTIN correlate with age for any 
zeitgeber time (P > 0.05, Linear regression) (see Table 5.2 for R2 values).
5.5.3.2.1 Type 2 diabetic patients: medicated versus non-medicated
There was no significant effect of medication, or interaction between time and medication, on 
LEPTIN or ADIPONECTIN gene expression (P > 0.05, Two-way ANOVA) (Figure 5.7, left 
panel). However, while there was no significant temporal effect on LEPTIN gene expression 
(P > 0.05, Two-way ANOVA), there was a significant effect of time on ADIPONECTIN 
expression (P < 0.01, Two-way ANOVA), with a trough at ZT16.5 as described in Section
5.5.5.2 (ZT4.5 compared to ZT16.5, P < 0.01, Tukey post-hoc) (Figure 5.7, left panel).
5.5.3.3 RIP140 and PGC-la gene expression in subcutaneous WAT
One overweight participant at ZT22.5 exhibited undetectable PGC-la mRNA expression, 
which was deemed to be below threshold. Therefore, the value was set as the lowest 
detectable value for this gene between all the groups, and included in all graphs and analyses 
thereafter.
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Figure 5.5: Adipokine and transcription factor gene expression profiles for subcutaneous WAT. Subcutaneous 
WAT was collected from lean (blue), overweight (pink), and type 2 diabetic (green) subjects at ZT4.5, ZT10.5, 
ZT16.5 and ZT22.5, RNA was extracted, cDNA synthesised and qtPCR carried out. There was significant 
temporal variation in all genes expression (P < 0.05, Two-way ANOVA) but no effect of cohort (P > 0.05, Two- 
way ANOVA). n = 8 for lean and type 2 diabetic subjects, n = 11 for overweight subjects ± SEM.
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Figure 5.6: Representative correlation analyses: LEPTIN. Subcutaneous WAT was collected from lean 
overweight, and type 2 diabetic subjects at ZT4.5, ZT10.5, ZT16.5 and ZT22.5, RNA was extracted, cDNA 
synthesised and qtPCR carried out. LEPTIN gene expression significantly correlated with BMI at ZT10.5, 
ZT16.5 and ZT22.5 {P < 0.01 for ZT10.5 and ZT22.5, and P < 0.05 at ZT16.5, Linear regression), n = 27 
subjects.
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Figure 5.7: Adipokine and metabolic factor gene expression profiles for subcutaneous WAT in medicated (full 
line) and non-medicated (dotted line) type 2 diabetic patients. Subcutaneous WAT was collected at ZT4.5, 
ZT10.5, ZT16.5 and ZT22.5, RNA was extracted, cDNA synthesised and qtPCR carried out. There was no 
significant effect of medication status on expression of ADIPONECTIN, LEPTIN, or RIP 140 (P > 0.05, Two- 
way ANOVA), but there was a significant interaction of time and group for RIP 140 and P G C -la  expression (P < 
0.05, Two-way ANOVA) and a significant effect of medication on P G C -la  expression (P < 0.05, Two-way 
ANOVA). n = 3 for the non-medicated group, n = 5 for the medicated cohort ± SEM.
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PGC-la exhibited significant temporal variation of gene expression (P < 0.05, Two-way 
ANOVA), with significantly lower expression at ZT22.5 compared to ZT10.5 (P < 0.05, 
Tukey post-hoc) (Figure 5.5, right panel). There was no obvious oscillatory profile of PGC- 
la  expression in lean and overweight cohorts, although type 2 diabetic patients appeared to 
exhibit a peak in expression at ZT10.5 (Figure 5.5, right panel). However, error bars were 
larger and there was no significant difference between cohorts or interaction between group 
and time (P > 0.05, Two-way ANOVA). PGC-la did not correlate with either BMI or age for 
any of the time points examined (P > 0.05, Linear regression) (see Table 5.2 for R2 values).
As with PGC-la, R1P140 exhibited no significant effect of cohort, or interaction between 
time and cohort, on gene expression (P > 0.05, Two-way ANOVA) (Figure 5.5, right panel). 
However, there was significant temporal variation in gene expression (P < 0.001, Two-way 
ANOVA), with a gradual decline in mRNA levels from ZT4.5 to ZT22.5 (ZT4.5 compared to 
ZT16.5 and ZT22.5, P  < 0.001, Tukey post-hoc) (Figure 5.5, right panel). Interestingly, while 
there was no significant correlation between RIP 140 gene expression and BMI for any of the 
time points examined (P > 0.05, Linear regression) (Figure 5.8, right panel), RIP140 mRNA 
levels negatively correlated with age at ZT16.5 (P < 0.05, Linear regression), but not at any 
other time point (P > 0.05, Linear regression) (Figure 5.8, left panel) (see Table 5.2 for R2 
values).
5.5.3.3.1 Type 2 diabetic patients: medicated versus non-medicated
Interestingly, not only did PGC-la expression exhibit significant temporal variation as 
described above, but there was also a significant effect of medication status and interaction 
between medication status and time on mRNA levels (P < 0.05, Two-way ANOVA) (Figure
5.7, right panel). While there was no significant difference between medicated and non- 
medicated type 2 diabetic patients at ZT4.5, 16.5 or 22.5 (P > 0.05, Tukey post-hoc), there 
was a significant elevation in PGC-la expression at ZT10.5 in diet and exercise controlled 
compared to medicated diabetic patients (P < 0.01, Tukey post-hoc). This resulted in a 
baseline temporal profile for the medicated cohort, with no significant differences between 
time points (P > 0.05, Two-way ANOVA), but with a rhythmic profile in diet and exercise 
controlled diabetic patients, peaking at ZT10.5 (comparison of ZT10.5 with ZT4.5 and 
ZT16.5 for diet and exercise controlled diabetic patients, P < 0.05, Tukey post-hoc) (Figure
5.7, right panel).
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Figure 5.8: Correlation analyses for RIP 140. Subcutaneous WAT was collected from lean, overweight, and type 
2 diabetic subjects at ZT4.5, ZT10.5, ZT16.5 and ZT22.5, RNA was extracted, cDNA synthesised and qtPCR 
carried out. RIP140 gene expression significantly correlated with age at ZT16.5 (P < 0.05, Linear regression), n 
= 27 subjects.
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In contrast, while there was a significant temporal effect on RIP 140 gene expression (P < 
0.001, Two-way ANOVA), there was no effect of medication on expression (P > 0.05, Two- 
way ANOVA) (Figure 5.7, right panel). However, there was a significant interaction between 
medication status and time (P < 0.05, Two-way ANOVA). This resulted in a baseline 
temporal profile for the medicated cohort, with no significant differences between time points 
(P > 0.05, Two-way ANOVA), but a rhythmic profile in diet and exercise controlled diabetic 
patients, with a trough at ZT16.5 (comparison of ZT4.5 and ZT16.5 for diet and exercise 
controlled diabetic patients, P < 0.01, Tukey post-hoc) (Figure 5.7, right panel).
5.6 DISCUSSION
Obesity is recognised as one of the major risk factors for the development of type 2 diabetes 
(Trujillo and Scherer, 2006). Furthermore, obesity exhibits a clear correlation with 
attenuation of adipose and adipokine rhythmicity. In obese mice, and obese mice that exhibit 
symptoms of type 2 diabetes, daily rhythms of adipokine and clock gene mRNA expression 
are suppressed in adipose depots (Ando et ah, 2005). Additionally, lean human subjects 
exhibit plasma leptin and adiponectin rhythmicity, which are severely attenuated in obese 
subjects (Calvani et a l, 2004; Matkovic et a l, 1997; Saad et a l, 1998). Although it has been 
proposed that abnormal rhythmic adipokine secretion may contribute to obesity (Matkovic et 
a l, 1997; Saad et a l, 1998), the relationship between adipokine rhythmicity and type 2 
diabetes per se is not well studied, particularly at the molecular level. To examine whether 
patients with type 2 diabetes exhibit attenuated clock and adipokine rhythmicity at the level of 
adipose gene expression, and plasma hormone concentrations, lean, overweight and type 2 
diabetic males were recruited and subjected to a single weekend of experimentation in the 
Surrey CRC. During this time, serial subcutaneous WAT biopsies were taken at ZT4.5, 
ZT10.5, ZT16.5 and ZT22.5, from which RNA was extracted, cDNA synthesised and real­
time qtPCR carried out to compare the expression of clock-related (PERI, PER2, PER3, 
BMAL1, REV-ERBa, CRY1, CRY2), clock-controlled (DBP), adipokine (LEPTIN and 
ADIPONECTIN) and metabolic (PGC-la and RIP 140) genes between the three cohorts.
5.6.1 Participant pre-screen parameters
Although the intention was to age match groups, due to restrictions in participant recruitment 
there was not the choice of subjects to achieve this and the overweight cohort was 
significantly younger than the type 2 diabetic group. In order to show that age had no, or
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minimal, effect on gene expression, correlation analyses were conducted retrospectively for 
each of the genes against age for all of the zeitgeber times, and these results will be discussed 
in Section 5.6.2.
There was no significant difference in HO, Epworth, or PSQI score between lean, overweight 
and type 2 diabetic participants. However, the type 2 diabetic cohort scored significantly 
higher than the lean group in the Becks Depression Inventory, with two diet and exercise 
controlled diabetic subjects scoring for moderate depression. Higher incidence of depression 
in type 2 diabetic patients has been shown in many studies previously. For example, a meta­
analysis of 39 scientific studies, combining a total of 20,218 subjects > 18 years of age 
showed that diabetes (either type 1 or type 2) doubles the chance of co-morbid depression 
(Anderson et a l, 2001). Additionally, patients with type 2 diabetes and associated 
complications had elevated Becks responses, with 74% of patients scoring within the range of 
clinical depression and 35% within the range of severe depression (Leedom et a l, 1991). 
Susceptibility to depression has been linked with clock gene polymorphisms (Lavebratt et a l, 
2009; Partonen et a l, 2007), and depression is associated with altered sleep/wake (Dorheim et 
a l, 2009; McNamara et a l, 2009) and hormonal parameters (Parry et a l, 2008; Schulze et a l, 
2009). However, to my knowledge, no studies have examined the effects of depression on 
peripheral oscillators. Therefore, although there was no significant effect of medication 
versus diet and exercise control observed between diabetic cohorts for the majority of genes 
examined, an effect of depression on the adipose circadian oscillator cannot be ruled out.
As expected, the lean cohort had significantly lower BMI than the overweight and type 2 
diabetic groups, supported by lower average weight and waist circumference in the lean 
group. However, there was no significant difference in BMI between overweight and type 2 
diabetic cohorts. This is to be expected as type 2 diabetes is frequently associated with the 
prevalence of obesity (Koopman et a l, 2009). Type 2 diabetic patients also exhibited 
significantly higher fasting insulin, glucose and HbAlc concentrations. Hyperinsulinaemia 
and hyperglycaemia form part of the pathology of type 2 diabetes. This is a result of impaired 
responsiveness of skeletal muscle and adipose tissue to insulin, which causes decreased 
glucose uptake by peripheral tissues, and increased compensatory insulin output from the 
pancreatic P-cells (Guilherme et a l, 2008; Reaven et a l, 1967). Elevated HbAlc, a marker of 
long term glucose levels in the blood, in the type 2 diabetic patients compared to the lean and 
overweight groups, is therefore supportive of the hyperglycemia expected in type 2 diabetes 
(Cefalu et a l, 1994). Additionally, type 2 diabetes has been associated with hypertension
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(Groop et a l, 1993), which accounts for significantly elevated systolic blood pressure in the 
type 2 diabetic compared to lean and overweight cohorts.
5.6.2 Gene expression in human WAT
Actigraphy data showed that participants maintained the prescribed sleep/wake pattern for 7 
days prior to the study, which should therefore result in synchronisation of internal body 
clocks between subjects before the sampling period. Studies conducted on the 
Per2:Luciferase transgenic mouse or Perl:Luciferase rat have shown that it takes the SCN 1- 
5 days and peripheral oscillators up to 8 days to resynchronise to a phase advance of 6 hours 
in the light schedule (Davidson et a l, 2008; Yamazaki et a l, 2000). As my subjects were 
undergoing shifts of no more than 2 hours from their normal sleep/wake patterns, internal
body clocks between subjects should be aligned by 7 days. Indeed, the small within groups
error bars, and phase alignment of data between cohorts, for clock gene rhythms in WAT 
biopsies, suggest that this was the case. However, melatonin assays will be performed in the 
future on plasma samples collected across the sampling period in order to adjust for any inter­
subject variations in circadian phase.
5.6.2.1 Clock gene expression
There was significant circadian temporal variation in PERI, PER2, PER3, BMAL1, REV- 
ERBa, DBP and CRY2 mRNA expression. In contrast, CRY1 exhibited no significant 
temporal variation in expression. Non-circadian temporal profiles for Cry mRNA expression 
have been reported previously, for example arrhythmicity of Cry2 expression in murine 
inguinal WAT from animals housed on a 12L:12D schedule (Zvonic et a l, 2006).
In my study, PER expression peaks at the end of the dark phase at ZT22.5, and BMAL1 
oscillates in antiphase, as expected based on the current circadian oscillator model, with a 
highest expression at ZT16.5. Additionally, REV-ERBa mRNA is maximal slightly earlier 
than PER gene expression, as has been shown previously (Balsalobre et a l, 1998). My data 
are consistent with clock gene rhythms observed in subcutaneous WAT biopsies extracted 
from overweight human subjects at approximately 8am, 2pm and 6pm, where PERI, PER2 
and PER3 exhibited reduced gene expression towards the evening, and elevations in the 
morning (Loboda et a l, 2009).
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The relative phasing of PER and BMAL1 with the light/dark schedule in the human biopsies is 
different to that reported for murine WAT. In murine visceral, inguinal and epididymal WAT 
from animals housed on a 12L:12D, Per peaks at the beginning of the dark phase at ZT12, 
when Email shows trough expression (Ando et a l, 2005; Zvonic et a l, 2006). These 
temporal variations could be due to species or depot differences. Differences in diurnal 
preference (nocturnal rodent versus diurnal human) and therefore eating patterns could play a 
role, as feeding rhythms have been shown to be instrumental in entraining peripheral 
oscillators (Damiola et a l, 2000), and sampling times and photoperiod were also different 
between my study and the Ando et a l (2005) experiment. Additionally, depot differences in 
clock gene expression have been observed in humans where subcutaneous WAT has been 
found to exhibit lower amplitude clock gene rhythms compared to visceral WAT (Gomez- 
Santos et a l, 2009). However, taken together, WAT from my study exhibited significant 
rhythmic gene expression in components of the molecular oscillator, consistent with the 
presence of a clock in human subcutaneous WAT.
Obesity has previously been shown to reduce clock amplitude rhythms in peripheral 
oscillators. For example, in the caudal brainstem nucleus of the solitary tract, expression 
profiles of Email and Rev-erba were attenuated in C57BL/6J mice with high fat diet-induced 
obesity as well as in genetically obese KK-Ay and ob/ob mice (Kaneko et a l, 2009). 
Similarly, in human type 2 diabetic and non-diabetic subjects, amplitude of mRNA expression 
rhythms of PERI and PER3 genes was diminished in leukocytes from patients with diabetes 
(Ando et a l, 2009). Additionally, Ando et a l (2005) showed that amplitude of clock gene 
and adipokine expression was attenuated in visceral WAT from obese and obese/diabetic 
mice. However, unlike the reduced amplitude clock gene expression observed in these 
studies, there was no difference in PERI, PER2, PER3, CRY1, CRY2, REV-EREa, or DBP 
gene expression between my cohorts.
Interestingly, the animals used in the Ando et a l (2005) study to examine effects of metabolic 
syndrome possessed different genetic backgrounds. For example, obesity generated in KK 
mice is thought to be of polygenic origin (Igel et a l, 1998). In contrast, KK-Ay mice are 
generated by crossing KK animals with Ay mice, the latter of which possess a mutation lethal 
in the homozygous state. There is now increasing evidence to suggest that mouse genetic 
background can profoundly affect the results of an experiment (Taft et a l, 2006). For 
example, the Clock?119 mutation on a murine C57BL/6J background causes the animal to 
exhibit hyperphagia, abnormal feeding rhythms, and reduced activity, resulting in 10%
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decreased energy expenditure. Consequent adipocyte hypertrophy causes obesity and other 
factors characteristic of metabolic syndrome, such as hypercholesterolemia, hyperglycaemia, 
hypoinsulinaemia and increased serum leptin levels (Turek et a l, 2005). In contrast, Oishi et 
al. (2006) and Kudo et a l (2007b) showed that ClockA19 mutant mice with an JcklCR 
background were protected against high fat diet-induced obesity, suggesting that genetic 
background alters the resultant phenotype. Therefore, the lack of effect of obesity and type 2 
diabetes on circadian gene expression observed in my data may suggest that the observations 
from Ando et a l (2005) are the result of different genetic backgrounds between cohorts, and 
not the presence of adiposity or type 2 diabetes.
However, despite lack of difference in the majority of clock gene expression amplitudes 
between my cohorts, overweight participants exhibited significantly reduced BMAL1 mRNA 
levels at the zenith expression time ZT16.5. This resulted in reduced amplitude circadian 
rhythm in BMAL1 expression in the overweight group, with approximately 4-fold changes in 
gene expression compared to the 6-fold changes observed in lean and type 2 diabetic subjects. 
Additionally, BMAL1 expression at ZT10.5 negatively correlated with BMI. These findings 
are particularly interesting as they suggest disruption of BMAL1 expression in the overweight 
phenotype, although my diabetic cohort had a similar BMI. To confirm that the observation 
was not chance, it would be useful to analyse BMAL1 protein levels to see if the same 
correlative results could be obtained. Furthermore, Small knock-down 3T3-L1 cells, created 
by siRNA delivery, fail to differentiate into adipocytes (Shimba et a l, 2005), while cells over­
expressing Bmall, or knock-out and re-introduction of Bmall, stimulate cellular lipid 
accumulation and induction of adipocyte-related genes, such as Ppary and aP2. BMAL1 
haplotypes have also been linked to type 2 diabetes (Woon et a l, 2007). Therefore, it is 
possible that reduced BMAL1 expression observed in overweight participants could affect 
adipogenesis and therefore the production of adipokines, resulting in increased incidence of 
obesity and related metabolic syndromes, such as type 2 diabetes. Further work would need 
to be conducted to establish whether this is the case and why type 2 diabetic patients in my 
study, who had matching BMI to the overweight cohort, should fail to exhibit suppressed 
rhythms of BMAL1 expression. Interestingly, there was no difference between cohorts in 
REV-ERBa expression, which has also been linked to adipogenesis (Laitinen et a l, 2005; 
Wang and Lazar, 2008).
The amplitude of the baseline PER3 rhythm in leukocytes has previously been shown to 
reduce with age (Ackermann et al, 2009). As my overweight cohort was significantly
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younger compared to the lean and type 2 diabetic groups, correlation analyses were conducted 
for age against gene expression for all clock genes studied. There was no significant 
correlation between age and clock gene expression, suggesting that effect of cohort on 
BMAL1 expression described above was not age related.
5.6.2.2 Adipokine gene expression in human WAT
In many studies, leptin and adiponectin exhibit daily rhythms in human plasma (Gaviila et a l, 
2003). Moreover, there appears to be a transcriptional basis for these rhythms. Microarray 
data of samples collected over a 24-hour cycle revealed widespread rhythmicity of mRNA 
expression within murine WAT that encompasses up to 20% of the entire WAT 
transcriptome, including multiple adipokine genes (Ptitsyn et a l, 2006; Zvonic et a l, 2006). 
Ando et a l (2005) have also shown that Leptin and Adiponectin exhibit approximately 2-fold 
amplitude circadian mRNA rhythms in murine visceral WAT. Additionally, Chapter 4 
provides evidence for an adipocyte role in rhythmic leptin secretion from these cells 
(unpublished data).
In my study, LEPTIN and ADIPONECTIN exhibited temporal variation but, in contrast to 
Ando et a l (2005), there was no obvious diurnal expression in either gene at the times 
examined, no difference in gene expression between lean, overweight and type 2 diabetic 
participants, or age effect. It has been shown previously that macrophage recruitment to 
adipose tissue during obesity increases levels of adipocyte- and macrophage-derived TNFa, 
which subsequently inhibits adipocyte adiponectin production (Lacasa et a l, 2007; Wame, 
2003). It is therefore surprising that, in my study the overweight and type 2 diabetic groups, 
which have significantly higher BMI, do not exhibit reduced ADIPONECTIN expression 
relative to lean individuals. However, it is possible that phenomena observed in vitro do not 
translate to in vivo situations, as Lacasa et a l (2007) used 3T3-L1 cells. However, studies 
showing effects of BMI on adipokine gene expression in subcutaneous human WAT used 
subjects with higher BMI than my overweight and type 2 diabetic participants (BMI 
approximately 30-40 versus approximately 25-30, respectively) (Kern et a l, 2001). There 
may, therefore, be a greater effect on ADIPONECTIN expression at BMI greater than 30.
Although there was no significant effect of cohort on LEPTIN mRNA levels, the overweight 
group showed a tendency towards higher expression. Therefore, correlation analysis of
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LEPTIN mRNA levels versus BMI was performed and LEPTIN expression was found to 
positively correlate with BMI at ZT10.5, ZT16.5 and ZT22.5. This supports previous 
observations, where Leptin mRNA expression is increased in epididymal or subcutaneous 
WAT from ob/ob mice (Frederich et a l, 1995) and in WAT derived from obese human 
subjects (Considine et a l, 1995; Hamilton et a l, 1995; Lonnqvist et a l, 1995; Maffei et a l, 
1995). Additionally, plasma leptin levels have been positively correlated with the amount of 
adipocyte triglyceride (Langendonk et a l, 1998), suggesting that Leptin mRNA levels 
translate to plasma protein concentrations.
Although diurnal expression of LEPTIN and ADIPONECTIN mRNA was not detectable at the 
zeitgeber times analysed, only low amplitude rhythms have been described previously 
(approximately 2-fold changes in expression) (Ando et a l, 2005). While it is possible that the 
6-hour sampling resolution in my study was too low to detect peaks and troughs in gene 
expression, considering the lack of leptin rhythmicity observed in 3T3-L1 adipocytes in 
Chapter 4, this may suggest that rhythmic leptin expression is not as important as diurnal 
secretion. Future leptin and adiponectin measurements in plasma samples collected during 
the sampling period should confirm the relationship between oscillatory gene expression and 
rhythmic circulating adipokine levels. Additionally, it would be interesting to ascertain 
temporal intracellular adipose protein levels to ascertain whether leptin or adiponectin are 
rhythmic at the protein level. Also, it is unknown whether leptin or adiponectin are stored in 
adipocytes prior to release, or released directly following synthesis. If the former 
phenomenon is correct, this would support a role for rhythmic secretion above rhythmic 
expression, thus explaining the presence of oscillatory plasma adipokine levels in the absence 
of rhythmic mRNA expression.
S.6.2.3 PGC-la and RIP140 gene expression in human WAT
PGC-la is a transcriptional co-activator that upregulates adaptive energy metabolism in many 
tissues, and is involved in mitochondrial biogenesis (Leone et a l, 2005). PGC-la is 
rhythmically expressed in murine liver and skeletal muscle, and induces expression of Clock 
and Bmall, most likely through transcriptional activation of RORa at the RORE promoter in 
the case of Bmall expression (Liu et a l, 2007a). As well as directly influencing the circadian 
oscillator, PGC-la interacts with nuclear receptors such as the PPARs, which have been 
shown to transactivate Clock and Bmall (Canaple et a l, 2006; Nakamura et a l, 2008; Oishi
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et a l, 2005). Therefore, PGC-la may provide a link between the circadian clock and energy 
metabolism. In contrast, RIP140 is a co-repressor responsible for repressing metabolic genes, 
including PGC-la, and upregulating lipogenic genes, such as fatty acid synthase in WAT 
(Leonardsson et a l, 2004). RIP140 is also capable of repressing the transcriptional activity of 
nuclear receptors such as the PPARs by direct binding (L'Horset et a l, 1996; Treuter et a l, 
1998), again providing a putative link to the circadian oscillator.
Although expression of PGC-la and RIP 140 exhibited significant temporal variation, there 
was no obvious diurnal pattern at the zeitgeber times studied, or difference in expression 
levels between lean, overweight and type 2 diabetic subjects. Neither was there a significant 
correlation of PGC-la mRNA levels with either age or BMI. This is interesting as there is 
evidence to suggest that the upregulation of TNFa causes suppression of PGC-la expression 
in the murine heart (Palomer et a l, 2009), and PGC-la expression is reduced by 43% in 
muscle from mice fed a high-fat diet for 1 week (Crunkhom et a l, 2007). Additionally, PGC- 
la  has been found to exhibit 3-fold lower expression in subcutaneous WAT from morbidly 
obese subjects (Semple et a l, 2004). However, my subjects were not morbidly obese, which 
may explain the lack of correlation between BMI and PGC-la expression.
Although there was no correlation between RIP 140 expression and BMI, age negatively 
correlated with RIP140 mRNA levels at ZT16.5. There is now evidence to suggest that the 
role played by PGC-la in mitochondrial biogenesis is suppressed by RIP 140 (Powelka et a l, 
2006). Disruption of normal mitochondrial biogenesis is associated with diseases of the 
neuromuscular system and ageing (Navarro and Boveris, 2007). Therefore, these data may 
add to the increasing link between RIP140 expression and the ageing process. In order to 
ascertain any further differences or interactions between metabolic factors, circadian rhythms 
and cohort effects, PCR arrays will be conducted in the future on the biopsy samples 
obtained.
S.6.2.4 Type 2 diabetics: medicated versus diet and exercise controlled
The original intention was to avoid confounding effects of medication by recruiting only diet 
and exercise controlled type 2 diabetic patients. However, due to local clinical policy, the 
majority of diabetic patients are immediately placed on medications and so type 2 diabetic 
patients within this trial were controlled by either diet and exercise, or medication. 
Medication included individually, or in combination, statins (simvastatin), blood pressure
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medication (ramipril or lisinopril), or metformin. Statins, such as simvastatin, reduce 
cholesterol levels by inhibiting the rate limiting enzyme in cholesterol synthesis (HMG-CoA 
reductase) in the liver (Law et a l, 2003). Statins also increase hepatic production of low 
density lipoprotein (LDL) receptor, resulting in removal of LDL molecules from circulation, 
and their subsequent degradation in the liver (Ma et a l, 1986).
Blood pressure medications that were used by participants, such as ramipril and lisinopril, are 
examples of angiotensin-converting enzyme (ACE) inhibitors that are used to treat 
hypertension. ACE inhibitors lower the production of angiotensin II, which normally causes 
vasoconstriction, and therefore result in relaxation of arterial muscles, enlargement of blood 
vessels, and reduced blood pressure (Finnegan and Gleason, 2003).
In contrast, metformin is an oral anti-diabetic drug that, among other roles, suppresses hepatic 
gluconeogenesis (Kirpichnikov et a l, 2002), increases insulin sensitivity (Ou et a l, 2006), 
enhances peripheral glucose uptake and increases glucose oxidation (Riccio et a l, 1991). 
Although, to my knowledge, none of these medications have been reported to affect the 
circadian timing system, such an effect cannot be discounted.
In order to ascertain whether there was an effect of medication on gene expression, diet and 
exercise controlled type 2 diabetic patients were compared with those taking any, or a 
combination of, the above medications. From the genes examined, PER2, RIP140 and PGC- 
la  exhibited a statistically significant difference between diet and exercise controlled versus 
medicated diabetic patients. Although PER2 was the only clock gene where mRNA 
expression showed a significant reduction in rhythm amplitude in the medicated group (3-fold 
compared to 7-fold changes, respectively), PERI and PER3 also showed a tendency towards 
lower amplitude rhythms in medicated subjects but this did not reach significance. 
Interestingly, variants of PER2 have been associated with elevated fasting blood glucose, 
which is characteristic of the diabetic phenotype (Englund et a l, 2009). Although the causal 
mechanisms are as yet unknown, and my data was generated from a small sample size, this is 
the first indication that these medications may affect biological rhythms in type 2 diabetic 
patients.
PGC-la expression exhibited significant cohort difference, and interaction between cohort 
and time, with 4-fold higher expression at ZT10.5 in diet and exercise controlled patients 
compared to those taking medication. This peak at ZT10.5 in the diet and exercise controlled
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group likely accounts for the elevation in PGC-la mRNA level observed in combined type 2 
diabetic patients at this time point, when compared to lean and overweight individuals. 
RIP 140 also exhibited higher expression, but this time at ZT4.5, in non-medicated compared 
to medicated type 2 diabetic patients. Taken together, these results are consistent with a 
negative effect of medication on PER2, PGC-la and RIP140 gene expression.
Although exercise has previously been shown to entrain the circadian clock (Edgar and 
Dement, 1991; Marchant and Mistlberger, 1996), there are no studies to date looking at the 
effect of exercise on adipose rhythms. However, diet and exercise controlled diabetic patients 
included in this study had no strict exercise regime. Therefore, the difference in gene 
expression between medicated versus non-medicated type 2 diabetic patients is more likely to 
be a side-effect of medication. However, without an increased subject number, it is 
impossible to ascertain which particular medication, or combination of medications, may be 
responsible for the effects on gene expression observed.
5.6.3 Conclusion
Ando et al. (2005) showed that, compared to adipose tissue of normal (C57BL/6J) mice, 
diurnal rhythms in Leptin, Adiponectin and clock gene expression was severely attenuated in 
obese (KK) and severe obese/diabetic (KK-Ay) mice. However, in my study, there was no 
effect of type 2 diabetes on clock gene rhythms, and no diurnal expression pattern could be 
observed in LEPTIN and ADIPONECTIN at the zeitgeber times studied. Interestingly, the 
animals used in the Ando et a l (2005) study to examine effects of metabolic syndrome 
possessed different genetic backgrounds. Therefore, the lack of effect of obesity and type 2 
diabetes on rhythmic gene expression observed in my data may suggest that the observations 
from Ando et a l  (2005) are the result of different genetic backgrounds between cohorts, and 
not the presence of adiposity or type 2 diabetes.
As described earlier, it is also possibile that variation in results between my study and Ando et 
a l (2005) could be due to species differences, or use of a different fat depot. Additionally, it 
may be that temporal resolution was not sufficient to detect differences in gene expression 
between cohorts in my trial. However, based on the small error bars for each group, and also 
the identical phasing of rhythms between cohorts, particularly for the clock genes, this is 
unlikely to be the case. Furthermore, attenuated clock gene expression rhythms in leukocytes 
from diabetic subjects have previously been compared to a control group that was not age
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matched (60 year old diabetic subjects compared to 28 year old controls) (Ando et a l, 2009) 
and it has previously been shown that PER3 amplitude rhythms are suppressed in older 
subjects (Ackermann et a l, 2009). Collectively, these data highlight the importance of 
studying circadian and adipose biology selectively in human model systems where possible, 
matching different cohorts in all parameters except those being tested, choosing appropriate 
controls, and selecting fat depots accordingly.
In conclusion, human subcutaneous WAT exhibits diurnal rhythms in all clock genes 
examined, except CRY1. However, there was no difference in gene expression between lean, 
overweight and type 2 diabetic subjects, except BMAL1, which showed lower amplitude 
rhythms in overweight participants. Additionally, there was no effect of cohort on 
ADIPONECTIN, LEPTIN, RIP 140 or PGC-la expression. There were also observable 
differences in both metabolic and clock gene expression patterns between medicated and non- 
medicated diabetic patients, which would be interesting to explore with a larger sample size. 
This is particularly important as newly-diagnosed type 2 diabetic patients are immediately 
placed on medication in many surgeries.
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CHAPTER 6:
Discussion
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Due to the associated risks of obesity in development of type 2 diabetes and the metabolic 
syndrome, it is increasingly important to understand adipose tissue biology at both the whole 
organism and molecular level. Furthermore, due to increasing evidence linking the circadian 
clock to metabolism, it is necessary to study how the molecular oscillator functions in WAT. 
Therefore, the central hypotheses addressed in this thesis were:
Hypothesis 1: Adipocytes possess an endogenous circadian clock, which drives rhythmic 
gene expression and adipokine secretion.
Hypothesis 2: Rhythmic gene expression and adipokine secretion is disrupted in individuals
with obesity or type 2 diabetes mellitus.
In order to address Hypothesis 1, murine 3T3-L1 cells were used to establish an in vitro pre­
adipocyte and adipocyte model (Chapters 3 and 4), as these cells have previously been used to 
study various aspects of adipocyte biology. Circadian clock gene expression was then 
analysed in pre-adipocytes and adipocytes, and adipokine gene expression and secretion 
examined in adipocytes. Attempts were then made to manipulate the triglyceride contents of 
3T3-L1 adipocytes and generate hypertrophic cells representative of the obese phenotype 
(Chapter 3). However, this proved unsuccessful. Instead, hypothesis 2 was addressed by 
comparing rhythmic expression of adipose clock and adipokine genes, and adipokine plasma 
levels between human subcutaneous WAT from lean, overweight and type 2 diabetic cohorts 
(Chapter 5). The relevance of the data obtained, overall conclusions drawn from this thesis, 
and how the work relates to current understanding of adipose rhythms, will now be outlined. 
Finally, limitations of this work and options for future research to extend the current data will 
be discussed.
6.1 CLOCK GENE EXPRESSION IN PRE-ADIPOCYTES.
ADIPOCYTES AND WAT
There are now data showing that approximately 20% of WAT transcriptome, including core 
clock genes, follow a daily oscillatory pattern, and many of these are linked to basic 
metabolism and adipose function (Ptitsyn et a i, 2006; Zvonic et a l, 2006). There is also 
evidence that some metabolic factors feed back into the core molecular oscillator to influence 
clock gene expression (Canaple et a l, 2006). Furthermore, circadian rhythms in adipose 
tissue are blunted in mice exhibiting components of the metabolic syndrome (Ando et a l,
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2005). However, due to limitations when studying WAT, diurnal rhythms cannot be 
attributed to an adipocyte-specific oscillator. This is due to masking by the changing 
environment, such as through the light/dark cycle (Ando et a l, 2005; Gomez-Abelian et a l, 
2008; Zvonic et a l, 2006), by rhythmic neuronal and/or humoral input to the tissue, and also 
by the presence of numerous adipose cell types in addition to the adipocyte. Therefore, until 
now, circadian regulation of clock genes and adipokines could not be attributed to an 
adipocyte-specific oscillator. To do this would require an in vitro adipocyte model.
Aoyagi et a l (2005) and Shimba et al (2005) had previously identified clock gene expression 
in murine 3T3-L1 adipocyte cells. However, my study is the first to show quantitatively that 
these pre-adipocytes and adipocytes possess an endogenous circadian oscillator. This is 
consistent with recently reported circadian rhythms in human adipose-derived stem cells 
(Huang et a l, 2009; Wu et a l, 2007). Interestingly, rhythm amplitudes were comparable in 
3T3-L1 pre-adipocytes and adipocytes to those reported in WAT. For example, Perl 
exhibited 6- and 2-fold changes in pre-adipocytes and adipocytes, respectively, compared to 
8-fold (Ando et a l, 2005) and 3-fold (Zvonic et a l, 2006) variation in murine visceral, or 
inguinal and epididymal, WAT, respectively. Rev-erba and Dbp also exhibited similar 
amplitude changes in 3T3-L1 cells to those reported in inguinal and epididymal WAT (Zvonic 
et a l, 2006), suggesting that rhythm changes in 3T3-L1 cells might be physiologically 
relevant. However, Perl, Cryl and Email failed to oscillate in my cells following a serum 
pulse, despite oscillating in murine liver and WAT.
Lack of a robust circadian rhythm in some of the clock genes reported here is consistent with 
other studies. For example, PERI expression exhibits extremely low (less than two-fold) 
amplitude changes in human adipose-derived stem cells following a serum pulse (Huang et 
a l, 2009), while Cryl fails to exhibit circadian expression after a serum pulse of murine GT1- 
7 neurons (Gillespie et a l, 2003). Human peripheral leukocytes derived from blood also 
exhibit less than two-fold changes in BMAL1 expression (Ando et a l, 2009), and BMAL1 
protein fails to oscillate in ex vivo murine cerebellum (Siepka et a l, 2007), both of which 
suggest that lack of clock gene rhythmicity is not an artefact of using a cell culture system. 
Additionally, BMAL1 and CRY1 are arrhythmic in human bone marrow CD34+ cells in the 
presence of rhythmic PERI (Tsinkalovsky et a l, 2007).
In contrast to 3T3-L1 data, circadian rhythms of all clock genes examined were detected as 
described previously in C57B1/6J murine adipose and liver tissue (AlonsoWale et a l, 2005;
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Ando et a l, 2006; Yang et a l, 2006; Zvonic et a l, 2006) (Chapter 4). Additionally, circadian 
gene expression was found for all clock genes examined, excepting CRY1, in human 
subcutaneous WAT biopsies (Chapter 5). Together with current adipose literature, my work 
in 3T3-L1 cells suggests that, although murine adipocytes and pre-adipocytes contain an 
endogenous circadian clock, some of the rhythmicity reported in adipose tissue may derive 
from rhythmical input to the tissue. This may be through diurnal changes in SNS innervation 
(Bartness and Bamshad, 1998; Turtzo et a l, 2001), plasma hormone levels (Amer, 2005; 
Brydon et a l, 2001; Mora et a l, 2004a) or nutrient fluxes (Balsalobre et a l, 1998; Damiola et 
a l, 2000) A role for rhythmic input in driving peripheral oscillators in some clock genes is 
supported by a study in which rhythmic expression of some genes in the liver, including Perl, 
persisted in the presence of a disrupted hepatocyte circadian clock (Kommann et a l, 2007). 
Such information is extremely useful in establishing the relationship between peripheral 
oscillators and central control by SCN-regulated outputs, such as through neural and 
hormonal control. Studies in this area have yet to be conducted to confirm which signal to 
adipose tissue is responsible for driving expression of clock gene rhythmicity.
While my adipocyte and WAT data support the presence of a peripheral circadian oscillator in 
adipose tissue (both Chapters 4 and 5), there is now emerging evidence to suggest that 
disruption of this rhythm may result in components of the metabolic syndrome. Such data is 
extremely relevant to understand effects of our modem 24-hour lifestyle. For example, it is 
common during shift-work for the endogenous clock to be dissociated from the external 
environment and behaviour, such as feeding and the sleep/wake cycle. This leads not only to 
dyssynchrony between the SCN pacemaker and external time cues, but also peripheral 
circadian clocks becoming desynchronised from the central pacemaker and each other 
(Davidson et a l, 2008). These disturbances in circadian rhythms lead to increased risk of 
metabolic syndrome, and metabolic disturbances such as elevated levels of triglyceride 
(Morgan et a l, 1998; Ribeiro et a l, 1998). Additionally, there is a plethora of evidence 
showing that ablation of the circadian oscillator across the organism results in a metabolic 
phenotype (Kudo et a l, 2007b; Oishi et a l, 2006), such as obesity and hyperglycaemia 
(Turek et a l, 2005). Conversely, circadian gene expression shows reduced amplitude 
rhythms in obese and severely obese/diabetic mice (Ando et a l, 2005) compared to lean 
healthy controls. However, while there are studies in humans linking clock gene variants with 
metabolic syndrome (Scott et a l, 2007; Sookoian et a l, 2008; Woon et a l, 2007), until now 
there have been no studies assessing temporal clock gene expression dynamics in patients
165
with components of the metabolic syndrome, such as in individuals who are overweight or 
type 2 diabetic.
In order to establish the role of triglyceride accumulation and hypertrophy on the circadian 
oscillator within adipocytes, an in vitro model free from rhythmic input to the tissue is 
required. While triglyceride levels in 3T3-L1 adipocytes could be manipulated using 
numerous hormone treatments, I was unable to achieve a lean versus hypertrophic adipocyte 
model (Chapter 3). However, Perl and Dbp circadian expression showed lower amplitude 
mRNA rhythms in 3T3-L1 adipocytes compared to pre-adipocytes, which could be the result 
of triglyceride presence within the adipocyte or a result of the differentiation process. To 
extend these observations, human adipose tissue was used from lean, overweight and type 2 
diabetic patients in order to address the hypothesis that obesity or type 2 diabetes reduces 
circadian rhythm amplitude in clock genes and adipokines.
My data conclusively show that human subcutaneous WAT exhibits diurnal clock gene 
expression in vivo. However, compared to Ando et a l (2005), no obvious difference in 
amplitude between lean, overweight or type 2 diabetic patients for PERI, PERI, PER3, REV­
ERB a, DBP or CRY2 was observed. This might suggest that the differences in gene 
expression between lean and obese/type 2 diabetic mice from Ando et al. (2005) are the result 
of different genetic backgrounds between cohorts, and not the presence of adiposity or type 2 
diabetes.
In contrast to the other clock genes examined, BMAL1 expression in my overweight cohort 
appeared to exhibit a lower amplitude rhythm compared to lean and type 2 diabetic groups. 
This has previously been reported in obese and obese/diabetic mice (Ando et a l, 2005). 
Interestingly, Small knock-down in 3T3-L1 pre-adipocytes, created by siRNA delivery, 
causes failure of cells to differentiate into adipocytes, while cells over-expressing Bmall, or 
knock-out and re-introduction of Bmall, stimulate cellular lipid accumulation and induction 
of adipocyte-related genes (Shimba et a l, 2005). Additionally, BMAL1 haplotypes have been 
linked to type 2 diabetes (Woon et a l, 2007). Therefore, my data supports the suggestion that 
Bmall has a pleiotropic role; in the molecular oscillator and in adipogenesis. This data also 
suggests a potential role for BMAL1 expression in the pathology of obesity.
My data also showed suppression of PER2 mRNA rhythm amplitude in subcutaneous WAT 
from medicated compared to non-medicated type 2 diabetic patients. This is a particularly
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interesting finding as Perl has previously been associated with fasting hyperglycaemia 
(England et a l, 2009), typical of the diabetic state. In many surgeries it is standard practice 
for newly diagnosed type 2 diabetic patients to be immediately prescribed medications, such 
as metformin (Filion et a l, 2009), due to other protective roles of the drugs (Libby et a l, 
2009). If one, all, or a combination of the medications included in my study result in 
suppressed amplitude clock gene rhythms, and if this has a detrimental physiological output, 
combinations of medications prescribed may have to be re-assessed. While my data provide 
an indication that medications may influence the molecular clock, more detailed studies 
should be conducted to assess the functional effects in both molecular oscillator dynamics, 
and whole organism circadian biology.
It is also important to note that both PER! and BMAL1, which appeared in this study to 
exhibit suppressed amplitude in human subcutaneous WAT, also show altered expression in 
livers of dbldb mice (Kudo et a l, 2004). These animals harbour a mutation in the long-form 
of the leptin receptor that is important for transducing the leptin signal to the brain, rendering 
the animal leptin resistant, genetically obese and diabetic (Chen et a l, 1996). Therefore, both 
genes require further examination in metabolic syndrome.
In summary, addressing the central hypotheses, my data show that not only does murine and 
human WAT exhibit circadian rhythms in clock gene expression, but murine adipocytes 
themselves also possess an endogenous oscillator. However, this oscillator is responsible for 
driving rhythmic expression of some, but not all, circadian rhythms observed in adipose 
tissue. These findings highlight a role for rhythmic input to WAT to drive circadian gene 
expression or, as arrhythmic genes in 3T3-L1 cells (Chapter 4) were rhythmic in human 
adipose-derived stem cells (Wu et a l, 2007), data may suggest that 3T3-L1 cells are not a 
good model for studying adipocyte circadian biology. Additionally, contrary to the findings 
in Ando et a l (2005), the majority of circadian clock gene rhythms observed in human 
subcutaneous WAT are not influenced by the presence of overweight or type 2 diabetic 
phenotypes. However, BMAL1 and PER! exhibit attenuated circadian rhythms in overweight 
and medicated type 2 diabetic cohorts, respectively.
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6.2 ADIPOKINE EXPRESSION AND RELEASE FROM
ADIPOCYTES AND WAT
Since the 1990’s, the discovery of adipokine secretion has lead to the acceptance that adipose 
is an active endocrine tissue. Leptin and adiponectin are particularly interesting as, not only 
are changes in their production implicated in pathology of the metabolic syndrome (Lacasa et 
ah, 2007; Meier and Gressner, 2004; Wame, 2003), but studies from rodents and humans 
have revealed diurnal changes in circulating adipokine concentration (Kalsbeek et a l, 2001; 
Saad et a l, 1998). Additionally, this rhythmicity may have a transcriptional basis, as 
adipokine mRNA is subject to low amplitude diurnal variation in murine WAT (Ando et a l, 
2005; Bray and Young, 2007).
Interestingly, 3T3-L1 adipocytes, murine epididymal WAT and human subcutaneous WAT 
failed to exhibit Leptin and Adiponectin circadian gene expression in my studies. Therefore, 
my data suggest that adipocytes are not responsible for the generation of low amplitude Leptin 
and Adiponectin rhythms reported previously in WAT, but that, as with some clock genes, 
oscillations are generated by rhythmic input to the tissue. However, LEPTIN mRNA levels in 
overweight participants positively correlated with BMI (Chapter 5), which suggests that 
elevated plasma leptin in obese individuals (Calvani et a l, 2004; Matkovic et a l, 1997; Saad 
et a l, 1998) is generated at the molecular level through increased LEPTIN expression. 
Interestingly, there was no effect of type 2 diabetes on LEPTIN ox ADIPONECTIN expression 
in human subcutaneous WAT. Again, this suggests that the reduced amplitude gene 
expression observed in Ando et a l (2005) may have been the result of genetic background 
differences between lean, obese and obese/diabetic murine cohorts.
Interestingly, my data from 3T3-L1 adipocytes suggest that there is rhythmic leptin, but not 
adiponectin, secretion from the adipocyte (Chapter 4). It is possible that rhythmic plasma 
adiponectin levels observed in vivo (Gaviila et a l, 2003) are generated by rhythmic input to 
the tissue, such as through neural or humoral cues. For example, plasma insulin exhibits 
diurnal rhythmicity (Van Cauter et a l, 1991) and has been shown to stimulate adiponectin 
secretion (Bogan and Lodish, 1999; Tzeng et a l, 2009). Additionally, adiponectin exhibits 
ultradian rhythmicity in vivo (Gavrila et a l , 2003), which may mask any circadian secretion. 
Therefore, a greater temporal resolution would be required to establish temporal ultradian 
versus circadian secretory dynamics, which will be discussed in Section 6.4.
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Despite lack of rhythmicity in adiponectin secretion, my data provide the first evidence that 
an adipocyte-specific oscillator might generate the diurnal variation of leptin levels observed 
in plasma, and this is in the absence of rhythmicity in adipokine mRNA. Similar findings 
have been described by previous studies of the liver proteome, in which hepatic protein 
rhythms do not necessarily reflect temporal mRNA expression patterns (Reddy et a l, 2006). 
Additionally, my leptin data provides an alternative explanation to the study conducted by 
Kalsbeek et a l (2001) who claimed, via analysis of lesion experiments in rats, that the SCN 
was required to drive diurnal changes in plasma leptin levels. If the adipocyte molecular 
clock does govern the diurnal leptin secretion, and subsequently plasma rhythms, it may be 
that the SCN is required to maintain synchrony of this rhythm between adipocytes rather than 
generate de novo circadian hormone release, although such a phenomenon has not been 
reported previously.
Therefore, my data provide evidence for an endogenous circadian clock driving leptin 
secretion in the absence of adipokine mRNA rhythmicity. This extends previous data by 
suggesting a source of the rhythmic plasma leptin levels observed in vivo (Calvani et a l, 
2004; Matkovic et a l, 1997; Saad et a l, 1998). However, there were no differences in 
ADIPONECTIN or LEPTIN expression levels between lean, overweight and type 2 diabetic 
patients in human subcutaneous WAT, although LEPTIN expression significantly correlated 
with BMI. Plasma samples obtained from the human study (Chapter 5) will be analysed to 
confirm diurnal rhythmicity in circulating plasma adipokine concentrations.
6.3 METABOLIC FACTOR EXPRESSION IN PRE­
ADIPOCYTES. ADIPOCYTES AND WAT
Approximately 20% of WAT transcriptome, including genes involved in regulating 
metabolism, has been shown to oscillate in vivo (Ptitsyn et a l, 2006). Additionally, some of 
these genes have been shown to regulate, or have potential to regulate via indirect pathways, 
the molecular oscillator. To date, it has been shown in various cell types that 
BMALI/CLOCK transactivates PPAR target genes by binding to the PPRE (Inoue et a l, 
2005; Nakamura et a l, 2008). Additionally, discovery of an E-box rich region in the 
promoter of the Ppara gene suggests that BMAL1/CLOCK controls Ppara expression (Oishi 
et a l, 2005). Supporting this, a Clock?19 mutation leads to loss of Ppara rhythmicity both in 
vivo and in vitro in murine liver (Oishi et a l, 2005). There is also evidence for reciprocal 
regulation between the molecular oscillator and Ppara, as Ppara v" mice failed to show phase
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shifts in Bmall mRNA expression under a restricted feeding paradigm, which was supported 
by discovery of a PPRE site in the Bmall promoter (Canaple et a l, 2006). SREBP1 is also 
capable of binding to E-boxes, and can be entrained by restricted feeding. In contrast, PGC- 
la  is rhythmically expressed in murine liver and skeletal muscle, and induces expression of 
Clock and Bmall (Liu et a l, 2007a). Furthermore, both PGC-la and RIP140 interact with 
nuclear receptors, such as the PPARs (L'Horset et a l, 1996; Treuter et a l, 1998), thereby 
providing an indirect regulatory role on the circadian oscillator. Therefore, examination of 
these genes in adipose tissue is beneficial to gain a better understanding of adaptive energy 
expenditure, and potential roles of metabolic factors in the pathology of metabolic syndromes.
In order to assess whether any of the above genes might be regulated at the transcriptional 
level by a circadian clock, expression of several nuclear receptors {Ppara and Ppary) and 
transcription factors (Srebpl, PGC-la, and R1P140) were assessed for diurnal oscillations in 
murine 3T3-L1 pre-adipocytes, 3T3-L1 adipocytes, murine liver and WAT {Ppara, Ppary and 
Srebpl), or human subcutaneous WAT {PGC-la, and RIP140).
Despite previous suggestions of a link with the molecular oscillator, Ppara, Ppary and Srebpl 
mRNA expression failed to oscillate in a circadian fashion in murine WAT, or in 3T3-L1 pre- 
and mature adipocytes, despite Bmall oscillations in murine WAT. It would therefore be 
useful to confirm that non-rhythmic mRNA is translated to arrhythmic protein by performing 
Western blotting. To date no studies have shown a functional intracellular clock mechanism 
is required for circadian Ppar or Srebp expression, and vice versa. However, results from 
previous studies, coupled with my data, suggest that reciprocal regulation between Ppars and 
Bmall is not sufficient to drive circadian regulation, but acts merely as a fine tuning 
mechanism. This would also provide a mechanism whereby the molecular oscillator in 
peripheral tissues can be entrained to feeding. Therefore, lack of rhythmicity of some clock 
genes in 3T3-L1 pre- and adipocytes, suggests that rhythmic input may be required to drive 
diurnal oscillations of some, but not all, circadian gene expression in adipocyte cells in vivo.
As with the Ppars in murine WAT, PGC-la and RIP 140 exhibited no obvious diurnal 
expression pattern at the zeitgeber times analysed, although PGC-la and RIP 140 exhibited 
significant temporal variation in human subcutaneous WAT. Nor was there a difference 
between lean, overweight and type 2 diabetic patients. However, as with PER2 expression, 
both RIP140 and PGC-la mRNA levels appeared to exhibit lower expression in medicated 
versus non-medicated diet and exercise controlled type 2 diabetic patients. While this study is
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the first to report expression differences in mRNA between type 2 diabetic patients, further 
work is necessary in order to establish the functional relevance of these observations.
6.4 LIMITATIONS. IMPROVEMENTS AND FUTURE
WORK
My data from Chapter 4 suggested that rhythmic input to WAT is important in driving the 
diurnal variation in gene expression observed in vivo. In order to ascertain which of the 
various input pathways might be important, neural ablation or constant hormone infusion 
experiments could be employed in an animal model. Alternatively, the lack of rhythmicity for 
some clock genes measured in 3T3-L1 adipocytes and pre-adipocytes, as well as a lack of 
adipokine and transcription factor rhythmicity, may be a result of the 3T3-L1 cell type. It is 
also possible that the serum pulse resulted in incomplete synchrony of intracellular clocks 
across the culture, and so the rhythms of genes that naturally exhibit lower amplitude 
oscillations may not be detected at the population level. It may therefore be useful to repeat 
the experiments using a different pharmacological stimulus, such as dexamethasone 
(Balsalobre et a l, 2000a), to synchronise the cells. It is also possible that the genes failing to 
exhibit rhythmic mRNA expression may show oscillatory protein levels. For example, 
previous studies of the liver proteome have provided evidence that protein rhythms do not 
necessarily reflect temporal mRNA expression (Reddy et a l, 2006). This could be assessed 
by carrying out Western blotting for the protein products of all genes examined.
In addition, it would be beneficial to repeat the experiments using an in vitro adipocyte model 
that is closer to an in vivo adipocyte. Isolation of pre-adipocytes from human WAT biopsies 
and subsequent differentiation into adipocytes would form the ideal model for analysis of 
adipocyte rhythms. Alternatively, as experiments requiring human participation are both 
labour intensive and expensive, further studies could be performed using adipocytes from the 
IMMORTO mouse, called IMMORTO WAT (IMWAT) cells. These are a useful model as 
they contain a mutated, temperature sensitive T-antigen under the control of a major 
histocompatability complex promoter, such that they proliferate at 33°C in the presence of 
interferon y, but can be induced to differentiate when cultured at 37°C in the absence of 
interferon (Morganstein et a l, 2008). This means that primary cells may be maintained in 
culture for longer periods of time before being utilised in experiments. Work is currently 
underway to compare circadian gene expression patterns in IMWAT cells following a serum 
pulse, to those obtained from the 3T3-L1 adipocytes described herein. Additionally, it is
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possible that the IMWAT cells may be more amenable to triglyceride manipulation in order to 
obtain a lean versus obese adipocyte model. Triglyceride manipulation could therefore be 
attempted in these cells and, if primary cells can be more easily manipulated, it may be 
possible to generate cultures from overweight versus lean Per2:Luciferase mice and perform 
real-time imaging.
While leptin secretion from 3T3-L1 adipocytes exhibited circadian rhythmicity in my serum 
pulse experiments, adiponectin secretion did not. However, ultradian rhythms in adiponectin 
plasma concentrations have also been observed in humans (Gavrila et a l, 2003), so it may be 
that ultradian adiponectin release from 3T3-L1 adipocytes in this study masked any circadian 
secretory patterns. Indeed, while plasma leptin concentration exhibits approximately 4 
ultradian peaks over 24 hours, occurring approximately 3 hours post-prandially (Saad et a l, 
1998), adiponectin has approximately 10 peaks and of a higher percentage increase (Gavrila 
et a l, 2003). Greater temporal resolution would be required to distinguish ultradian from 
circadian secretory dynamics and ensure that lack of circadian adiponectin secretion was not 
due to low temporal resolution. While my study utilises a static culture system, flow cultures 
of adipocytes could be used to increase temporal resolution of culture medium sampling. 
Further work may also be carried out to establish a direct connection between the adipocyte 
molecular clock and leptin release, for example by measuring adipokine release from cells in 
which the molecular oscillator has been ablated. It will also be essential to study the 
mechanism underlying the secretory leptin profile from adipocytes, and ascertain whether the 
adipokines are directly released following synthesis, or whether they are stored within the 
adipocyte. If adipokines, such as leptin, are stored within the adipocyte for a period of time 
prior to release, then rhythmic mRNA expression would not be as essential as a circadian 
secretory mechanism.
As with 3T3-L1 adpokine data, one key limitation for the human study was the low temporal 
resolution for biopsy sampling. This could mean that genes deemed arrhythmic in my study 
could indeed have been oscillating but, due to sampling times, the peaks and troughs of the 
rhythm were missed. There are, however, ethical limitations to the number of biopsies that 
can feasibly be obtained from a human subject. As such, it may be interesting in future 
studies to sample human biopsies at different zeitgeber times. This would make it possible to 
ascertain whether circadian rhythms could be detected in genes that were found to be 
arrhythmic using the temporal sampling protocol in my trial. However, as Ando et a l (2005) 
detected rhythmic gene expression utilising 6 hourly sampling times, the temporal resolution
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in my study should be adequate to detect diurnal rhythmicity. This is supported by the clear 
diurnal rhythms exhibited by clock genes in my human subcutaneous WAT.
Interestingly, there were differences in WAT gene expression between type 2 diabetic patients 
who were diet and exercise controlled and those who were medicated. It would therefore be 
beneficial to run a further study assessing the effects of different medications on both clock 
and metabolic genes in WAT.
In order to understand the contribution of different WAT cell types to adipose rhythmicity, 
and how this might vary in different disease states, it would also be interesting to compare the 
contribution of stromo-vascular versus adipocyte adipose fractions to rhythmic WAT 
transcription. Furthermore, the human results obtained within this study were collected from 
subjects entrained to a light/dark schedule. It may be useful to place subjects in a constant 
routine with constant nutrient infusion in order to assess the impact of feeding and light/dark 
cycles on underlying adipose rhythms, as feeding in particular has been shown to be a potent 
zeitgeber for peripheral oscillators (Balsalobre et a l, 1998; Schibler et a l, 2003). It would 
also be interesting to examine whether eating at night, as shift workers frequently do, can 
cause phase shifts in WAT rhythms, and whether re-entrainment is affected by presence of the 
metabolic syndrome. Generated data would improve understanding of links between shift 
work, metabolism and the increased incidence of metabolic disturbances observed in shift 
workers (Morgan et a l, 1998; Ribeiro et a l, 1998).
In order to test whether there there is a diurnal expression pattern for metabolic factors found 
in human subcutaneous WAT, qtPCR arrays will be performed on the biopsies collected in 
Chapter 5. This will aim to examine the circadian variation of a plethora of metabolic genes 
associated with obesity and type 2 diabetes, and to establish whether any of these exhibit 
altered expression patterns in overweight and diabetic individuals when compared to lean 
controls. Rhythmicity in leptin and adiponectin will also be confirmed in the plasma samples 
obtained from the subjects in my study.
Further limitations of my human study include long term nutrient intake. It has previously 
been shown that caloric restriction, or high fat diet, in rodents can affect circadian timing in 
the central and peripheral oscillators (Mendoza et a l, 2005; Resuehr and Olcese, 2005). Long 
term food intake prior to my study was not regulated or recorded and, as such, the effects of 
long term eating habits cannot be ruled out when explaining differences between cohorts.
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However, as part of the study design, my participants were diet controlled for one week prior 
to the study session, which will have minimised any long term dietary effects on the WAT 
oscillator.
6.5 CONCLUDING REMARKS
Not only do my results add to the current understanding of adipose circadian biology, but they 
provide novel preliminary data to support new lines of research that could provide insight into 
aetiology of metabolic syndrome. Information gleaned from such studies would be invaluable 
in elucidating targets for therapy to treat a wide range of metabolic abnormalities, and may 
also reveal further genetic markers for pre-disposition towards the metabolic syndrome. With 
greater understanding of the link between the circadian oscillator, metabolism and disease 
states, new drug targets might be identified to help manage metabolic diseases. Greater 
knowledge of WAT diurnal rhythmicity might also identify the optimal time for drug 
administration, such as in type 2 diabetic patients, and improve the efficacy of treatments 
through chronotherapy.
A review article, of which I am co-author, is published as Johnston, J. D., 
Frost, G., and Otway, D. T. (2009). Adipose tissue, adipocytes and the 
circadian timing system. Obes Rev 10(supp. 2): 52-60 (see Appendix M)
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Appendix B
Murine genomic DNA standards calculation
Calculation of the number of single stranded copies per microlitres
The mouse genome is 3.42 x 109 base pairs (bp) and the molecular weight of one base pair is 
approximately 660g/mol. Therefore, the molecular weight of the mouse genome is
3.42 x 109 x 660 = 2.26 x 1012g/mol
However, the mouse genome is diploid, such that one genome is equal to two copies, 
therefore the mouse haploid genome contains
2.26 x lO 12 -r  2 = 1.13 x 1012g/mol
Therefore, a 1M solution of the mouse haploid genome contains 1.13 x 1012g/l.
Avogadro’s number states that 1 mole contains 6.02 x 1023 DNA molecules, but DNA 
contains two single strands (ss) so each mole of the mouse haploid genome contains
6.02xlO 23 x 2 = 1.2x 1024ss
Therefore a 1.13 x 1012 g/1 solution contains 1.2 x 1024 ss, and so lg/1 contains
1.2 x 1024 ss 4- 1.13 x 1012 g/1 = 1.06 x 1012 ss
So Ig contains 1.06 x 1012 ss/1 and Ipg contains 1.06 x 106 ss/pl. Therefore, a Ipg/pl solution 
contains 1.06 x 106 ss.
Calculation of stock dilution
As 5 pi is used for the PCR reaction, the stock needs to be diluted to 1 x 105 ss/5pl = 2 x 104 
ss/ul. Mouse genomic DNA (Promega) is supplied at 210 pg/ml = 0.21 pg/pl. Therefore, 
there is
0.21 x 1.06 x # = 2 . 2  x 105 ss/pl
To get 2 x 104 ss/pl, a 1 in 11 dilution would be performed (i.e. 100pi genomic DNA diluted 
with lOOOpl O.lxTE buffer).
Standard dilutions
A serial dilution was performed using the 1 x 105 ss/5pl diluted stock of mouse genomic 
DNA. The dilutions required were 105, 104, 103, 102 and 10'ss/5pl (i.e. 100pi DNA dilution 
plus 900pl O.lxTE buffer. The dilutions were stored in aliquots.
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Human genomic DNA standards calculation
Calculation of the number of single stranded copies per microlitres
The human genome is 3.25 x 109 base pairs (bp) and the molecular weight of one base pair is 
approximately 660g. Therefore, the molecular weight of the human genome is
3.25 x 109 x 660 = 2.15 x 1012 g
However, the human genome is diploid, such that one genome is equal to two copies, 
therefore the human haploid genome contains
2.15 x lO 12 4-2 = 1.08 x 1012 g/1
Therefore, a 1M solution of the human haploid genome contains 1.08 x 1012 g/1.
Avogadro’s number states that 1 mole contains 6.02 x 1023 molecules, but DNA contains two 
single strands (ss) so each mole of the human haploid genome contains
6.02xlO 23 x 2 = 1.2x 1024ss
Therefore a 1.08 x 1012 g/1 solution contains 1.2 x 1024 single strands, and so lg/1 contains
1.2 x 1024 4- 1.08 x 1012 = 1.11 x l0 12ss
So Ig contains 1.11 x 1012 ss/1 and Ipg contains 1.11 x 106 ss/pl. Therefore, a 1 pg/pl solution 
contains 1.11 x 106ss.
Calculation of stock dilution
As 5 pi is used for the PCR reaction, the stock needs to be diluted to 1 x 105 ss/5 pi, or 2 x 104 
ss/ul. Human genomic DNA (Promega) is supplied at 213 pg/ml = 0.213 pg/pl. Therefore, 
there is
0.213 x 1.1 x 10*= 2.34 x 105 ss/pl
To get 2 x 104 ss/pl, a 1 in 11.7 dilution would be performed (i.e. 100pi genomic DNA diluted 
with 1070pl O.lxTE buffer).
Standard dilutions
A serial dilution was performed using the 1 x 105 ss/5pl diluted stock of human genomic 
DNA. The dilutions required were 105, 104, 103, 102 and lOWSpl (i.e. 100pi DNA dilution 
plus 900pl O.lxTE buffer. The dilutions were stored in aliquots.
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family history of TYPE 2 DIABETES 
required
For a non-drug study investigating the 
effects of DIABETES and INSULIN 
RESISTANCE on BIOLOGICAL 
RHYTHMS of FAT TISSUE
MUST BE BETWEEN 40 & 65 
YEARS OF AGE
Please Contact: Daniella Otway 
Telephone(01483)689705 
Email: d.otway@surrey.ac.uk 
Room 19 AY 02 
Faculty of Health and Medical Sciences 
University of Surrey
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Appendix E
Power calculations
The best estimate of expected response comes from Ando et al. (2005). Based upon the 
mRNA rhythms of Per and Dbp clock genes and Adiponectin, we could reasonably expect the 
difference of peak expression to be > 1.5 SD between our control and obese-diabetes groups. 
For a < 0.05 and 80% power, and considering a potential 10% drop-out rate based on previous 
studies, we would thus require > 9 subjects per group (control, overweight, type 2 diabetic) 
(see table below).
Sample size calculation 
parameters
Comparison between 
cohorts
Type of study ANOVA
Design Repeated measures
Alpha 0.05
Power 80%
Difference between the 
means
1.5
Mean standard deviation 1.5
Drop out rate 10%
Sample size per cohort 9
Table: Calculation of sample size based on results between subjects.
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Appendix F
Dr Carr-Bains 
Student Health Centre 
University'of Surrey 
GU2 7XH
UNIVERSITY OF
SURREY
Fsculty of
Health and Medical Sciences
RE: DOB:
u.werai:; c: Surra;
C-'JiiZlDti. Surra/ GU2 7XH UK
01/06/09
Dear Or Carr-Bains,
W e are currently investigating th e  e ffec ts  o f type  2 d ia b etes and insulin  res istan ce  on  ad ip o se  
biological rhythms. Recent animal studies have revealed that most biological processes in adipose tissue 
have daily rhythms, including the production of adipokines that control blood sugar levels. T hese rhythms 
are much smaller in animals v.ith diabetes, suggesting that reduced rhythmicity may be an important factor 
relating to diabetes.
W e v.ill measure Tat hormone’ rhythms in fat tissue and in the blood o f  individuals v.ith or without diabetes. 
W e predict that this work v.ill open an exciting new area of research that v.ill help us understand the 
biological cause of diabetes and thus assist in the development of more effective treatment for this d isease  
(see attached a more detailed description of the study).
Mr Smith (DOB) has already undergone a screening visit and qualifies a s having type 2 diabetes mel'itus 
which is being controlled using diet/exercise and not drug treatment/insulin resistance syndrome which is 
being controlled using diet/exercise and not drug treatment/being lean and insulin sensitive based on EGIR 
criteria. W e therefore wish to recruit him for this study.
There will be a single study period consisting of two nights at the Clinical Research Centre (CRC), at the 
University of Surrey, Guildford. Here, your patient vill undergo hourly blood sampling over 25 hours in 
addition to four adipose tissue biopsies, which will taken under local anaesthetic to measure gene expression 
relating to both biological rhythm generation and adipckine production. The University'of Surrey and Surrey 
Research Ethics Committees have given favourable ethical opinions forall aspects of this study.
Mr Smith has agreed to take part in our study starting on ???. Your patient understandsthat this is purely a 
research study, that participation will not affect his normal medical care, that all results will be treated in 
confidence, and that he is free to withdraw at anytime.
W e w ould b e  grateful if you  would let u s  know  if you  feel that there are any rea so n s w hy th is  patient 
may b e  un sintab le  for the study or whether he has any other significant medical problems and/or is taking 
any long-term medication (please refer to our inclusion /  exclusion criteria attached). Your patient has given 
consent for you to be contacted and for you to provide us v.ith their medical infcnmation (consent form 
enclosed). Any information which you may provide v.ill be held in strictest confidence and v.ill not be 
disclosed to anyone vho is not part of the research team. All data collected during the study v.ill be coded 
and remain confidential in compliance with the Data Protection Act (1996).
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If you have any additional questions, please contact us. t hank you for your assistance in advance.
Y ours sincerely,
Daniella Otv.ay
Dr Jonsihsn Johns ten. FhB 
Prindpsl Inves tigstor 
Tel: *44{14S3) £85470 
E-msil: j.johrstor®surrey.scuk
L!iss Dsniells O tesy. ESc 
Resesrch Project Idsnsger 
Tel: 01483683705  
Emsil: d .ctw ey@ s urrey. s& uk
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Inclusion / Exlcusion Criteria
In c lu s io n  C riteria
P a rtic ip a n ts  m u st:
a) b e  betw een 40-55 y e a r s  o f a g e ,
b) b e  m ale,
c ) b e  able anti v illin g tc  give infcrmeti oral anti vxitten consent,
d) h a v e  authorisation from their m edical practitioner,
e )  com plete anti m eet th e  defined criteria o f pre-study question naires anti screen s,
f) h a v e  a regular s leep /w ak e cycle  with a s leep  duration between 6  anti 8  hours,
g) tic not exhibit extrem e morning or even ing preference (Horne anti O stberg, 1 9 76)
h) a g ree  to  keep a constant s leep /w ak e cycle  with a se lf-se lected  8 hour s le e p  duration (from which it 
cannot b e  deviated  by m ore than 30 m inutes) for o n e  w eek  prior to the lab study,
i) obtain 1 5  m inutes o f sunlight within 1 .5  hours o f waking up anti agree to  nap only within a 4 h designated  
nap w indow  for one w eek prior to the lab study,
j) a llow  confirmation of com pliance to th ese  instructions by reporting wake up and sleep  tim es to th e  lab 
voicem ail, wearing A ctiw atches (AWL) continuously and com plete  daily sleep  and event d iaries for on e  
w eek  before th e  study se ss io n ,
k) a g ree  to refrain from alcohol, caffeine, heavy exercise  and certain food com p on en ts three d a y s before  
th e  study se ss io n ,
I) a g ree  to  eat sp ec ia lly  provided m ea ls (based  on individual en erg y  requirem ents) for three d a y s prior to 
th e  study,
m ) a g ree  to  refrain from prescribed and "'over th e  counter’ m edication and food/vitamin su pp lem en ts for a 
w ash-out period three w eek s before and during th e  study (except an y  m edication describ ed  in main 
letter above).
E x c lu s io n  C riteria
P a rtic ip a n ts  will b e  ex c lu d e d  if they :
a) are taking regular m edication (also ncn-prescribed) or food su pp lem en ts (e .g  vitam ins, m inerals, fish oil, 
antioxidant tablets) from which it is not possib le  to refrain, known to  influence:
1 ) sleep /alertnes& the circadian tim in g system  (e.g  (3-blcckers, barbituates, antidepressants, 
benzodiazep in es, m elatonin, ritalin, modafinil, soporifics, S t  John’sW crt),
2 )  any of the m etabolic functions (e .g . affecting thyroid, kidney, liver or gastrointestinal function)
3 )  any of the inflammatory m arkers (e .g . aspirin, ibuprofen, anticbictics, hay  fever m edication, 
m edication for sore throats and co ld s)
4 )  and/or any o f the endothelial markers (e .g . ACE inhibitors and angiotensin (receptor) blockers, 
diuretics, (5-blockers, anti-throm bosis m edication),
b) h a v e  a history o f an y  circadian or s le ep  disorder or m etab olic  cardiovascular or chronic infectious /  
inflammatory d ise a se  a s  confirmed by the GP or th e  pre-study q u estion naires (e .g . a Pittsburgh S leep  
Quality Index > 5 vill result in exclusion),
c ) h a v e  a history o f psychiatric or neurological d ise a se  or drug and alcohol abuse,
d) h a v e  a positive drug screen . A  urine screen  will b e  carried out to  ensu re that th e  participants are  
negative  for drugs of abu se ,
e ) h a v e  donated over 40 0  ml o f blood in th e  three m onths preceding th e  study,
f) are anaem ic, confirmed by a haem atology screen,
g) ha v e  participated in shift work or h a v e  travelled a cross m ore than two tim e z o n e s  within three w e ek s of 
th e  study,
h) do not keep a regular sleep -w a k e  cycle,
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a) do not refrain from alcohol, caffeine containing drinks (e.g. coffee , coke, tea , redbull). heavy ex ercise  
and certain foods (e.g. th ose  high in fat and green v eg eta b le s) three d a y s before and during the 
laboratory se ss io n ,
b) co n su m e m ore than 4 cu p so fca ffe in a ted  beverages (e .g . coffee, tea , co la)d aily  over the preceding 1 
month
c) are sm okers.
Details of the  study
T he study v.ill be conducted at th e  Clinical R esearch Centre at th e  University o f Surrey and v.ill involve 2  
nights in th e  laboratory. T h e  first night (day 0) v.ill b e  acclimatisation. On the folic v,in g morning (day 1), an 
indwelling cannula v.ill be inserted into one arm under local anaesth etic  (Lignocaine) by a qualified nurse. 
Blood sa m p le s  v.ill then be taken hourly over 25  hours, not exceed in g  400 ml throughout th e  whole study. 
Plasm a will b e  used to m easure m etabolic param eters and severa l horm ones, such a s  leptin and 
atiiponectin. Four b iop sies o f su b cu tan eou s upper buttock ad ip ose tissu e  will also be taken ev ery  six  hours 
on day  1 to look for expression o f adipokines (such a s  leptin and atiiponectin) and g e n e s  involved in the 
biological dock  m echanism  (such a s  Perl).  B iopsies will be taken by making a sm all indsion in th e  skin 
(~1 .5cm ) and cutting a va y  a p ea-sized  section  o f ad ipose tissu e  under local anaesth etic  (Lignocaine). The  
wound will then b e  closed with a s in g le  stitch that can then b e  rem oved 1 week later.
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Appendix G
< f UNIVERSITY OF
SURREY
INFORMED CONSENT FORM
Participants Name:
Title of Project: Effects of type 2 diabetes and insulin resistance on daily-biological rhythms in
fat tissue and blood
Investigators: D. Otway; Dr S Bretschneider, Dr J. Johnston, Dr. D. Robertson and Prof. D.
Skene
Please indicate your willingness to take p a rt by ticking the boxes below:
1. I confirm that I have read and understood the information sheet provided. I have been 
given a full explanation of the nature and purpose of the study, and what I will be 
expected to do. I have been given the opportunity- to ask questions on all aspects of the 
study*
I understand that my participation is voluntary and that I am free to withdraw at any* time, 
without explanation and without prejudice.
4. I agree to the investigators contacting m y medical practitioner about m y participation in 
the study, and I authorise my medical practitioner to disclose details of my relevant 
medical or drug history; in confidence.
7. I agree to comply with any instruction given to me during the study* and to co-operate 
fully with the investigators. I shall inform them immediately if  1 suffer any deterioration 
of any kind in my health or well-being, or experience any unexpected or unusual 
symptoms.
□
□
3. I acknowledge that in consideration for completing the study* I shall receive the sum of j j
£250. I recognise that the sum would be less, and at the discretion o f the investigators, if  
I withdraw before completion of the study*
□
□5. I consent to my personal data, as outlined in the participant information sheet, being used for the research project stated in the informa non sheet, and agree that data collected may­
be shared with other researchers or interested parties. I understand that all personal data 
relating to volunteers is held and processed in the strictest confidence, and in accordance 
with the Data Protection Act (1998).
6. I consent to provide samples of fat tissue from my upper buttock and blood samples for | | 
DNA analysis for the presence of genes involved in daily rhythms.
□
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S. I understand that in the event of my suffering a significant and enduring injury (including 
illness or disease) as a direct result of my participation in the study, compensation will be 
paid to me by  the university of Surrey, subject to certain provisos and limitations. The 
amount of compensation will be appropriate to the nature, severity and persistence of the 
injury and will, in general terms, be consistent with the amount o f damages commonly 
awarded for similar injury b y  an English court in cases where the liability has been 
admitted.
9. I confirm that I have read and understood the above and freely consent to participating in 
the study. I have been given adequate time to consider my participation and agree to 
comply with the instructions and restrictions of the study.
Name of volunteer (BLOCK CAPITALS) ......................
Signed ..............................................  Date
Name of Witness (BLOCK CAPITALS) .................
Signed ..........................................  Date
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BIOPSY CONSENT FORM
Participants Name:,
Title ofProj ect: Effects of $pe 2 diabetes and insulin resistance on daily biological rhythms in 
fat tissue and blood
Investimators: Miss D. Otv^y, Dr S. Bretschneider, Dr J. Johnston, Dr. D. Robertson and Prof.
D.Skene
Please indicate your willingness to take part by ticking the boxes below:
1. I confirm that I have had the procedure clearly explained to me___________________________ __ _
and have had the opportunity to ask questions. I am happy to have 
tissue biopsies taken from my upper buttock under local anaesthetic.
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time even during the procedure itself, without 
giving any reason, without m y medical care or legal rights being affected.
3. I have been given a copy of the biopsy aftercare sheet
□
□
Name of Patient Date Signature
In thepresence of
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
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Appendix H
UNHVERSHY OF
t J  SURREY
Participant information sheet: Lean and healthy 
Title
Effects of type 2 diabetes and obesity on daily biological rhythms in fat tissue and circulation
We are writing to invite you to take part in a study investigating the effects of type 2 diabetes and 
obesity on daily biological rhythms in fat tissue and blood. We are conducting this study to help us 
understand the potential link between daily biological rhythms and the incidence of obesity and type 2 
diabetes mellitus. Before you decide, it is important for you to understand why the research is being 
carried out and what it will involve. Please take time to read the following information carefully and 
discuss it with your friends, relatives and anyone involved with your care. Please ask us if there is 
anything that is not clear or if  you would like more information.
W hat is the study about?
Our internal ‘body clock’ regulates most bodily functions, including hormone secretion and the 
metabolism of sugar and fat. Recent animal studies have revealed that most biological processes in fat 
tissue have daily rhythms, including the production of ‘fat hormones’ that control blood sugar levels. 
These rhythms are much smaller in animals with diabetes, suggesting that reduced rhythmicity may be 
an important factor relating to diabetes.
We will measure ‘fat hormone’ rhythms in fat tissue and in the blood of individuals with or without 
diabetes. We predict that this work will open an exciting new area of research that will help us 
understand the biological cause of type 2 diabetes and thus assist in the development of more effective 
treatment for this disease.
Aims
The aim of this study is to investigate the effect of type 2 diabetes and obesity on rhythmic production 
and blood circulation of a range of fat-derived factors. Different people (type 2 diabetics, individuals 
who are overweight, and lean healthy individuals) will be compared.
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Why have I been chosen?
In this study we are looking for healthy people who are free from disease or other medication 
and who are not exhibiting any signs of insulin resistance (such as high level of insulin in 
your blood during a fasting, being overweight or obese, having a large waist circumference, 
having elevated blood fat/cholesterol levels, having slightly elevated fasting glucose 
concentrations, or having high-blood pressure).
W hat does the study involve?
10 type 2 diabetics, 10 overweight subjects and 10 healthy lean volunteers will participate in the study. 
You will be asked to do the following:
Before the study starts:
Confirm that you are not participating in another study other than this study.
Report whether you have a phobia of needles or blood.
Give a single blood sample for a standard haematological and biochemical screen and to 
ensure that you are not anaemic. Any abnormalities detected in these screens, will be 
discussed with you by Dr John Wright (medical practitioner, FHMS) and suitability for 
participation will be assessed by the research team.
Keep a constant sleep/wake cycle for one week before the lab study starts. We will ask you to 
sleep for a block of 8 hours, waking at 6.30 am and going to bed trying to sleep at 10.30pm. 
You have to stick to this duration for one week and can not deviate from it by more than 30 
minutes.
Confirm your constant sleep/wake cycle by reporting wake up and sleep times to the lab 
voicemail, filling in sleep diaries and wearing acti-watches. A sleep diary is filled in once a 
day and records time of waking up and falling asleep. The acti-watch records activity. They 
measure objectively how regular your sleep-wake cycle is. The watch is worn on the non­
dominant hand, day and night (except for showering as they are not waterproof).
- Refrain from alcohol and caffeine containing drinks (e.g. coffee, coke, tea, redbull), heavy 
exercise 1 week before the study session and certain foods (e.g. those high in fat) 3 days 
before the laboratory session. You will be provided with a list with further details and an event 
diary to record your consumptions pattern 1 week before the start of the study.
Consume food provided by the research team 3 days prior to the study, which will be 
formulated based on calculated energy requirements.
Refrain from prescribed, ‘over the counter’ medication and food supplements for 2 weeks 
prior to the laboratory study, unless it has been approved by the research team.
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Only if  this is possible, will you be able to take part in this study.
During the study (see also Figure 1 for a diagram of the study):
To spend 2 nights in the laboratory (1 adaptation night, 1 study night). Throughout the study 
you will be in controlled conditions regarding light, body position and food intake. There will 
be no solid food, but you will be provided with small hourly feedings of a liquid nutrient drink 
during wake periods (Fortisip).
Provide 25 blood samples taken hourly over the 25 hour sampling period. Samples will be 
taken from a cannula inserted into one arm by a qualified nurse.
Provide 4 fat tissue biopsies (see below) from the upper buttock region. Samples will be taken 
by a qualified medical practitioner.
Biopsies
Biopsies, taken from the upper buttock region (see Figure 2), will be performed under sterile conditions 
i.e. similar to those you would have if you were undergoing an operation. The site will be injected with a 
local anaesthetic (lidocaine) and after the site has gone numb it will be cleaned in an antiseptic solution 
(Unisept). A small incision (1.5cm) will be made and a section of fat tissue about the size of a pea will be 
cut away. The wound will then be closed with a single stitch, which can be removed 1 week later.
Contact with your GP
After you agree to take part in this study, your GP will be contacted to ask whether there are any 
reasons why you may be unsuitable to take part in the study and whether you have any other 
significant medical problems and/or are taking any long-term medication. Any information provided 
by your GP will be held in strictest confidence and will not be disclosed to anyone who is not part of 
the research team.
Potential benefits of the study
There will be no direct benefits for research participants. However, we predict that this work will open 
an exciting new area of research that will help us understand the biological cause of diabetes and thus 
assist in the development of more effective treatments for this disease.
Potential inconvenience during the study
There are some potential inconveniences inherent to the study, such as slight discomfort during 
cannulation, and discomfort at the upper buttock biopsy sites. There is also potential for bruising and
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infection following cannulation and biopsy. However, bruising and discomfort is harmless and 
transient, and risk of infection will be minimised by cleaning the biopsy site and providing aftercare 
sheets. Please note there may be some scarring at the biopsy site.
What if something goes wrong?
If you are harmed by taking part in this research project then you may have grounds for legal action. 
Regardless of this, if  you wish to complain about any aspect o f the way you have been approached or 
treated during the course of this study, complaints mechanisms are available to you through The 
University of Surrey and the University Indemnity Scheme.
Would mv taking part in this study be kept confidential?
All information which is collected about you during the course of this research would be kept strictly 
confidential. All research records will be assigned alphanumeric codes to ensure confidentiality and 
collected data will not be available to unauthorised persons. The aim of the study is to identify group 
trends and patterns, and thus, data from individual participants would not normally form any part of a 
subsequent report. In the event that data from an individual participant warrants comment, all 
reference to participants identifying characteristics will be removed. Also, any information about you 
which leaves the hospital or University would have your name and address removed so that you 
cannot be recognised from it. Your GP would be notified of your participation in this study.
What will happen to the results of the research study?
The results of this study will be published in the scientific press and you will not be identifiable in any 
way. It is our usual practice to send copies of any resultant publications to research participants.
Who is organising funding for the research?
This research is being funded Diabetes UK.
Obligations and commitments of the participant
As a volunteer you are asked to comply to the given instructions the best you can. In case of deviation 
from the given instructions, you are asked to report this to the investigator immediately. Any 
deviations from the instructions, both prior to and during the study, may result in having to exclude 
you from the study.
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Rights of the participant
Each participant has the right to withdraw from the study without giving a reason. When you have 
read and understood this information sheet and decide to take part in the study, you will be asked to 
sign a consent form which states that you are entering the study voluntarily but are free to withdraw at 
any time.
All information in this study is treated as strictly confidential. Data will be collected, retained and 
disposed of only by those who are stated to be investigators or collaborators in this study. Participant 
information will be coded and when the study is reported, your identity will not be disclosed. All 
information obtained in this study will be handled in accordance with the Data Protection Act 1998.
Payment
You will be paid £250 upon completion of the study, in addition to any pre-screen and study travel 
costs incurred. In case of early withdrawal, you will be paid pro rata.
Ethical approval
The University of Surrey Ethics Committee and Surrey Research Ethics Committee have given 
favourable ethical opinion to all aspects of this study.
Who to contact for further information, concerns and complaints?
If you have any further questions, complaints or concerns about any aspects of the way you have been 
dealt with during the course of the study, please contact:
Daniella Otway, BSc (PhD student) Dr Jonathan Johnston, PhD
Faculty of Health and Medical Sciences Faculty of Health and Medical Sciences
University of Surrey University of Surrey
Guildford, Surrey Guildford, Surrey
GU2 7XH GU2 7XH
Tel: +44 (1483) 689705 Tel: +44 (1483) 686470
E-mail: d.otway@surrey.ac.uk E-mail: j.johnston@surrey.ac.uk
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FIGURE 2- Biopsy site diagram
/
Biopsy site
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Participant information sheet: Overweight 
Title
Effects of type 2 diabetes and obesity on daily biological rhythms in fat tissue and circulation
We are writing to invite you to take part in a study investigating the effects of type 2 diabetes and 
obesity on daily biological rhythms in fat tissue and blood. We are conducting this study to help us 
understand the potential link between daily biological rhythms and the incidence of obesity and type 2 
diabetes mellitus. Before you decide, it is important for you to understand why the research is being 
carried out and what it will involve. Please take time to read the following information carefully and 
discuss it with your friends, relatives and anyone involved with your care. Please ask us if there is 
anything that is not clear or if you would like more information.
What is the study about?
Our internal ‘body clock’ regulates most bodily functions, including hormone secretion and the 
metabolism of sugar and fat. Recent animal studies have revealed that most biological processes in fat 
tissue have daily rhythms, including the production of ‘fat hormones’ that control blood sugar levels. 
These rhythms are much smaller in animals with diabetes, suggesting that reduced rhythmicity may be 
an important factor relating to diabetes.
We will measure ‘fat hormone’ rhythms in fat tissue and in the blood of individuals with or without 
diabetes. We predict that this work will open an exciting new area of research that will help us 
understand the biological cause of type 2 diabetes and thus assist in the development of more effective 
treatment for this disease.
Aims
The aim of this study is to investigate the effect of type 2 diabetes and obesity on rhythmic production 
and blood circulation of a range of fat-derived factors. Different people (type 2 diabetics, individuals 
who are overweight, and lean healthy individuals) will be compared.
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Why have I been chosen?
In this study we are looking for people who are overweight with a body mass index of 27-35 kg/m2, 
but who are not diabetic.
What does the study involve?
10 type 2 diabetics, 10 overweight subjects and 10 healthy lean volunteers will participate in the study. 
You will be asked to do the following:
Before the study starts:
Confirm that you are not participating in another study other than this study.
Report whether you have a phobia of needles or blood.
Give a single blood sample for a standard haematological and biochemical screen and to 
ensure that you are not anaemic. Any abnormalities detected in these screens, will be 
discussed with you by Dr John Wright (medical practitioner, FHMS) and suitability for 
participation will be assessed by the research team.
Keep a constant sleep/wake cycle for one week before the lab study starts. We will ask you to 
sleep for a block of 8 hours, waking at 6.30 am and going to bed trying to sleep at 10.30pm. 
You have to stick to this duration for one week and can not deviate from it by more than 30 
minutes,
Confirm your constant sleep/wake cycle by reporting wake up and sleep times to the lab 
voicemail, filling in sleep diaries and wearing acti-watches. A sleep diary is filled in once a 
day and records time of waking up and falling asleep. The acti-watch records activity. They 
measure objectively how regular your sleep-wake cycle is. The watch is worn on the non­
dominant hand, day and night (except for showering as they are not waterproof).
Refrain from alcohol and caffeine containing drinks (e.g. coffee, coke, tea, redbull), heavy 
exercise 1 week before the study session and certain foods (e.g. those high in fat) 3 days 
before the laboratory session. You will be provided with a list with further details and an event 
diary to record your consumptions pattern 1 week before the start of the study.
Consume food provided by the research team 3 days prior to the study, which will be 
formulated based on calculated energy requirements.
Refrain from prescribed, ‘over the counter’ medication and food supplements for 2 weeks 
prior to the laboratory study, unless it has been approved by the research team.
Only if this is possible, will you be able to take part in this study.
During the study (see also Figure 1 for a diagram of the study):
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- To spend 2 nights in the laboratory (1 adaptation night, 1 study night). Throughout the study 
you will be in controlled conditions regarding light, body position and food intake. There will 
be no solid food, but you will be provided with small hourly feedings of a liquid nutrient drink 
during wake periods (Fortisip).
- Provide 25 blood samples taken hourly over the 25 hour sampling period. Samples will be 
taken from a cannula inserted into one arm by a qualified nurse.
- Provide 4 fat tissue biopsies (see below) from the upper buttock region. Samples will be taken 
by a qualified medical practitioner.
Biopsies
Biopsies, taken from the upper buttock region (see Figure 2), will be performed under sterile conditions 
i.e. similar to those you would have if you were undergoing an operation. The site will be injected with a 
local anaesthetic (lidocaine) and after the site has gone numb it will be cleaned in an antiseptic solution 
(Unisept). A small incision (1.5cm) will be made and a section of fat tissue about the size of a pea will be 
cut away. The wound will then be closed with a single stitch, which can be removed 1 week later.
Contact with vour GP
After you agree to take part in this study, your GP will be contacted to ask whether there are any 
reasons why you may be unsuitable to take part in the study and whether you have any other 
significant medical problems and/or are taking any long-term medication. Any information provided 
by your GP will be held in strictest confidence and will not be disclosed to anyone who is not part of 
the research team.
Potential benefits of the study
There will be no direct benefits for research participants. However, we predict that this work will open 
an exciting new area of research that will help us understand the biological cause of diabetes and thus 
assist in the development of more effective treatments for this disease.
Potential inconvenience during the study
There are some potential inconveniences inherent to the study, such as slight discomfort during 
cannulation, and discomfort at the upper buttock biopsy sites. There is also potential for bruising and 
infection following cannulation and biopsy. However, bruising and discomfort is harmless and 
transient, and risk of infection will be minimised by cleaning the biopsy site and providing aftercare 
sheets. Please note there may be some scarring at the biopsy site.
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What if something goes wrong?
If you are harmed by taking part in this research project then you may have grounds for legal action. 
Regardless of this, if you wish to complain about any aspect of the way you have been approached or 
treated during the course of this study, complaints mechanisms are available to you through The 
University of Surrey and the University Indemnity Scheme.
Would mv taking part in this study be kept confidential?
All information which is collected about you during the course of this research would be kept strictly 
confidential. All research records will be assigned alphanumeric codes to ensure confidentiality and 
collected data will not be available to unauthorised persons. The aim of the study is to identify group 
trends and patterns, and thus, data from individual participants would not normally form any part of a 
subsequent report. In the event that data from an individual participant warrants comment, all 
reference to participants identifying characteristics will be removed. Also, any information about you 
which leaves the hospital or University would have your name and address removed so that you 
cannot be recognised from it. Your GP would be notified of your participation in this study.
What will happen to the results of the research study?
The results of this study will be published in the scientific press and you will not be identifiable in any 
way. It is our usual practice to send copies of any resultant publications to research participants.
Who is organising funding for the research?
This research is being funded Diabetes UK.
Obligations and commitments of the participant
As a volunteer you are asked to comply to the given instructions the best you can. In case of deviation 
from the given instructions, you are asked to report this to the investigator immediately. Any 
deviations from the instructions, both prior to and during the study, may result in having to exclude 
you from the study.
Rights of the participant
Each participant has the right to withdraw from the study without giving a reason. When you have 
read and understood this information sheet and decide to take part in the study, you will be asked to
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sign a consent form which states that you are entering the study voluntarily but are free to withdraw at 
any time.
All information in this study is treated as strictly confidential. Data will be collected, retained and 
disposed of only by those who are stated to be investigators or collaborators in this study. Participant 
information will be coded and when the study is reported, your identity will not be disclosed. All 
information obtained in this study will be handled in accordance with the Data Protection Act 1998.
Payment
You will be paid £250 upon completion of the study, in addition to any pre-screen and study travel 
costs incurred. In case of early withdrawal, you will be paid pro rata.
Ethical approval
The University of Surrey Ethics Committee and Surrey Research Ethics Committee have given 
favourable ethical opinion to all aspects of this study.
Who to contact for further information, concerns and complaints?
If you have any further questions, complaints or concerns about any aspects of the way you have been 
dealt with during the course of the study, please contact:
Daniella Otway, BSc (PhD student) Dr Jonathan Johnston, PhD
Faculty of Health and Medical Sciences Faculty of Health and Medical Sciences
University of Surrey University of Surrey
Guildford, Surrey Guildford, Surrey
GU2 7XH GU2 7XH
Tel: +44 (1483) 689705 Tel: +44 (1483) 686470
E-mail: d.otway@surrey.ac.uk E-mail: j.johnston@surrey.ac.uk
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FIGURE 2- Biopsy site diagram
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Participant information sheet: Type 2 Diabetic 
Title
Effects of type 2 diabetes and obesity on daily biological rhythms in fat tissue and circulation
We are writing to invite you to take part in a study investigating the effects of type 2 diabetes and 
obesity on daily biological rhythms in fat tissue and blood. We are conducting this study to help us 
understand the potential link between daily biological rhythms and the incidence of obesity and type 2 
diabetes mellitus. Before you decide, it is important for you to understand why the research is being 
carried out and what it will involve. Please take time to read the following information carefully and 
discuss it with your friends, relatives and anyone involved with your care. Please ask us if there is 
anything that is not clear or if you would like more information.
What is the study about?
Our internal ‘body clock’ regulates most bodily functions, including hormone secretion and the 
metabolism of sugar and fat. Recent animal studies have revealed that most biological processes in fat 
tissue have daily rhythms, including the production of ‘fat hormones’ that control blood sugar levels. 
These rhythms are much smaller in animals with diabetes, suggesting that reduced rhythmicity may be 
an important factor relating to diabetes.
We will measure ‘fat hormone’ rhythms in fat tissue and in the blood of individuals with or without 
diabetes. We predict that this work will open an exciting new area of research that will help us 
understand the biological cause of type 2 diabetes and thus assist in the development of more effective 
treatment for this disease.
Aims
The aim of this study is to investigate the effect of type 2 diabetes and obesity on rhythmic production 
and blood circulation of a range of fat-derived factors. Different people (type 2 diabetics, individuals 
who are overweight, and lean healthy individuals) will be compared.
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Why have I been chosen?
In this study we are looking for people who suffer from type 2 diabetes. Type 2 diabetes, also known 
as non-insulin dependent diabetes, normally occurs after the age of 40 years. The disease is typified 
by development of insulin resistance, leaving the pancreas unable to produce enough insulin to 
compensate. The result is elevated plasma fasting glucose concentrations, among other metabolic 
factors, and a dysregulation of hormones, including those from fat tissue. We are basing the presence 
of type 2 diabetes on a number of factors, including mid- to large waist circumference (BMI 27 -  35 
kg/m2), and elevated fasting glucose.
What does the study involve?
10 type 2 diabetics, 10 overweight subjects and 10 healthy lean volunteers will participate in the study. 
You will be asked to do the following:
Before the study starts:
Confirm that you are not participating in another study other than this study.
Report whether you have a phobia of needles or blood.
Give a single blood sample for a standard haematological and biochemical screen and to 
ensure that you are not anaemic. Any abnormalities detected in these screens, will be 
discussed with you by Dr John Wright (medical practitioner, FHMS) and suitability for 
participation will be assessed by the research team.
Keep a constant sleep/wake cycle for one week before the lab study starts. We will ask you to 
sleep for a block of 8 hours, waking at 6.30 am and going to bed trying to sleep at 10.30pm. 
You have to stick to this duration for one week and can not deviate from it by more than 30 
minutes,
Confirm your constant sleep/wake cycle by reporting wake up and sleep times to the lab 
voicemail, filling in sleep diaries and wearing acti-watches. A sleep diary is filled in once a 
day and records time of waking up and falling asleep. The acti-watch records activity. They 
measure objectively how regular your sleep-wake cycle is. The watch is worn on the non­
dominant hand, day and night (except for showering as they are not waterproof).
Refrain from alcohol and caffeine containing drinks (e.g. coffee, coke, tea, redbull), heavy 
exercise 1 week before the study session and certain foods (e.g. those high in fat) 3 days 
before the laboratory session. You will be provided with a list with further details and an event 
diary to record your consumptions pattern 1 week before the start of the study.
Consume food provided by the research team 3 days prior to the study, which will be 
formulated based on calculated energy requirements.
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Refrain from prescribed, ‘over the counter’ medication and food supplements for 2 weeks 
prior to the laboratory study, unless it has been approved by the research team.
Only if this is possible, will you be able to take part in this study.
During the study (see also Figure 1 for a diagram of the study):
To spend 2 nights in the laboratory (1 adaptation night, 1 study night). Throughout the study 
you will be in controlled conditions regarding light, body position and food intake. There will 
be no solid food, but you will be provided with small hourly feedings of a liquid nutrient drink 
during wake periods (Fortisip).
Provide 25 blood samples taken hourly over the 25 hour sampling period. Samples will be 
taken from a cannula inserted into one arm by a qualified nurse.
Provide 4 fat tissue biopsies (see below) from the upper buttock region. Samples will be taken 
by a qualified medical practitioner.
Biopsies
Biopsies, taken from the upper buttock region (see Figure 2), will be performed under sterile conditions 
i.e. similar to those you would have if you were undergoing an operation. The site will be injected with a 
local anaesthetic (lidocaine) and after the site has gone numb it will be cleaned in an antiseptic solution 
(Unisept). A small incision (1.5cm) will be made and a section of fat tissue about the size of a pea will be 
cut away. The wound will then be closed with a single stitch, which can be removed 1 week later.
Contact with your GP
After you agree to take part in this study, your GP will be contacted to ask whether there are any 
reasons why you may be unsuitable to take part in the study and whether you have any other 
significant medical problems and/or are taking any long-term medication. Any information provided 
by your GP will be held in strictest confidence and will not be disclosed to anyone who is not part of 
the research team.
Potential benefits of the study
There will be no direct benefits for research participants. However, we predict that this work will open 
an exciting new area of research that will help us understand the biological cause of diabetes and thus 
assist in the development of more effective treatments for this disease.
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Potential inconvenience during the study
There are some potential inconveniences inherent to the study, such as slight discomfort during 
cannulation, and discomfort at the upper buttock biopsy sites. There is also potential for bruising and 
infection following cannulation and biopsy. However, bruising and discomfort is harmless and 
transient, and risk of infection will be minimised by cleaning the biopsy site and providing aftercare 
sheets. Please note there may be some scarring at the biopsy site.
What if something goes wrong?
If you are harmed by taking part in this research project then you may have grounds for legal action. 
Regardless of this, if  you wish to complain about any aspect o f the way you have been approached or 
treated during the course of this study, complaints mechanisms are available to you through The 
University of Surrey and the University Indemnity Scheme.
Would mv taking part in this study be kept confidential?
All information which is collected about you during the course of this research would be kept strictly 
confidential. All research records will be assigned alphanumeric codes to ensure confidentiality and 
collected data will not be available to unauthorised persons. The aim of the study is to identify group 
trends and patterns, and thus, data from individual participants would not normally form any part of a 
subsequent report. In the event that data from an individual participant warrants comment, all 
reference to participants identifying characteristics will be removed. Also, any information about you 
which leaves the hospital or University would have your name and address removed so that you 
cannot be recognised from it. Your GP would be notified of your participation in this study.
What will happen to the results of the research study?
The results of this study will be published in the scientific press and you will not be identifiable in any 
way. It is our usual practice to send copies of any resultant publications to research participants.
Who is organising funding for the research?
This research is being funded Diabetes UK.
Obligations and commitments of the participant
As a volunteer you are asked to comply to the given instructions the best you can. In case of deviation 
from the given instructions, you are asked to report this to the investigator immediately. Any
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deviations from the instructions, both prior to and during the study, may result in having to exclude 
you from the study.
Rights of the participant
Each participant has the right to withdraw from the study without giving a reason. When you have 
read and understood this information sheet and decide to take part in the study, you will be asked to 
sign a consent form which states that you are entering the study voluntarily but are free to withdraw at 
any time.
All information in this study is treated as strictly confidential. Data will be collected, retained and 
disposed of only by those who are stated to be investigators or collaborators in this study. Participant 
information will be coded and when the study is reported, your identity will not be disclosed. All 
information obtained in this study will be handled in accordance with the Data Protection Act 1998.
Payment
You will be paid £250 upon completion of the study, in addition to any pre-screen and study travel 
costs incurred. In case of early withdrawal, you will be paid pro rata.
Ethical approval
The University of Surrey Ethics Committee and Surrey Research Ethics Committee have given 
favourable ethical opinion to all aspects of this study.
Who to contact for further information, concerns and complaints?
If you have any further questions, complaints or concerns about any aspects of the way you have been 
dealt with during the course of the study, please contact:
Daniella Otway, BSc (PhD student) Dr Jonathan Johnston, PhD
Faculty of Health and Medical Sciences Faculty of Health and Medical Sciences
University of Surrey University of Surrey
Guildford, Surrey Guildford, Surrey
GU2 7XH GU2 7XH
Tel: +44 (1483) 689705 Tel: +44 (1483) 686470
E-mail: d.otway@surrey.ac.uk E-mail: j.johnston@surrey.ac.uk
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FIGURE 2- Biopsy site diagram
Biopsy site
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Appendix I
& UNIVERSITY OF
t i i  SURREY
SLEEP DIARY
R e m e m b er  to  f i l l  one  o u t f o r  n a p s too !!!
Participant’s code:..............................................................
Date:.............................  Day of week:..........................................
Instructions for completing sleep and nap diaries
Please complete a sleep diary in the morning EACH DAY for 7 days prior to and throughout 
the entire study (on study night and the week before). Questions need to be answered as 
accurately as possible. Please don’t worry too much about the exact times of the night-time 
waking periods, an approximation is fine. It is more important that you sleep as naturally as 
possible.
This form is to be completed
What time did you go to bed? (hh:mm)
At what time did you try to sleep? (if different to above answer)
How long did it take you to fall asleep? (minutes)
How many times did you wake up?
How long were you awake for? (minutes) Please estimate the time & Woke up Fell asleep
duration o f each night awakening!
What time did you wake up? (hh:mm)
What time did you get up? (hh:mm)
Would you describe this as a typical night? □  Yes □  No
If permitted, could you have slept longer? □  Yes □  No
What time did the nap start? (hh:mm)
What time did the nap end? (hh:mm)
How long was the nap? (minutes)
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Please record any times you would have liked to nap but were unable to for whatever reason,
e.g. wanted a nap 16:00 -17:30 ....................................................................................................
How would you rate your quality of sleep? (circle one)
best ever 1 2 3 4 5 6 7 8 9  worst ever
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Appendix .1
UNIVERSITY OF
SURREY
Instructions for wearing the Actiwatch-L monitors
The Actiwatch-L is about the size of a wristwatch and is light so can easily be worn without 
discomfort.
Please wear one Actiwatch-L monitor for the duration of the study. An Actiwatch-L is designed to 
monitor activity and light intensity. The Actiwatch-L is to be worn on your non-dominant wrist 
(i.e. on the left wrist if you are right handed) using the velcro strap. It needs to be worn at all times, 
including during sleep. Please vigorously shake your wrist for 10 seconds immediately prior to 
bedtime, and immediately after waking. It must be worn over clothing to ensure the light sensing 
window is not covered. The activity monitor is not waterproof so please remember to remove it 
before showering or bathing. Information extracted from the monitor will confirm that you have 
adhered to the constant sleep-wake and light exposure requirements of the study. The monitors 
will be collected from you on the last morning of the study, and the information downloaded and 
checked.
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Appendix K
UNIVERSITY OF
t u  SURREY
Patient Information Sheet: Aftercare of Biopsy Site
Care of the Biopsy S ites
Upper buttock fat biopsy
The biopsy site will be stitched and covered by a plaster/sterile dressing. The bandage may be 
removed after two days. After one week, the stitches can be taken out. You will be provided 
with a stitch remover and shown how to use it. Alternatively, you may have your stitches 
removed at either your local GP or the Cedar Centre, Royal Surrey County Hospital.
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CIRCADIAN RHYTHMICITY IN MURINE PRE-ADIPOCYTE AND 
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Adipose tissue is central to metabolic homeostasis, signaling in part through the 
secretion of molecules termed adipokines. Circadian rhythms play an important role 
in adipose physiology, with plasma adipokine concentration and ~20% of the 
murine adipose transcriptome undergoing 24 h variation. However, due to the hetero­
geneity of adipose tissue and rhythmical input from both neuronal and humoral 
signals, the cellular basis of adipose rhythms is unclear. We tested the hypothesis 
that adipocyte cells contain a circadian clock that drives rhythmic mRNA expression 
and adipokine secretion. From the murine pre-adipocyte 3T3-L1 cell line, we gener­
ated populations of both pre-adipocytes and differentiated adipocytes. Cells were 
then treated with a 2 h serum pulse and sampled every 4 h over a 48 h period. 
Expression of clock gene, ‘metabolic’ gene {PPARa, P P A R y, SREBP1), and adipokine 
mRNA was analyzed by quantitative real-time PCR, and secretion of the adipokines 
leptin and adiponectin was measured in culture medium from differentiated adipo­
cytes. In pre-adipocytes, we observed robust rhythms of clock genes Per2, Rev-erba, 
and Dbp, but not of P erl, C ryl, E m ail, or any of the ‘metabolic’ genes. Adipocytes pro­
duced similar temporal profiles of mRNA expression, albeit with a markedly reduced 
amplitude of Per2 and Dbp rhythms. Despite no circadian rhythm of adipokine mRNA 
expression, leptin accumulation in the culture medium suggested circadian control of 
leptin secretion from adipocytes. Adiponectin secretion showed temporal variation, 
but without any apparent circadian rhythmicity. Our data, therefore, suggest that 
an endogenous adipocyte clock controls the rhythmic expression of only a subset 
of genes that are reported to exhibit 24 h rhythmicity in murine adipose tissue. 
Moreover, secretion of leptin may also be regulated by the adipocyte clock. (Author 
correspondence: j.johnston@surrey.ac.uk).
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INTRODUCTION
Circadian clocks are present in multiple tissues throughout the body 
(Dardente & Cermakian, 2007). Moreover, many aspects of metabolic physi­
ology are under circadian control (Bray Sc Young, 2007; G reen et al., 2008; 
Hastings et al., 2007; Zvonic et al., 2007). Analysis o f transgenic mouse 
models has recendy provided compelling molecular links between com­
ponents of the circadian clock and metabolism. Although the resulting pheno­
type appears partially dependent on genetic background, m utation o f clock- 
related genes results in metabolic dysregulation (Green et al., 2007; Kenn- 
away et al., 2007; Oishi et al., 2006; T urek  et al., 2005). Similar genetic links 
have been found in humans, with clock gene polymorphisms being associated 
with obesity, metabolic syndrome, and type 2 diabetes mellitus (Monteleone 
et al., 2008; Scott et al., 2008; Sookoian et al., 2008; Woon et al., 2007).
W hite adipose tissue (WAT) is a key metabolic structure. In  addition to 
storing energy as triglycerides, WAT has endocrine activity and regulates 
many distal tissues. Among the molecules secreted by WAT is a g roup of 
metabolically active horm ones, called the adipokines (Trujillo Sc Scherer, 
2006). W ithin WAT, rhythm ic gene expression is widespread, with 
approxim ately 20% o f the m urine WAT transcriptom e exhibiting 24 h 
variation (Ptitsyn et al., 2006; Zvonic et al., 2006). Furtherm ore, circadian 
regulation o f endocrine activity is likely to be an im portant ou tpu t o f this 
tissue. 24 h variation o f adipokine concentration has been repo rted  in 
blood (Gavrila et al., 2003; Kalsbeek et al., 2001; Sinha et al., 1996); this 
rhythmicity may have a transcriptional basis, as adipokine mRNA is 
subject to 24 h variation in m urine WAT (Ando et al., 2005).
However, rhythmicity in adipocyte cells per se is poorly understood. 
WAT contains many cell types, including adipocytes, pre-adipocytes, fibro­
blasts, macrophages, and vascular endothelial cells, that may contribute to 
the reported  rhythm s of gene expression in m urine WAT (Balsalobre 
et al., 1998; Hayashi et al., 2007; Takeda et al., 2007; Wu et al., 2007). M ore­
over, WAT, like other peripheral tissues, receives many rhythm ic hum oral 
and neuronal inputs (Balsalobre et al., 2000; Bartness et al., 2001; Pévet 
et al., 2006) that can directly regulate clock gene expression (Balsalobre 
et al., 2000; Johnston et al., 2006; K ornm ann et al., 2007; Reddy et al., 
2007; W agner et al., 2007). This rhythmical input may be driven both by 
endogenous circadian timing and also from  masking effects o f the LD cycle 
in which animals were kept in previous studies. Here, we used an in vitro 
approach to study rhythmicity in m urine pre-adipocyte and adipocyte cells.
MATERIALS AND METHODS
All experim ental procedures conform ed to published ethical standards 
(Portaluppi et al., 2008).
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Cell C ulture
3T3-L1 pre-adipocytes (ATCC, LGC Standards, Teddington, M iddle­
sex, UK) were cultured in grow th m edium  DMEM (Invitrogen Ltd, 
Paisley, UK) supplem ented with 10% fetal bovine serum  (Invitrogen), anti­
biotic / antimycotic (Invitrogen), and  sodium  pyruvate (Sigma-Aldrich Co 
Ltd, Poole, Dorset, UK). Two days post-confluence (day 0), differentiation 
was induced by adding 0.5 mM IBM X (Sigma-Aldrich), 1 jxM dexam etha- 
sone (Sigma-Aldrich), and  10 p g /m l insulin (Invitrogen). After 48 h, 
m edium  was exchanged for grow th m edium  containing 10 p g /m l 
insulin. 48 h later, this was exchanged for norm al grow th m edium , 
which was replaced every two days thereafter. To characterize differen­
tiation, RNA was extracted using TRIzol (Invitrogen) for semi-quantitative 
reverse transcriptase PCR, and triglyceride analyses were carried out on 
days 0, 2, 4, 6, 8, and 10. 3T3-L1 pre-adipocytes (two days post­
confluence) and differentiated adipocytes (day 8 post-differentiation 
induction) were pulsed with 50% horse serum  (Invitrogen) in DMEM 
for 2 h, as described previously (Balsalobre et al., 1998). M edium  was 
then replaced with serum -ffee DMEM for the rem ainder o f the exper­
iment. Every 4 h  from  initiation o f the serum  pulse (0 h), RNA was 
extracted for real-time quantitative PCR, and m edium  was collected for 
analysis of adipokine secretion.
Oil Red O Stain
Cells were washed with 10% formalin in 1 x PBS and then  incubated in 
fresh formalin solution for 1 h  at room  tem perature. Cells were washed 
twice with 60% ethanol, twice with distilled water, and incubated in 
0.18% oil red  O solution (Sigma-Aldrich) for 10 min. Cells w ere washed 
three times with distilled water, and  then  photographed.
Q uantitative Triglyceride Analysis
Cells were rinsed twice with 1 x PBS, scraped into 0.1M SDS solution in 
IxP B S , and  lysed by vortex mixing and sonication. Triglyceride was 
m easured using an Alfa W asserm ann one-step triglyceride assay 
(Randox Laboratories Ltd, Crum lin, County Antrim , UK) adapted for 
96-well plates. Intra-assay coefficient o f variance was 3.8%.
Reverse T ranscrip tase PCR
Total RNA was reverse transcribed using random  prim ers and  
M-MLV Reverse Transcriptase (Promega Corporation, Southam pton, 
UK). cDNA was then used for semi-quantitative reverse-transcriptase
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PCR using G oTaq G reen M aster Mix (Promega) according to the m anu­
facturer’s instructions. Prim ers are shown in Table 1.
Q uantita tive  Real-Time PCR (qPCR)
cDNA was synthesized as described above. cDNA was then  used 
for qPCR using ABsolute™  QPCR ROX Mix (Abgene, Epsom, UK). 
Prim er-probe sets are shown in Table 2. S tandard curves (R2 >  0.99) 
were generated using m urine genomic DNA (Promega).
Adipokine Assays
Adipokine concentration was m easured using Q uantikine ELISA 
kits (R&D Systems Europe Ltd, Abingdon, UK). Intra-assay coefficient 
o f variance was 2.2% and 6.5% for leptin and  adiponectin assays, 
respectively.
S tatistica l Analysis
Quantitative data represen t the m ean +  SEM of n  — 3 groups o f cells 
from  a representative experim ent. Serum  pulse experim ents were 
repeated two (pre-adipocyte) o r three (adipocyte) times, with similar 
data obtained from  each replicate experim ent. Triglyceride accumulation 
and  qPCR data were analyzed by one-way o r two-way ANOVA, with least
TABLE 1 Primers used for semi-quantitative PCR analysis of gene expression during adipocyte 
differentiation.
Gene
Upper 
prim er 
(5' to 3')
Lower 
prim er 
(S' to 3')
PPARy GAACCT A TT T G T
GCATCT CCG TTG
CCA CCT T C P TTC
TAT TAT CTGTCA
Leptin CACACG AGG GCT
CAG TCG AACATC
GTATC CAACTG
Glut4 GCC GTC CGC CCA
G G G TTT ACACGG
CCA GCA CCA AGA
GAT CAT
/3-actin GGT GAC CGC GGC
GAG GCC CAG CCA
CAG AGC GGT CCA
AAGAGA G
Annealing 
temp °C
GenBank
accession
num ber
Region
amplified
(bp)
Product 
size (bp)
57
55
64
67
NM 011146 364-856 493
NM 008493 198-554 357
NM 009204 212-576 365
NM 007393 243-630 388
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square difference post-hoc test, as appropriate. Rate o f adipokine secretion 
was m easured by testing the departu re  o f horm one accumulation from 
linearity, using a runs test. Significant difference was defined asp <  0.05.
RESULTS 
D ifferentiation of 3T3-L1 Cells
Lipid droplets were first observed four days after onset o f differen­
tiation, and  by day 8 many cells had  large unilocular droplets (see 
Figure 1A). Quantitative analysis revealed triglyceride elevation above 
undifferentiated cells by day 4, followed by rap id  accumulation thereafter 
(see Figure IB). P P A R y  mRNA was detectable in undifferentiated cells, 
bu t was elevated from  days 2 through 10. In  contrast, expression of 
Glut-4 and  Leptin was only detected after two and  four days o f differen­
tiation, respectively (see Figure 1C).
Clock G ene Expression in Pre-A dipocytes and A dipocytes
Following a serum  pulse, significant (p < 0.001, one-way ANOVA) 
tem poral variation o f mRNA expression was observed in pre-adipocytes 
for all genes exam ined except Perl (p > 0.05, one-way ANOVA). For 
Per2 and Dbp, a rapid  (within 4 h) effect was followed by a peak around  
24 h post-pulse and an additional elevation in gene expression 24 h 
later. Rev-erba exhibited two peaks, approxim ately 20 and 44 h post­
pulse. By contrast, Cryl and  Email expression was acutely stim ulated by 
the serum  pulse, bu t then showed no clear circadian variation (see 
Figure 2, left).
T reatm ent of differentiated adipocytes with a serum  pulse induced 
significant (p <  0.001, one-way ANOVA) variation in the expression o f 
all clock genes (see Figure 2, right). As in pre-adipocytes, expression of 
Perl, Cryl, and Email in serum  pulsed adipocytes did no t appear to 
exhibit circadian rhythm s. T em poral variation o f Per2, Dbp, and 
Rev-erba expression was similar to that previously observed in the p re ­
adipocytes. However, for all three genes, there  were significant effects 
o f both time and cell type (p < 0.001, two-way ANOVA) around  the 
main peak, as m easured between 16 and  32 h post-pulse. T here  was 
also a significant (p <  0.001) interaction between time and cell type for 
Per2 and Dbp. Subsequent post-hoc analysis revealed that although 
there was no effect o f cell type on gene expression 16 h post-pulse, 
Per2 and Dbp expression was significantly elevated in pre-adipocytes 
over the next three to four timepoints, indicating that the am plitude of 
Per2 and Dbp rhythm s in differentiated adipocytes was greatly attenuated 
(see Figure 3).
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2000
0 2 4 6 8 10
D ays post-differentiation  induction
Tim e (days)
PPAR-y
Leptin
fi-actin
FIGURE 1 Differentiation of 3T3-L1 cells. Pre-adipocytes were differentiated into adipocytes as 
described herein. At two-day intervals, cells were analyzed by (A) Oil Red O histological stain, (B) tri­
glyceride quantification, and (C) gene expression by reverse transcriptase PCR. Data show 
mean + SEM of n =  3 groups of cells/timepoint.
M etabolic Gene Expression in 3T3-L1 Pre-Adipocytes and
Adipocytes
Following a serum  pulse, both pre-adipocytes and adipocytes exhibited 
significant (p <  0.05) tem poral variation in SREBP1, PPARa, and PPARy  
mRNA expression. In pre-adipocytes, SREBP1 and PPARy  expression
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FIGURE 2 Temporal profiles of clock gene expression in pre-adipocytes and adipocytes following a 
serum pulse. Cells were treated with a serum pulse, and gene expression was measured by qPCR. 
Data show mean ±  SEM of n =  3 groups of cells/timepoint.
gradually decreased following the pulse, whereas PPARa  exhibited an 
acute, transient suppression (see Figure 4, left). In  adipocytes, expression 
o f SREBP1 and PPARa  gradually increased, with expression o f PPARa  
decreasing again by 44 h post-pulse, bu t rem aining constant in SREBP1
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■ Pre-adipocyte □ Adipocyte
Time (hours)
FIGURE 3 Differential amplitude of Per2 and Dbp expression in pre-adipocytes and adipocytes. Cells 
were treated with a serum pulse, and gene expression was measured by qPCR. Data represent 
mean +  SEM for n  =  3 groups of pre-adipocyte (black bars) and adipocyte (white bars) cells between 
16-32 h post-pulse. **p < 0.01, ***p < 0.001 pre-adipocyte vs. adipocyte gene expression at a given 
timepoint.
(see Figure 4, right). However, none o f the genes showed circadian 
variation o f expression in either cell type.
Adipokine mRNA Expression and Secretion  from  D ifferentiated  
A dipocytes
Following a serum  pulse, leptin and adiponectin concentration 
increased in the culture m edium  in a non-linear fashion (p <  0.05; see 
Figure 5A). T he rate o f secretion was estim ated by plotting the difference 
in m ean concentration between adjacent timepoints (see Figure 5B). 
Leptin secretion was low between 8 -1 2  h post-pulse and  then appeared 
to exhibit circadian rhythmicity, with a second nadir 24 h later (see 
Figure 5B). We were unable to detect circadian changes in adiponectin 
secretion. Expression o f Leptin (Figure 5C, left) and Adiponectin (Figure 
5C, right) mRNA exhibited significant tem poral variation {p <  0.001) fol­
lowing a serum  pulse. However, neither showed evidence o f  circadian 
rhythmicity.
DISCUSSION
In  o rder to direcdy address adipocyte rhythmicity, we studied the well- 
characterized 3T3-L1 cell model. A lthough these cells are known to 
express clock genes (Shimba et al., 2005; W ang & Lazar, 2008), there 
are no available quantitative data describing tem poral changes in their 
physiology. Consistent with the recent finding o f circadian rhythm s in 
hum an adipose-derived stem cells (H uang et al., 2009; Wu et al., 2007), 
we observed circadian variation o f Per2, Dbp, and Rev-erba expression in
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FIGURE 4 Temporal profiles of metabolic gene expression in pre-adipocytes and adipocytes following 
a serum pulse. Cells were treated with a serum pulse, and gene expression was measured by qPCR. 
Data show mean +  SEM of n — 3 groups of cells/timepoint.
both pre-adipocytes and differentiated adipocytes. However, we surpris­
ingly failed to observe circadian rhythmicity o f Perl, Cryl, Email, 
PPARa, PPARy, SREBP1, Leptin, and Adiponectin mRNA, which are all 
rhythm ic in m urine WAT (Ando et al., 2005; Ptitsyn et al., 2006; Yang 
et al., 2006; Zvonic et al., 2006). O ur data, therefore, suggest that some 
o f the reported  rhythmicity in m urine WAT may derive from  non-adipo­
cyte cell types a n d /o r  rhythm ical inpu t signal(s).
Following the original description o f circadian rhythm s in a serum  
pulsed cell line, it was suggested that the effect o f the pulse was either to 
initiate circadian rhythm s in individual cells o r synchronize a population 
o f cells, each o f which contains a pre-existing intracellular clock (Balsalobre 
et al., 1998). Elegant single-cell im aging studies later provided strong 
experim ental support for the second o f these possibilities (Nagoshi et al., 
2004; Welsh et al., 2004). T he fact that we observed rhythm s o f Rev-erba, 
Per2, and Dbp in this study dem onstrates that the serum  pulse em ployed 
was successful in synchronizing ou r cell population. T he lack o f rhythm i­
city o f o ther genes was thus unexpected. A lthough very low-amplitude 
rhythm s o f these genes may exist, ou r data suggest that an adipocyte 
clock is insufficient to drive rhythm ic expression o f these mRNAs in
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FIGURE 5 Temporal expression and secretion of leptin and adiponectin following a serum pulse of 
differentiated adipocytes. Adipokine concentration was measured in culture medium by ELISA and 
gene expression measured by qPCR. (A) Concentration of leptin and adiponectin in culture medium 
following the serum pulse (mean +  SEM of n  =  3 groups of cells/timepoint). Dashed lines show the 
linear regression for the data. (B) Rate of secretion, estimated by plotting the difference in mean adi­
pokine concentration between consecutive timepoints from (A). (C) Adipokine gene expression 
measured by qPCR (mean +  SEM of n =  3 groups of cells/timepoint).
3T3-L1 cells. Future work will investigate the m olecular basis o f this 
surprising finding.
T he am plitude o f Per2 and Dbp rhythm s in adipocyte cells was clearly 
less than that of the equivalent pre-adipocytes. As circadian clocks reside 
within individual cells (Nagoshi et al,. 2004; Welsh et al., 1995, 2004), 
the dam pened rhythm s observed in ou r experim ents may conceivably 
be due to an attenuated intra-cellular rhythm  am plitude or a decreased
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ability o f the serum  pulse to synchronize the cell population. Although we 
cannot yet rule ou t poorer inter-cellular synchronization behind the 
reduced rhythmicity in the 3T3-L1 adipocytes, the attenuated am plitude 
o f the rhythmicity in adipose tissue from  obese mice (Ando et al., 2005; 
Kohsaka et al., 2007) is consistent with a possible inhibition o f the molecu­
lar clock mechanism by intra-cellular triglyceride accumulation.
In  addition to control o f mRNA expression, our data indicate that adi­
pocyte clocks may drive circadian secretion o f leptin bu t not adiponectin. 
Although the reduction o f leptin secretion between 8 and  12 h post-pulse 
coincides with reduced mRNA expression, later tem poral fluctuations of 
leptin secretion do not parallel mRNA levels. This finding is consistent 
with a previous observation that hepatic protein rhythm s do not necessarily 
reflect tem poral mRNA expression in the same tissue (Reddy et al., 2006). 
24 h rhythm s of plasm a leptin and adiponectin have previously been 
reported  in hum ans and rodents by some investigators (Gavrila et al., 
2003; Kalsbeek et al., 2001 ; Sinha et al., 1996). However, this is the first indi­
cation o f an adipocyte-based mechanism driving rhythm ic plasma leptin 
concentration, as opposed to o ther possible contributory factors, such as 
changes in horm one clearance o r secretory control by inpu t pathway(s). 
Based on our data, such mechanisms may contribute toward the 24 h 
variation o f plasma adiponectin concentrations that have been reported  
in vivo. Future analysis of rhythm ic adipokine secretion from  adipocyte cul­
tures will need to consider horm one half-life. Previous studies o f plasma 
and intracellular horm one dynamics have estim ated half-lives o f approxi­
mately 30 min for leptin (Harris et al., 1997; Klein et al., 1996) and  3 h 
for adiponectin (Clasen et ak, 2005; H offstedt et al., 2004), bu t their half-life 
in culture m edium  is unclear.
Although this study increases cu rren t knowledge o f the interaction 
between circadian clocks and adipocyte biology, there are a num ber o f 
ways in which the work could be usefully extended. Despite the 3T3-L1 
cell line being frequently used as a m odel for adipocyte physiology, it is 
quite possible that there are differences in circadian biology between 
these cells and prim ary mouse adipocytes. Thus, we have em ployed 
some caution when com paring ou r data with published data describing 
m urine WAT gene expression. I t would also be beneficial to lengthen 
the time course o f the study in o rder to allow m ore detailed analysis of 
the nature o f adipocyte rhythmicity, including calculation o f rhythm  
period and phase. O ne way o f achieving this aim would be to employ 
real-time repo rte r im aging technology. Indeed , real-time analysis of 
Email, P erl, and Cryl prom oter activity in living cells may reveal circadian 
changes o f gene expression that were not detected using ou r standard 
serum  pulse protocol.
In  summary, this study provides evidence for an endogenous adipo­
cyte clock that controls rhythm ic expression o f a subset o f genes found
Do
wn
lo
ad
ed
 
By
: 
[U
ni
ve
rs
it
y 
Of
 
Su
rr
ey
] 
At
: 
10
:0
2 
13 
No
ve
mb
er
 
20
09
1 3 5 2 D. T. Otway et al.
to be rhythm ic in WAT. T he adipocyte clock may also regulate endocrine 
activity. These data, therefore, strengthen the view that circadian rhythm s 
have functional relevance to adipose biology, lipid metabolism, and related 
pathophysiology.
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Summary
Circadian clocks time the daily occurrence of multiple aspects o f behaviour and 
physiology. Through studies o f chronic misalignment between our internal clocks 
and the environment (e.g. during shift work), it has long been postulated that 
disruption of circadian rhythms is detrimental to human health. Recent advances 
in understanding o f the cellular and molecular basis o f mammalian circadian 
timing mechanisms have identified many key genes involved in circadian rhythm 
generation and demonstrated the presence of clocks throughout the body. Fur­
thermore, clear links between sleep, circadian rhythms and metabolic function 
have been revealed, and much current research is studying these links in more 
detail. Here, we review the evidence linking circadian rhythms, clock genes and 
adipose biology. We also highlight gaps in our understanding and finally suggest 
avenues for future research.
Keywords: Adipogenesis, adipokines, entrainment, metabolic syndrome, 
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Introduction
Circadian rhythms are endogenously controlled changes in 
physiology and behaviour that enable organisms to regu­
late their biology in anticipation o f predictable daily 
changes in the environment. These rhythms occur with a 
periodicity of approximately 24 h and, in order to maintain 
an appropriate temporal relationship with the outside 
world, the phase of endogenous clocks is synchronized 
(entrained) by external time cues, termed zeitgebers (1).
In mammals, the master circadian clock resides within 
the suprachiasmatic nuclei (SCN) of the anterior hypo­
thalamus (2,3). For a number o f years, it was believed that 
the SCN represented one o f only a few tissues capable of 
generating circadian rhythms; indeed, the SCN clock was 
believed to ultimately drive most rhythmic aspects of physi­
ology and behaviour. However; circadian clocks have now  
been identified in nearly all tissues (4,5) and even in immor­
talized cell lines (6). These findings have necessitated a 
change in the perception o f the cellular organization of the 
clock, which is now conceptualized as an integrated circa­
dian timing system (7) (Fig. 1). In this complex system,
clocks present in peripheral tissues drive local aspects o f  
physiology. These so-called peripheral clocks are synchro­
nized by multiple output pathways from the SCN (8), 
which thus retains its position as the master clock but acts 
by coordinating daily rhythms throughout the body.
The molecular basis o f the mammalian circadian clock 
has been reviewed in detail elsewhere (1). In brief, the clock 
is based on transcriptional-translational feedback loops. In 
the central clock loop, the basic helix-loop-helix transcrip­
tion factors BMAL1 and CLOCK (or its paralog NPAS2) 
stimulate transcription o f three Period (P erl-3 )  and two  
Cryptochrome (Cry 1-2) genes via E-box elements within 
their promoter regions. The translated PER and CRY pro­
teins then form the basis o f inhibitory complexes that trans­
locate back into the nucleus and bind to CLOCK-BMAL1 
proteins to inhibit their activity and thus the transcription 
of the Per and Cry genes. Within this cyclical process, the 
stability o f PER and CRY proteins is tightly controlled by 
casein kinases (CKlS/e) and the F-box protein FBXL3 
respectively (9-15). Such post-translational control is 
believed to be critical in determining the length o f the 
molecular oscillations (16).
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Figure 1 Modelling the mammalian circadian 
timing system, (a) The master circadian clock 
in the hypothalamic suprachiasmatic nuclei 
(SCN) was previously thought to directly drive 
rhythms throughout the body, (b) It is now 
recognized that autonomous clocks are 
present in most tissues. The role of the SCN is 
now considered to be synchronization of these  
peripheral clocks to ensure that they oscillate 
in an appropriate phase to each other. This 
synchronization occurs through multiple 
neuroendocrine pathways and temporal 
regulation of behaviour, such as feeding.
Secondary feedback loops also exist within the circadian 
mechanism. The best characterized of these drives rhyth­
mical expression o f B m all via retinoic acid-related orphan 
receptor response elements (ROREs) present within its pro­
moter (17). In this loop, CLOCK-BMAL1 dimers stimulate 
the rhythmic transcription o f Rev-erboc, which represses 
Bm all transcription following translation into REV-ERBa 
protein. The purpose of these secondary loops is unclear 
but may provide additional robustness to the central loop 
or perhaps provide mechanisms through which external 
processes (e.g. metabolic state) may interact with circadian 
biology.
In order for the molecular clock mechanism described 
above to regulate cellular physiology, it must be able to 
communicate temporal information to other intracellular 
pathways. It is now recognized that core clock proteins not 
only regulate the expression of other clock genes but also of  
output (or ‘clock-controlled’) genes by binding to circadian 
promoter elements, including E-boxes and ROREs (1 8 -  
20). Many o f these clock-controlled genes are themselves 
transcription factors that then regulate the expression of 
further downstream target genes; for example, the D- 
element binding protein gene (Dbp; also known as D site 
of albumin promoter binding protein) is rhythmically 
expressed via E-boxes in its promoter, and the resulting 
circadian profile of DBF protein then rhythmically induces 
transcription o f downstream genes via activation o f D- 
boxes. Through such mechanisms, the circadian clock is 
believed to drive rhythmical expression o f approximately 
10% of the transcriptome of most tissues (21).
Following from these advances in our knowledge of basic 
circadian mechanisms, importance is now being attached to 
understanding how the circadian timing system interacts 
with other physiological systems. Indeed, one of the key
challenges o f the field is to determine the functional role of 
circadian timing processes in health and disease.
Linking the clock to adipose function
There are multiple lines o f evidence that suggest a close 
relationship between circadian rhythms and adipose 
biology. Indeed, multiple aspects o f adipose-related physi­
ology display daily variation. For instance, in humans 24-h  
rhythms have been reported in the circulating blood-borne 
concentration of leptin and adiponectin (22,23), which are 
members o f the fat-derived hormone family, the adipokines 
(24). M ost o f these studies have been performed with the 
experimental subjects being kept in fluctuating external 
conditions, including a fight-dark cycle. As a result, the 
reported rhythms are not necessarily circadian in nature, as 
they may be in part driven by the presence o f rhythmic 
zeitgebers. However, the importance o f endogenous circa­
dian mechanisms in driving circadian adipokine secretion 
has been demonstrated in rodent models, in which leptin 
and adiponectin secretion is dependent on a functional 
SCN and persists in constant darkness (25,26). Whether 
human adipokine rhythms persist in the absence o f envi­
ronmental cues remains to be determined.
Further finks between circadian and adipose physiology 
fie at the molecular level, in cellular, animal and human 
models. There is now  in vitro  evidence to suggest that 
multiple clock genes play a role in adipocyte differentia­
tion. N ot only does the expression of both R ev-erba  and 
B m all mRNA increase approximately 3 -4  d following the 
onset o f differentiation of cultured adipocytes (27,28), but 
manipulation of gene expression in cultured cells indicates 
that they both promote the differentiation process (28,29). 
However, their expression is apparently not necessary for
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Journal compilation © 2009 International Association for the Study of Obesity, obesity reviews 10 (Suppl. 2), 52-60
54 Adipose and adipocyte clocks J. D. Johnston et al. obesity reviews
adipocyte differentiation in vivo  as juvenile mice
and adult Rev-erbor/~ mice do not exhibit any gross adipose 
abnormalities compared with their respective wild type 
controls (30,31).
Despite this lack of gross adipose abnormalities in juve­
nile Bmat~l~ mice and adult Rev-erbor4* mice, many mutant 
mouse lines bearing genetic lesions of clock or clock-related 
genes exhibit abnormal lipid processing. Mice expressing 
the dominant negative allele ClockA19 on a C57BL/6J 
background display many of the symptoms o f metabolic 
syndrome, including adipocyte hypertrophy, hyperleptine- 
mia, hyperlipidemia, hepatic steatosis, hyperglycaemia and 
hypoinsulinemia (32). In addition, serum VLDL triglycer­
ides and apolipoprotein C m  concentration are elevated in 
Rev-erbcr/~ mice (33), and mice with targeted disruption of  
the Nocturnin  gene, which encodes a clock-controlled 
deadenylase, are resistant to diet-induced obesity (34). 
Adult Bmall~/~ mice exhibit a reduction of fat and other 
tissues, although this may be as a result o f premature 
ageing, rather than a specific abnormality o f adipose physi­
ology per se (31).
One caveat when considering the metabolic phenotype of 
genetically altered mice is the effect o f genetic background. 
As has been reported in other models (35), the background 
genotype o f mice appears to influence the resulting meta­
bolic phenotype induced by the ClockA19 mutation 
(36,37). After crossing the ClockA19 mutation onto an ICR 
background, Oishi et al reported a reduction in dietary fat 
absorption and subsequent protection against obesity 
induced by a high-fat diet. Kennaway et al. crossed the 
ClockA19 mutation onto a melatonin-proficient CBA line 
and reported an altered metabofic phenotype including 
elevated plasma adiponectin and reduced plasma-free fatty 
acid concentration. However, despite these phenotypic dif­
ferences, a common thread through the studies described 
above is that disruption of clock and clock-related genes 
alters metabolism and lipid homeostasis.
Building on the rodent studies, a number o f groups have 
now reported associations between metabolic disruption 
and polymorphisms of human clock genes. Variants of  
BM AL1,NPAS2  and PER2 have been linked to components 
of metabolic syndrome, including hypertension and glucose 
dys-regulation (38,39). Moreover studies o f both British 
(40) and Argentinean (41) populations have investigated 
polymorphisms o f the C LO C K  gene and found significant 
relationships between C LO C K  haplotypes and the presence 
of obesity and metabolic syndrome. These data therefore 
complement the animal studies and are consistent with an 
interaction between clock genes and lipid metabolism.
Finally, consistent with the existence of a localized 
peripheral clock within fat depots, rhythmical clock gene 
expression has been reported in white (WAT) and brown 
(BAT) adipose tissue. These studies are discussed in detail 
below.
Adipose tissue rhythmicity
Rhythms in adipose tissue and the effect of diet
Analysis of murine adipose tissue has revealed robust 24-h  
rhythms o f clock gene expression. The relative phasing of 
genes in WAT and BAT is consistent with SCN rhythms and 
the molecular model of the circadian clock, suggesting the 
presence of an intrinsic adipose clock (42,43). Moreover, 
use o f microarrays suggests that up to 20% o f the murine 
adipose transcriptome is expressed according to a diurnal 
rhythm, with many o f the identified rhythmic genes being 
involved in metabolism (43,44). Similar data have also 
been reported with human WAT arrays, albeit with a 
limited number o f diurnal sampling time points (45). It 
therefore appears that many aspects o f mammalian adipose 
biology are regulated on a 24-h basis.
Interestingly, WAT tissue rhythms are altered in obese 
individuals and are sensitive to diet. Ando et al. compared 
rhythms o f clock gene expression in WAT taken from three 
mouse lines; one was lean, another was obese with mild 
type 2  diabetes mellitus (T2DM) and a third was obese 
with severe T2DM . The data revealed markedly reduced 
rhythm amplitude in obese mouse lines, compared with 
lean mice (42). This finding has notable similarities with 
previous reports o f reduced amplitude rhythms of plasma 
adipokines in obese human subjects (22,46—48), suggesting 
that rhythms o f both gene expression and endocrine activ­
ity may be attenuated in WAT of obese individuals. The 
role o f diet on adipose rhythms has been investigated using 
different experimental paradigms. Administration o f a 
high-fat diet to mice for 6 weeks had multiple effects on 
circadian physiology, including a lengthening o f the period 
o f behavioural rhythms and also altered diurnal gene 
expression profiles in both WAT and liver (49). Consistent 
with data relating to other peripheral tissues, restriction of 
food availability to the daytime regulates the phase of  
adipose rhythms in mice (43). Finally, in overweight human 
subjects, short-term fasting also alters diurnal human sub­
cutaneous WAT rhythms (45). Together these data not only 
indicate the importance o f time o f day in adipose function, 
but that there is a functional relationship between meta­
bolic state and the phasing and/or robustness o f adipose 
rhythms.
Despite their importance in identifying molecular 
rhythms in adipose tissue, there are some limitations with 
the above studies. As with the reports o f adipokine rhythms 
in human plasma, they were conducted in changing light- 
dark cycle and so the contribution o f endogenous timing 
mechanisms cannot be readily distinguished from possible 
masking effects o f environmental rhythms. Also, the com­
plex composition o f adipose tissue and its input pathways 
makes the cellular basis o f adipose rhythms unclear. These 
factors are discussed in detail below.
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White adipose tissue cellular heterogeneity
White adipose tissue is comprised o f multiple different cell 
types and this heterogeneity causes difficulty interpreting 
which cells contribute to rhythmicity at the tissue level. In 
addition to adipocytes and pre-adipocytes, WAT contains a 
wide variety of cells that are believed to contain endog­
enous clocks (Table 1).
Other potential confounding factors when interpreting 
rhythmicity in WAT are: (i) The inflammatory state o f the 
tissue and (ii) The origin o f the WAT explant. One aspect of 
obesity is the presence of chronic inflammation within 
adipose tissue (50). During this time, the balance o f the 
WAT cellular composition changes, notably including an 
increase in the macrophage content o f the tissue. It is now  
clearly understood that different adipose depots have 
markedly different influences over body metabolism; for 
example, visceral fat is a much better predictor o f meta­
bolic syndrome than subcutaneous fat (51). This differen­
tial function of adipose depots also appears to extend to 
circadian rhythmicity, as the phase o f clock gene rhythms in
Table 1 Presence of circadian clocks in adipose tissue cell types
Cell type Presence of a 
circadian clock
References
Pre-adipocyte Yes (79,84)
Adipocyte Yes (79)
Fibroblast Yes (6,82,83)
Macrophage Yes (87)
Vascular endothelial cell Yes (88)
Interpretation of adipose rhythms is complicated by the identification of 
circadian clocks in multiple cell types found in adipose tissue.
adipose tissue is dependent upon anatomical location 
(52,53).
Rhythmical inputs
As with other peripheral tissues, WAT is subject to a variety 
of rhythmical input signals (Fig. 2). Many of these inputs 
are neuroendocrine in origin; neuronal inputs include auto­
nomic mnervation, whereas endocrine inputs include mela­
tonin and glucocorticoids. Other putative rhythmical 
inputs include feeding and paracrine factors from other 
WAT cells, e.g. macrophage cytokines. Although the likeli­
hood o f physiological redundancy makes it difficult to iden­
tify the role of individual signalling pathways in the 
synchronization o f WAT rhythms in vivo, there is evidence 
that all o f these neuroendocrine and behavioural rhythms 
are involved in the entrainment o f at least some peripheral 
clocks.
Feeding behaviour
It has been recognized for a number o f years that temporal 
restriction o f food availability acts as a powerful environ­
mental time cue that regulates circadian rhythms (54). In 
nocturnal rodents, restriction of food availability to the 
daytime synchronizes rhythms o f food anticipatory activity 
and gene expression in peripheral tissues, including WAT 
(43). In most experimental models, the SCN remain 
entrained to the light-dark cycle, resulting in an uncoupling 
with many peripheral tissues. However in some mouse 
strains and during both temporal and caloric food restric­
tion, SCN rhythms also entrain to food availability 
(55-57).
The mechanisms through which temporal food availabil­
ity regulate circadian clocks are poorly understood.
Figure 2 Complexity of adipose rhythms. 
Interpretation of the underlying mechanisms of 
adipose tissue rhythms is complicated by both 
the multiple rhythmic input pathways and also 
the heterogeneous nature of adipose cells.
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Changes in metabolite concentration are able to synchro­
nize cultured cells in vitro  (58) and so may also contribute 
to synchronization in vivo. Furthermore, there is a wealth 
of evidence supporting the existence o f a food-entrainable 
oscillator, which lies outside o f the SCN and is capable of  
driving physiological and behavioural rhythms (54). 
Although the location(s) of the food-entrainable oscillator 
is the subject o f much current debate (59,60), its role within 
the circadian timing system is likely to be of great physi­
ological importance.
Autonomic innervation
The autonomic nervous system is a major physiological 
regulator of many peripheral tissues. Neuronal outputs 
from the SCN directly regulate the activity of hypothalamic 
pre-autonomic neurones, and thus the activity o f the auto­
nomic nervous system exhibits circadian changes (61). In 
particular, sympathetic innervation has a key role in driving 
many peripheral rhythms, including pineal melatonin syn­
thesis, hepatic glucose metabolism and adrenal corticoster­
oid secretion. Interestingly, denervation o f the sympathetic 
input to the submaxillary glands made these tissues more 
receptive to the synchronizing effects of temporal food  
availability (62), indicating that a complex interaction 
between different physiological entraining stimuli may 
exist for peripheral clocks.
There is some controversy in the literature regarding the 
parasympathetic control of WAT (63,64). However, clear 
evidence for sympathetic innervation o f WAT function has 
been available for many years (65). This sympathetic inner­
vation exerts physiological control over WAT, e.g. increas­
ing lipolysis, and may conceivably also entrain circadian 
rhythms in this tissue.
Melatonin
Melatonin is the primary product o f the pineal gland and 
exhibits an extremely robust daily rhythm of secretion, 
with elevated plasma melatonin concentration at night 
(66). In many model systems, melatonin has proven to be a 
powerful entraining signal for circadian rhythms. At the 
molecular level, much of our understanding o f melatonin 
signalling on circadian rhythms comes from studies of the 
pars tuberalis of the anterior pituitary. In this tissue, mela­
tonin signals through its MT1 receptor subtype to regulate 
the expression of multiple clock genes (67-69). Further­
more, recent array studies have demonstrated that melato­
nin is likely to have acute stimulatory and inhibitory effects 
on a wide range of signalling pathways (70,71).
Pinealectomy modifies the sensitivity o f rats to insulin, 
suggesting a role for melatonin in energy balance in vivo  
(72). Studies of cultured cells indicate that melatonin recep­
tors are expressed on adipocytes (73,74) and that melato­
nin may directly regulate lipolysis and leptin expression
(74,75). However; the ability o f melatonin to regulate 
adipose rhythms is currently unknown.
Glucocorticoids
The secretion o f glucocorticoids from the adrenal cortex 
also exhibits a clear circadian rhythm, controlled by a 
combination of: (i) SCN regulation o f the hypothalamo- 
pituitary-adrenal axis; (ii) SCN regulation o f autonomic 
input to the adrenal gland and (iii) Rhythmic sensitivity to 
adrenocorticotrophic hormone driven by a local adrenal 
clock (76). Administration of the glucocorticoid receptor 
agonist dexamethasone entrains liver clock gene rhythms in 
vivo  (77) and can synchronize cultured cells, including 
fibroblasts and adipocytes, in vitro (78,79). Although 
physiological glucocorticoid signalling does not appear to 
regulate fiver expression of core clock genes, rhythmic 
expression of a large proportion of cycling fiver genes 
appears to be dependent upon a functional adrenal gland 
(80). Moreover, liver-specific loss of glucocorticoid signal­
ling accelerates the entrainment of mice to a temporally 
restricted feeding paradigm (81). Thus, there is evidence 
that both exogenous and endogenous glucocorticoid hor­
mones are capable o f regulating peripheral clock function.
Adipocyte rhythmicity in vitro
A recent study has investigated rhythmic gene expression in 
explants o f human WAT. Here, visceral and subcutaneous 
adipose tissue was removed from obese subjects, kept in 
tissue culture conditions overnight and then analysed every 
6 h over a 24-h period (53). Rhythmic expression was 
observed for selected clock genes and also other adipose- 
related genes, consistent with the hypothesis that WAT 
contains its own autonomous clock. However, it is still 
unclear from this study whether the clock lies in the adi­
pocytes, or some other cell type(s). In order to address this 
question, some groups have begun to study cultures of  
adipose-derived cells.
The ability to use cultured cells to analyse circadian 
rhythms was first demonstrated using hepatic fibroblast 
cultures (6). Application o f a ‘pulse’ of high serum concen­
tration or one o f many pharmacological stimuli has been 
shown to induce molecular rhythms within a cell popula­
tion using many different cell types, including immortalized 
cell fines (78). Elegant reporter gene analysis o f single cell 
fibroblast rhythms shows that the effect of the pulse is not 
to induce rhythmicity within cells, but rather to synchro­
nize existing cellular rhythms that have drifted out of phase 
with one another (82,83).
The first study to apply the pulse technique to adipose 
physiology utilized human subcutaneous adipose-derived 
stem cells (ASCs). Following a 2-h pulse with either dex­
amethasone, rosiglitazone or 30% foetal bovine serum, 
circadian expression o f selected clock genes was observed
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in both undifferentiated and adipocyte-differentiated ASCs 
(79). Similarly, a later study reported rhythms o f P erl and 
B m all mRNA in undifferentiated ASCs following a 1-h 
pulse with 50% foetal bovine serum (84).
We have taken a similar approach to investigate murine 
adipocyte rhythms and have studied the well-characterized 
3T3-L1 cell model (D. Otway, G. Frost and J.D. Johnston, 
unpublished observations). Although these cells are known 
to express clock genes (28,85), there are no available quan­
titative data describing temporal changes in their physiol­
ogy. Our data are consistent with some of the ASC findings 
described above, but also add extra levels o f analysis and 
reveal some interesting differences. Consistent with the 
ASC data (79,84), w e observed rhythmical variation of 
Per2, D bp  and R ev-erba  expression in 3T3-L1 pre­
adipocytes. However, we failed to observe circadian rhyth­
micity o f other genes involved in the circadian clock (Perl, 
C ryl, B m all) or other aspects of adipocyte biology 
(PPARa, PPARy, SREBP1). This result was surprising 
given that all of the genes are rhythmic in murine WAT 
(42—44,86) and therefore suggest that some o f the reported 
rhythmicity in murine WAT may derive from non­
adipocyte cell types and/or rhythmical input signal(s). 
Alternatively, 3T3-L1 cells may not be an accurate model 
of circadian rhythmicity in primary adipocytes and pre­
adipocytes.
In differentiated 3T3-L1 adipocytes, we found that 
expression o f Per2, D bp  and Rev-erba  was again rhythmic, 
but the other genes tested exhibited no obvious circadian 
pattern. Although the rhythmic expression o f R ev-erba  
was similar to that in the pre-adipocytes, the amplitude of 
Per2 and D bp  rhythms was markedly attenuated. The 
reason for this could potentially be as a result of attenuated 
intracellular rhythm amplitude or a decreased ability o f the 
serum pulse to synchronize the cell population. Finally, in 
contrast to a lack of circadian Leptin  and Adiponectin  
mRNA expression, our data indicate that adipocyte clocks 
may drive circadian secretion o f leptin, but not adiponec­
tin. Although the mechanism of circadian leptin secretion is 
currently unclear, this is the first indication of an adipocyte- 
based mechanism driving the plasma leptin rhythms 
described above.
Conclusion
There is an increasing body o f evidence linking circadian 
rhythms and clock genes with adipose physiology and 
pathophysiology. Despite the progress made in understand­
ing adipose rhythms over the past few years, there are a 
number of important research avenues that remain to be 
explored. Of particular importance will be an understand­
ing of rhythmic input pathways and intercellular commu­
nication, the relationship between circadian and metabolic 
dysfunction, and the generation o f cell- and tissue-specific
clock knockout models. It w ill also be important to trans­
late cell and animal data to human studies. In this regard, 
the relative ease o f sampling o f subcutaneous WAT makes 
it one of the few peripheral tissues amenable to serial 
sampling in humans. Given the importance of obesity and 
metabolic disease in contemporary society, a clearer under­
standing o f the function of adipose clocks has great poten­
tial therapeutic value.
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Short Courses and Personal Development
• Good Clinical Practise course (2008)
• Food hygiene course (2008)
• BBSRC media training day (radio interviews, newspaper articles) (2008)
• Adult basic life support course (anaphylaxis, basic first aid, choking, resuscitation) (2008)
• Lectures from the Marie Curie training program (use of Actiwatches and RIA theory)
(2008)
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(2007)
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• BS346 Biological Rhythms undergraduate module (2006)
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• European Biological Rhythms Society conference, Strasbourg (oral presentation) (2009)
• University of Surrey FHMS Festival of Research, Surrey (poster presentation) (2008)
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(2008)
• UK Adipose Discussion Group, Warwick (poster presentation, won prize) (2008)
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prize) (2007)
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(2007)
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• Otway, D. T., Frost, G., and Johnston, J. D. (2009). Circadian rhythmicity in murine pre­
adipocyte and adipocyte cells. Chronobiol Int 26(7): 1340-1354 (see Appendix L)
• Johnston, J. D., Frost, G., and Otway, D. T. (2009). Adipose tissue, adipocytes and the
circadian timing system. Obes Rev 10(supp. 2): 52-60 (see Appendix M)
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